{"meta":{"query_hash":"5f0ee675a940","filters":{"venue":"Clinical Drug Investigation"},"cohort_total":101,"direct_labels_cover":0,"predictions_cover":101,"exported":101,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/5f0ee675a940","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Drug+Investigation"},"results":[{"id":"W1070976522","doi":"10.2165/0044011-200828120-00002","title":"Metabolism, Distribution and Elimination of Lisdexamfetamine Dimesylate","year":2008,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Center for Diagnosis and Research on Alzheimer's Disease","funders":"","keywords":"Tolerability; Pharmacokinetics; Urine; Medicine; Pharmacology; Adverse effect; Volume of distribution; Whole blood; Internal medicine","score_opus":0.09007126275613525,"score_gpt":0.36019622267936857,"score_spread":0.2701249599232333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1070976522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950105,0.0023669612,0.0006901719,0.00010267363,0.000018424069,0.000027768541,0.00029509168,0.000026538655,0.0014619227],"genre_scores_gemma":[0.996369,0.0009833779,0.0003859653,0.00007029262,0.000019569285,0.000016501037,0.00032368142,0.000013215405,0.0018183438],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998173,0.000071870316,0.00001054968,0.000033339933,0.000031531286,0.000035360412],"domain_scores_gemma":[0.9997993,0.000056950757,0.00005228069,0.00001949853,0.00003225186,0.000039649363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028807943,0.00030293298,0.00037005005,0.0004578156,0.00025869734,0.00041748767,0.00028202494,0.00046038203,0.0018585782],"category_scores_gemma":[0.00073061825,0.00030728598,0.00031098386,0.00030873137,0.00039358082,0.0006325904,0.00016367105,0.0005575707,0.0009088763],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15224731,0.0015060826,0.07416452,0.00035558414,0.00041105895,0.004147777,0.000813164,0.0022922195,0.5521135,0.0020483444,0.0024436738,0.20745686],"study_design_scores_gemma":[0.0024871826,0.03124002,0.23417148,0.0000585335,0.0005736959,0.01211075,0.0006417055,0.014486259,0.6867562,0.00070018263,0.016648386,0.00012561391],"about_ca_topic_score_codex":0.004450025,"about_ca_topic_score_gemma":0.0020442517,"teacher_disagreement_score":0.004450025,"about_ca_system_score_codex":0.00085315993,"about_ca_system_score_gemma":0.00073889876,"threshold_uncertainty_score":0.00884825},"labels":[],"label_agreement":null},{"id":"W1151626562","doi":"10.1007/s40261-015-0313-7","title":"Effect of Inhaled Corticosteroids on Salival Composition: A Cross-Sectional Study in Patients with Bronchial Asthma","year":2015,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Salivary Gland Disorders and Functions","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine and Dentistry, University of Alberta; Ministerio de Ciencia e Innovación; Novartis","keywords":"Medicine; Asthma; Inhaled corticosteroids; Saliva; Cross-sectional study; Internal medicine; Corticosteroid; Pathology","score_opus":0.041395273605322684,"score_gpt":0.35589457898629273,"score_spread":0.31449930538097004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1151626562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991008,0.00046907354,0.000027695987,0.000027428168,0.000008559295,0.000008019348,0.00009861677,0.0000018427075,0.00025783552],"genre_scores_gemma":[0.99944216,0.00016414585,0.000038895174,0.000054779317,0.000012341006,0.000007910169,0.00016337885,0.0000014973225,0.000114851675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918395,0.0002710975,0.00012201971,0.00015472354,0.0001536305,0.00011461315],"domain_scores_gemma":[0.99852645,0.0004603873,0.00043190276,0.00010867882,0.00017324742,0.0002993604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007413554,0.0004218147,0.00090871344,0.0007302482,0.00073183456,0.0011652207,0.00029459965,0.0011264817,0.0011153457],"category_scores_gemma":[0.0024204992,0.000533773,0.00096785655,0.0009293579,0.00043492706,0.0007488018,0.00047750826,0.0010522301,0.00032489208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029572396,0.00016041796,0.99811375,0.000011490819,0.00010233424,0.00010825021,0.00012737865,0.000011310296,0.00043732932,0.0000039944343,0.000022050664,0.00060593255],"study_design_scores_gemma":[0.0000070851615,0.00030107834,0.9990791,0.0000027863784,0.000048956103,0.00021548352,0.00022933356,0.000028127663,0.000036903366,0.00000335798,0.000044720062,0.0000031183022],"about_ca_topic_score_codex":0.003000318,"about_ca_topic_score_gemma":0.0035189479,"teacher_disagreement_score":0.003000318,"about_ca_system_score_codex":0.00035172285,"about_ca_system_score_gemma":0.00030053954,"threshold_uncertainty_score":0.0059657097},"labels":[],"label_agreement":null},{"id":"W127233696","doi":"10.2165/00044011-200020050-00005","title":"Efficacy and Safety of Inhaled Zanamivir for the Treatment of Influenza in Patients with Asthma or Chronic Obstructive Pulmonary Disease","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Saint Jerome","funders":"","keywords":"Medicine; Zanamivir; Asthma; Placebo; COPD; Exacerbation; Internal medicine; Disease","score_opus":0.03052877370913406,"score_gpt":0.3122925710824548,"score_spread":0.28176379737332075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W127233696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861443,0.012094249,0.00012502604,0.00029619483,0.00007650747,0.00006843281,0.00017011148,0.000013541641,0.0010115661],"genre_scores_gemma":[0.9974076,0.0019193455,0.000115419156,0.00014439644,0.00006858154,0.000014359208,0.00014901604,0.0000025571717,0.00017867144],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99940765,0.00024703814,0.000070356204,0.00005753933,0.00013631364,0.00008105073],"domain_scores_gemma":[0.9990221,0.0004025684,0.0002693398,0.000059450773,0.00011309729,0.00013330275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013130803,0.00032290627,0.0015220287,0.00021702526,0.00027558373,0.0005188791,0.0003591214,0.00077268435,0.00097509206],"category_scores_gemma":[0.002360132,0.00021431153,0.0012485363,0.00017070911,0.00042197536,0.00064286403,0.00017896398,0.0018041966,0.00018832389],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4619481,0.006574982,0.07888706,0.0020898876,0.005045049,0.0008038999,0.00049868674,0.0023297644,0.059027158,0.00037770325,0.0012562206,0.38116145],"study_design_scores_gemma":[0.091105744,0.26658767,0.5997447,0.00031661757,0.0077417963,0.0019332786,0.0004957632,0.005796828,0.0211497,0.00030872898,0.004701202,0.00011804339],"about_ca_topic_score_codex":0.0015066931,"about_ca_topic_score_gemma":0.0026109994,"teacher_disagreement_score":0.0015220287,"about_ca_system_score_codex":0.000610243,"about_ca_system_score_gemma":0.00048141356,"threshold_uncertainty_score":0.0069442987},"labels":[],"label_agreement":null},{"id":"W1677866495","doi":"10.1007/s40261-015-0327-1","title":"Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study","year":2015,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; NIH Clinical Center; Ajou University; Clinical Trial Center, China Medical University Hospital","keywords":"Medicine; Epoetin alfa; Pharmacokinetics; Crossover study; Pharmacodynamics; Bioequivalence; Erythropoietin; Confidence interval; Internal medicine; Pharmacology; Adverse effect; Area under the curve; Gastroenterology; Placebo","score_opus":0.1443688003860833,"score_gpt":0.4558119339915855,"score_spread":0.3114431336055022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1677866495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738234,0.00069931423,0.0005612231,0.000062941064,0.00010442801,0.0006779269,0.00019207159,0.000032823493,0.00028687305],"genre_scores_gemma":[0.9949622,0.00078327546,0.0013068045,0.00033697818,0.00013772126,0.00088527094,0.00034337238,0.000024577623,0.0012197873],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990381,0.0004362882,0.000079389974,0.00023967982,0.00009452172,0.00011194115],"domain_scores_gemma":[0.9988176,0.0002667138,0.00021981267,0.00016231961,0.00010964016,0.00042384048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016339528,0.0016578552,0.0032151681,0.00033502965,0.0005018148,0.00075886416,0.00074967754,0.0015098735,0.0032992314],"category_scores_gemma":[0.0018342573,0.001320933,0.0011796195,0.000378214,0.0016085084,0.0014410664,0.0004270243,0.0022529745,0.00075757224],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9360004,0.0264397,0.0013310593,0.00034960682,0.000685371,0.000058722228,0.00018355186,0.00024821778,0.022778735,0.00006788428,0.000263996,0.011592795],"study_design_scores_gemma":[0.41641492,0.5559217,0.017771173,0.00002394085,0.0015129879,0.0001699192,0.00016759624,0.0010824593,0.0055277394,0.00013774369,0.0011694944,0.00010038312],"about_ca_topic_score_codex":0.0006546492,"about_ca_topic_score_gemma":0.00072243146,"teacher_disagreement_score":0.0032992314,"about_ca_system_score_codex":0.00045495952,"about_ca_system_score_gemma":0.00095284154,"threshold_uncertainty_score":0.011037052},"labels":[],"label_agreement":null},{"id":"W1898364441","doi":"10.2165/00044011-200727100-00001","title":"The Concept of Complete Remission of Gastro-Oesophageal Reflux Disease","year":2007,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Gastroesophageal reflux and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Esomeprazole; Pantoprazole; Medicine; Reflux; Disease; Internal medicine; Gastro-; Proton-pump inhibitor; Gastroenterology; Symptom relief; Omeprazole","score_opus":0.20328624441495483,"score_gpt":0.4660601266133393,"score_spread":0.2627738821983845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1898364441","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014941285,0.99822456,0.00022588503,0.00047172233,0.00022679313,0.0000059535655,0.000009630213,0.0000034230993,0.0006825705],"genre_scores_gemma":[0.002937218,0.99424535,0.00054901774,0.0011131588,0.00052824354,0.000017176451,0.000038892224,0.0000019815927,0.0005688759],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936503,0.00018587626,0.00013206167,0.000099026474,0.00018241047,0.000035599485],"domain_scores_gemma":[0.9990319,0.0006089143,0.00016443201,0.000030713716,0.00012380333,0.000040109273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001765124,0.00071503175,0.0030585437,0.0014742251,0.00025512144,0.0012560884,0.0015853898,0.0014382545,0.0021529244],"category_scores_gemma":[0.0013414283,0.0002485818,0.00074310036,0.001224575,0.0015032098,0.0020143595,0.00087518786,0.0030107598,0.00093928806],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023624163,0.000116693736,0.0003345633,0.02664469,0.00024856915,0.0004160992,0.00011134261,0.0002617581,0.0021738342,0.013425963,0.019320613,0.9367097],"study_design_scores_gemma":[0.00018654444,0.0003621257,0.002176723,0.0064109922,0.0003547,0.0047638766,0.0001344929,0.00015417159,0.00076995837,0.006444419,0.97820413,0.00003786058],"about_ca_topic_score_codex":0.00063811435,"about_ca_topic_score_gemma":0.0012481748,"teacher_disagreement_score":0.0030585437,"about_ca_system_score_codex":0.000632402,"about_ca_system_score_gemma":0.0009929196,"threshold_uncertainty_score":0.009334922},"labels":[],"label_agreement":null},{"id":"W1963571177","doi":"10.2165/00044011-200424090-00005","title":"Efficacy and Safety Assessment of a Novel Once-Daily Tablet Formulation of Tramadol","year":2004,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Veterinary Pharmacology and Anesthesia","field":"Veterinary","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeshore General Hospital; Université de Montréal","funders":"","keywords":"Tramadol; Medicine; Anesthesia; Dosing; Osteoarthritis; Analgesic; Adverse effect; Nausea; Internal medicine","score_opus":0.14750340375279625,"score_gpt":0.4335215681560633,"score_spread":0.28601816440326705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963571177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971718,0.0011892346,0.00074694253,0.00009373547,0.00003972168,0.000156184,0.00014235941,0.000033953984,0.0004262126],"genre_scores_gemma":[0.9967648,0.00096219004,0.0012303476,0.000054558528,0.000061973675,0.00004745564,0.000182979,0.000009288897,0.0006865028],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99977154,0.00007132326,0.000021472448,0.00004854556,0.00005778876,0.000029324794],"domain_scores_gemma":[0.99964476,0.0000898895,0.000116979674,0.000035809557,0.00004268291,0.00006990047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038496417,0.00034078376,0.0005904557,0.00028454588,0.00022685013,0.00036809716,0.0004640991,0.00049859507,0.0020034171],"category_scores_gemma":[0.0006112558,0.00025501347,0.00042421056,0.00016142307,0.00041307995,0.0006527226,0.00012448138,0.00084427063,0.00031811054],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06343793,0.013648761,0.0015310814,0.00054535095,0.00018093978,0.00048753113,0.00022912578,0.0004717745,0.81987447,0.00025760004,0.00044258058,0.0988929],"study_design_scores_gemma":[0.021347778,0.6356592,0.030285088,0.000045309647,0.0008937976,0.0026890934,0.00024194329,0.00703317,0.29778144,0.00012387295,0.0038153043,0.000083995226],"about_ca_topic_score_codex":0.00056544703,"about_ca_topic_score_gemma":0.001182215,"teacher_disagreement_score":0.0020034171,"about_ca_system_score_codex":0.00022791809,"about_ca_system_score_gemma":0.00039410664,"threshold_uncertainty_score":0.006702125},"labels":[],"label_agreement":null},{"id":"W1971473849","doi":"10.1007/s40261-013-0085-x","title":"Pharmacokinetics, Tolerability, and Safety of Intranasal Administration of Reformulated OxyContin® Tablets Compared with Original OxyContin® Tablets in Healthy Adults","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"Purdue Pharma; Purdue University","keywords":"Tolerability; Medicine; Pharmacokinetics; Crossover study; Adverse effect; Dosing; Nasal administration; Anesthesia; Area under the curve; Pharmacology","score_opus":0.026866076236207424,"score_gpt":0.3231715285779246,"score_spread":0.2963054523417172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971473849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992772,0.00044165243,0.000062276056,0.000010951527,0.000006397474,0.000049225153,0.00004971069,0.0000043228893,0.00009830418],"genre_scores_gemma":[0.999172,0.00025466754,0.00024296701,0.00005385544,0.000020662852,0.000037289028,0.00008633095,0.0000019752154,0.00013034653],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9997557,0.00007850629,0.000020726786,0.000060237653,0.000059767393,0.000025081805],"domain_scores_gemma":[0.99939954,0.00013782296,0.00026727462,0.00003048234,0.00005174936,0.00011319787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006155795,0.00028625032,0.0005841586,0.00011681871,0.00012649725,0.00028542103,0.0001192409,0.0002986322,0.0009883665],"category_scores_gemma":[0.0011680747,0.00022324453,0.00033908724,0.00011134986,0.00028569385,0.000346214,0.00013770886,0.00043775904,0.00014913482],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5098584,0.01620889,0.17462769,0.0009867765,0.0013228635,0.00056715467,0.00095746253,0.0015291272,0.14717133,0.00013454004,0.0008248213,0.14581089],"study_design_scores_gemma":[0.014877225,0.4579946,0.5102823,0.000045172983,0.00072208396,0.0009739515,0.00025100028,0.0026825385,0.011174208,0.000070950875,0.0008811333,0.00004479734],"about_ca_topic_score_codex":0.00061237946,"about_ca_topic_score_gemma":0.00057184114,"teacher_disagreement_score":0.0009883665,"about_ca_system_score_codex":0.00023350668,"about_ca_system_score_gemma":0.00024979873,"threshold_uncertainty_score":0.0033063889},"labels":[],"label_agreement":null},{"id":"W1976361964","doi":"10.2165/00044011-200828110-00001","title":"Perindopril for Control of Blood Pressure in Patients with Hypertension and Other Cardiovascular Risk Factors","year":2008,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Integre de Sante et de Services Sociaux de Laval; Dr. Georges-L.-Dumont University Hospital Centre; Toronto Western Hospital; University of Toronto","funders":"","keywords":"Perindopril; Tolerability; Medicine; Blood pressure; Internal medicine; Adverse effect; Risk factor; Pharmacotherapy; Cardiology","score_opus":0.04654721880806912,"score_gpt":0.25812353976106234,"score_spread":0.21157632095299322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976361964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95331794,0.043595433,0.00012048894,0.00043621202,0.00017895518,0.000111188936,0.00023786792,0.000008502834,0.001993409],"genre_scores_gemma":[0.98598665,0.01225465,0.000385683,0.0004627382,0.00024452602,0.000076977136,0.00022653856,0.0000036163076,0.0003585829],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99788326,0.0013913652,0.00020059489,0.00015671873,0.00022206944,0.00014599366],"domain_scores_gemma":[0.99716276,0.0015507754,0.0005295418,0.00014819528,0.00012822467,0.00048036245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024736915,0.00033834807,0.0014272967,0.00031752454,0.00036816366,0.00052785035,0.00032144698,0.0005933789,0.0012504428],"category_scores_gemma":[0.0057660006,0.00033537953,0.0011525566,0.0005351418,0.00030549918,0.000644675,0.00038953795,0.0015158672,0.000111834015],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45016366,0.006198445,0.32198602,0.0030179191,0.00942895,0.0006416455,0.00047255517,0.00028345225,0.005868861,0.00043260917,0.002789617,0.19871627],"study_design_scores_gemma":[0.13152549,0.116729826,0.72966295,0.0006042553,0.010047553,0.0011341921,0.00039647668,0.00066506764,0.002004905,0.00024789554,0.006912961,0.0000684548],"about_ca_topic_score_codex":0.0014754527,"about_ca_topic_score_gemma":0.003173016,"teacher_disagreement_score":0.0024736915,"about_ca_system_score_codex":0.00050060585,"about_ca_system_score_gemma":0.0010009406,"threshold_uncertainty_score":0.013082325},"labels":[],"label_agreement":null},{"id":"W1983647616","doi":"10.2165/11315290-000000000-00000","title":"Shortness of Breath, a ‘Wearing-Off’ Symptom in Parkinsonʼs Disease","year":2009,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Parkinson's Clinic of Eastern Toronto & Movement Disorders Centre","funders":"","keywords":"Medicine; Pharmacotherapy; Disease; Parkinson's disease; Intensive care medicine; Physical therapy; Psychiatry; Internal medicine","score_opus":0.0409931398489421,"score_gpt":0.34352859934577046,"score_spread":0.30253545949682836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983647616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9251025,0.05108552,0.00067638344,0.0019000575,0.00025064094,0.0000696904,0.0002735694,0.000053301366,0.020588284],"genre_scores_gemma":[0.9917242,0.0061944756,0.00029837998,0.0005359829,0.00019514772,0.000009055841,0.00015789336,0.000003894705,0.0008809576],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9997563,0.000058924266,0.00005168323,0.00002696713,0.00007307943,0.000033043023],"domain_scores_gemma":[0.9994294,0.0001836849,0.0001523965,0.000017727762,0.00008290167,0.00013382899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049436284,0.0003883172,0.0007975648,0.00051818934,0.00030779385,0.0004083663,0.00025271965,0.00074123533,0.0011521621],"category_scores_gemma":[0.0014348386,0.00010878482,0.0002690848,0.00043546967,0.00050536287,0.000397751,0.0002452848,0.00063995307,0.00021704182],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012114325,0.001076967,0.37531346,0.002723543,0.00053303485,0.07977543,0.001001115,0.00036809617,0.06280894,0.0012635628,0.0098028965,0.4532186],"study_design_scores_gemma":[0.0004611618,0.0062009995,0.88233984,0.00032612542,0.0004098714,0.09241287,0.0008700278,0.0006503207,0.0046045915,0.00068484235,0.010970197,0.000069128415],"about_ca_topic_score_codex":0.002086977,"about_ca_topic_score_gemma":0.0031075133,"teacher_disagreement_score":0.002086977,"about_ca_system_score_codex":0.00031811115,"about_ca_system_score_gemma":0.0002709507,"threshold_uncertainty_score":0.0041496754},"labels":[],"label_agreement":null},{"id":"W1984348569","doi":"10.2165/11319610-000000000-00000","title":"Perioperative Use of Nonsteroidal Anti-Inflammatory Drugs","year":2009,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Ketorolac; Ketoprofen; Diclofenac; Perioperative; Ibuprofen; Nonsteroidal; Analgesic; Anesthesia; Pharmacology","score_opus":0.04449040060894345,"score_gpt":0.3261087660218128,"score_spread":0.2816183654128694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984348569","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8477242,0.106469996,0.0027767413,0.0021642437,0.0019095715,0.00013617106,0.0006425754,0.00009924073,0.038077265],"genre_scores_gemma":[0.9655146,0.026926652,0.0017792458,0.00083871704,0.0007752627,0.00006711787,0.0004919659,0.000012708833,0.0035936679],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99945194,0.000081257174,0.00011795639,0.000038497623,0.00021682843,0.00009352938],"domain_scores_gemma":[0.998993,0.00025976702,0.00034157388,0.000058480502,0.00018507084,0.00016221718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033112612,0.0002162754,0.00040229168,0.0005732288,0.00040113728,0.0006494878,0.00015075805,0.00021171875,0.002572113],"category_scores_gemma":[0.0021118089,0.000069433394,0.00042267726,0.00045739397,0.00019882053,0.00024881228,0.00025140747,0.0006820825,0.00044886637],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069418233,0.00091709924,0.3768994,0.0014490723,0.0009845445,0.006159953,0.00049563753,0.00025801794,0.0503422,0.001730828,0.0050029983,0.5488184],"study_design_scores_gemma":[0.00025550433,0.012100456,0.782292,0.0015073139,0.0026320233,0.028090464,0.001997036,0.0011104891,0.07678099,0.0009143655,0.092230745,0.00008861696],"about_ca_topic_score_codex":0.00078636245,"about_ca_topic_score_gemma":0.0016430104,"teacher_disagreement_score":0.002572113,"about_ca_system_score_codex":0.00030163207,"about_ca_system_score_gemma":0.0009932081,"threshold_uncertainty_score":0.008604586},"labels":[],"label_agreement":null},{"id":"W1989110922","doi":"10.2165/11319800-000000000-00000","title":"Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination","year":2009,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada)","funders":"","keywords":"Rosuvastatin; Medicine; Simvastatin; Atorvastatin; Combination therapy; Statin; Internal medicine; Pharmacology; Pharmacotherapy; Rosuvastatin Calcium; Fenofibrate; Gastroenterology; Population","score_opus":0.04619729645364628,"score_gpt":0.3819313796049937,"score_spread":0.3357340831513474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989110922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98393863,0.0018704442,0.0005799938,0.0008430571,0.0003057936,0.00040218048,0.0036368473,0.00009928753,0.008323858],"genre_scores_gemma":[0.9876271,0.0004085688,0.00023357573,0.00066449796,0.00017196746,0.00013862838,0.0035863118,0.000007596813,0.0071617696],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99907136,0.00021802666,0.000088288376,0.00017916178,0.00017411768,0.00026910173],"domain_scores_gemma":[0.9982199,0.0002509409,0.00026994376,0.00013956314,0.00037923735,0.0007404494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009826228,0.000809938,0.00194847,0.000746541,0.0008435686,0.00092181953,0.00046842833,0.002029475,0.0038541623],"category_scores_gemma":[0.0025929653,0.0003426835,0.0012852338,0.00042655558,0.00032080617,0.0011291465,0.00048680376,0.0019100696,0.0008632862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5809376,0.022529148,0.27907354,0.00029759618,0.002134445,0.003462909,0.00037035756,0.0012117955,0.009830748,0.0003118787,0.006198458,0.093641505],"study_design_scores_gemma":[0.012776151,0.11263689,0.8552488,0.00005977115,0.0025195547,0.0011311726,0.0003789029,0.0012223418,0.004367912,0.00051041745,0.009000802,0.00014737007],"about_ca_topic_score_codex":0.007945146,"about_ca_topic_score_gemma":0.013479158,"teacher_disagreement_score":0.007945146,"about_ca_system_score_codex":0.0008483859,"about_ca_system_score_gemma":0.0012357192,"threshold_uncertainty_score":0.015797794},"labels":[],"label_agreement":null},{"id":"W1992770459","doi":"10.1007/s40261-014-0187-0","title":"Availability of Data on Adverse Reactions to Antiretroviral Drugs in Medical Charts According to the Naranjo Algorithm: An Example of a Brazilian Historical Cohort","year":2014,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Adverse effect; Medical record; Cohort; Medical prescription; Dyslipidemia; Lipodystrophy; Referral; Pharmacy; Human immunodeficiency virus (HIV); Antiretroviral therapy; Family medicine; Internal medicine; Viral load; Disease; Pharmacology","score_opus":0.2423668398692314,"score_gpt":0.48011020635694857,"score_spread":0.23774336648771716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992770459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94982874,0.0018155685,0.0042936555,0.0013480951,0.0000761108,0.0004132093,0.025037602,0.00009269997,0.017094333],"genre_scores_gemma":[0.98439515,0.0013552824,0.00398541,0.00019903271,0.000039481438,0.0001697291,0.008854745,0.000059839105,0.00094135234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765575,0.0006327086,0.00032269766,0.00049363397,0.0005929062,0.0003023063],"domain_scores_gemma":[0.9873976,0.0026939681,0.0040493603,0.0018470822,0.0033232183,0.00068874774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038996413,0.00029486857,0.0006401034,0.0034929481,0.0009832863,0.0010020813,0.0006046209,0.00034635927,0.002399229],"category_scores_gemma":[0.018421222,0.00028017838,0.0006282512,0.0042986837,0.00040973988,0.0004922872,0.000758296,0.0005843313,0.00026901605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014553776,0.000055837296,0.97983325,0.00014168292,0.0001232178,0.00060743035,0.0014182655,0.00018714188,0.00055272155,0.0011098961,0.0019979568,0.013827142],"study_design_scores_gemma":[0.000017935841,0.000062026986,0.9850182,0.0001962641,0.00012406254,0.0015874085,0.0010342948,0.00080399774,0.0003151342,0.0004440135,0.010365661,0.00003099952],"about_ca_topic_score_codex":0.14665234,"about_ca_topic_score_gemma":0.11786822,"teacher_disagreement_score":0.14665234,"about_ca_system_score_codex":0.0013316681,"about_ca_system_score_gemma":0.0029793312,"threshold_uncertainty_score":0.2915975},"labels":[],"label_agreement":null},{"id":"W1995273109","doi":"10.2165/00044011-200020050-00001","title":"Randomised, Multicentre Phase III Study of Saquinavir plus Zidovudine plus Zalcitabine in Previously Untreated or Minimally Pretreated HIV-Infected Patients","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary General Hospital; Foothills Medical Centre","funders":"","keywords":"Zalcitabine; Zidovudine; Medicine; Saquinavir; Context (archaeology); Didanosine; Regimen; Internal medicine; Clinical endpoint; Clinical trial; Phases of clinical research; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Virology; Viral disease","score_opus":0.03442539373868219,"score_gpt":0.3394667003142452,"score_spread":0.305041306575563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995273109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98310465,0.0031874722,0.0010614055,0.0009913755,0.0010661792,0.006141515,0.0015770933,0.00015671329,0.0027136968],"genre_scores_gemma":[0.98096424,0.0024708174,0.002245068,0.0018856759,0.00064837333,0.004662631,0.00171134,0.000043410786,0.005368498],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988175,0.0006731856,0.00005408159,0.00017503595,0.000064755644,0.00021543221],"domain_scores_gemma":[0.9982298,0.00046136192,0.00027084173,0.0001646289,0.00010192876,0.0007714379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026320282,0.0023047864,0.005190666,0.0006659707,0.00079245,0.0019128161,0.0015603973,0.0022973816,0.010517954],"category_scores_gemma":[0.0027306033,0.0014037417,0.0024645422,0.0007398049,0.00264135,0.0016354136,0.00076409214,0.004698954,0.0019717754],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9876051,0.004180399,0.00034223916,0.00022092089,0.00046111696,0.000027926499,0.000052448297,0.00022224245,0.0014982773,0.0000804872,0.00037926142,0.0049295956],"study_design_scores_gemma":[0.9610595,0.037506066,0.00082883897,0.0000071388845,0.00012251642,0.000014522533,0.000017522198,0.00009388994,0.0000699551,0.00006344096,0.00020894338,0.000007699263],"about_ca_topic_score_codex":0.0032125544,"about_ca_topic_score_gemma":0.0058416664,"teacher_disagreement_score":0.010517954,"about_ca_system_score_codex":0.0013790329,"about_ca_system_score_gemma":0.0019890761,"threshold_uncertainty_score":0.035186052},"labels":[],"label_agreement":null},{"id":"W2003069609","doi":"10.2165/11533440-000000000-00000","title":"Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee","year":2010,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Tapentadol; Medicine; Oxycodone; Placebo; Anesthesia; Osteoarthritis; Discontinuation; Analgesic; Tramadol; Chronic pain; Opioid; Internal medicine; Physical therapy","score_opus":0.01585256211730917,"score_gpt":0.29155836713003985,"score_spread":0.2757058050127307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003069609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99800664,0.0014218051,0.00006422215,0.000057967667,0.000025438594,0.00003653584,0.00007686253,0.0000066708703,0.00030387053],"genre_scores_gemma":[0.9985494,0.000729055,0.0001247864,0.000048129128,0.00005420564,0.000024320994,0.00009402571,0.0000028122952,0.00037332988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996182,0.00018968257,0.00003436331,0.000039783787,0.000068030735,0.00004995895],"domain_scores_gemma":[0.99829155,0.0008318774,0.00040883245,0.00011458813,0.00008713723,0.0002661194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006731719,0.00032086126,0.00097427727,0.00017764974,0.00017324969,0.0004923926,0.00036982488,0.00048633327,0.0021628889],"category_scores_gemma":[0.0027389002,0.0002057538,0.00060473994,0.0001554259,0.00042376172,0.0005651308,0.00016139583,0.0010018827,0.00020390352],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88418317,0.0045694094,0.005117908,0.0004499663,0.0005810523,0.0001334561,0.00024661046,0.000584178,0.015721988,0.000089551366,0.00025690283,0.0880658],"study_design_scores_gemma":[0.21125554,0.607692,0.1641984,0.00017473548,0.0022069274,0.0007219056,0.00036224688,0.0045203003,0.0070440443,0.00019832667,0.0015235244,0.000102108526],"about_ca_topic_score_codex":0.0014098858,"about_ca_topic_score_gemma":0.0025896956,"teacher_disagreement_score":0.0021628889,"about_ca_system_score_codex":0.00035409493,"about_ca_system_score_gemma":0.00048353925,"threshold_uncertainty_score":0.0072356462},"labels":[],"label_agreement":null},{"id":"W2004371282","doi":"10.2165/00044011-200121090-00005","title":"Comparison of Salmeterol/Fluticasone Propionate Combination with Budesonide in Patients with Mild-to-Moderate Asthma","year":2001,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Salmeterol; Fluticasone propionate; Budesonide; Tolerability; Morning; Evening; Fluticasone; Asthma; Combination therapy; Anesthesia; Spirometry; Internal medicine; Adverse effect","score_opus":0.04419868005731209,"score_gpt":0.3507770570434884,"score_spread":0.3065783769861763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004371282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844328,0.012355791,0.00013735061,0.0005567362,0.0004316024,0.0001628171,0.00034738338,0.000023354067,0.0015521618],"genre_scores_gemma":[0.9953491,0.002753068,0.0001983912,0.00027328212,0.00057851285,0.000067874505,0.0003744986,0.000005265506,0.0003999886],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998906,0.0005808593,0.00013151372,0.00011211246,0.0001205,0.00014898223],"domain_scores_gemma":[0.99776375,0.0011062647,0.00020109606,0.00008483946,0.00011036781,0.00073360535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013847802,0.00089937483,0.0048885667,0.00054201006,0.00042772113,0.0008030821,0.00073504273,0.0014188545,0.0029155144],"category_scores_gemma":[0.0030242184,0.0004744159,0.0024357105,0.0005463931,0.00049110147,0.0011423592,0.0004391979,0.0018074268,0.00053822773],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9534986,0.0022863315,0.0125651015,0.00046780973,0.0010118092,0.00024200276,0.00009245784,0.000240388,0.0029018587,0.00006013467,0.00031406793,0.02631935],"study_design_scores_gemma":[0.38777992,0.39992726,0.19997922,0.0001676952,0.0047544963,0.00086849375,0.00045489808,0.0015836739,0.0019072372,0.00018316813,0.0023064238,0.00008750204],"about_ca_topic_score_codex":0.0012880898,"about_ca_topic_score_gemma":0.0028845118,"teacher_disagreement_score":0.0048885667,"about_ca_system_score_codex":0.0007118261,"about_ca_system_score_gemma":0.00085242285,"threshold_uncertainty_score":0.009753346},"labels":[],"label_agreement":null},{"id":"W2005805496","doi":"10.1007/s40261-013-0053-5","title":"Effect of Implantation of Augment® Bone Graft on Serum Concentrations of Platelet-Derived Growth Factors: A Pharmacokinetic Study","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Periodontal Regeneration and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"BioMimetic Therapeutics","keywords":"Augment; Medicine; Pharmacokinetics; Pharmacology; Platelet; Pharmacotherapy; Internal medicine","score_opus":0.03752778564131822,"score_gpt":0.3616140800555922,"score_spread":0.324086294414274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005805496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980433,0.0007337626,0.0003552039,0.00004715177,0.000070909875,0.00005487005,0.00012414038,0.000021902113,0.0005487628],"genre_scores_gemma":[0.99741733,0.00060428854,0.0004457381,0.00004984991,0.00009335963,0.000049038554,0.0001896972,0.000010119456,0.0011406613],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99949574,0.00014965648,0.00004345212,0.00010092309,0.00008465718,0.00012548611],"domain_scores_gemma":[0.9989598,0.0006032621,0.00012664359,0.00012809732,0.00005426972,0.00012790407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006964676,0.0005793143,0.0006378091,0.00038976863,0.0002023022,0.00044669906,0.00033103742,0.0005885325,0.0019062962],"category_scores_gemma":[0.0012092809,0.0003172788,0.0006650558,0.0003911893,0.0011554995,0.00069050066,0.00020857978,0.0010236108,0.0002605993],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3189653,0.014070273,0.004646749,0.00025154714,0.00020374074,0.0007765048,0.00045736713,0.00095367,0.6276283,0.0003870553,0.00044640445,0.031212991],"study_design_scores_gemma":[0.0061753476,0.32897606,0.04250415,0.000026121335,0.0006582048,0.0011465751,0.0004114957,0.0042725564,0.612452,0.00042573846,0.002859929,0.000091915535],"about_ca_topic_score_codex":0.0010372171,"about_ca_topic_score_gemma":0.0010293865,"teacher_disagreement_score":0.0019062962,"about_ca_system_score_codex":0.0003221707,"about_ca_system_score_gemma":0.000602074,"threshold_uncertainty_score":0.00637722},"labels":[],"label_agreement":null},{"id":"W2006812895","doi":"10.1007/s40261-014-0192-3","title":"Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users","year":2014,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"Purdue Pharma; Regeneron Pharmaceuticals; Purdue University","keywords":"Oxycodone; Medicine; (+)-Naloxone; Placebo; Anesthesia; Opioid; Tolerability; Narcotic antagonist; Crossover study; Opioid antagonist; Pharmacology; Adverse effect; Internal medicine","score_opus":0.026012143143953177,"score_gpt":0.3055863440596846,"score_spread":0.27957420091573143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006812895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993198,0.0003583448,0.00005015836,0.000008291965,0.0000027885758,0.000047929632,0.000035261208,0.0000015892525,0.00017593318],"genre_scores_gemma":[0.9991154,0.00031945232,0.00023282354,0.00002831377,0.000008483114,0.000038935334,0.000054743912,8.80448e-7,0.00020104533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995683,0.00020371206,0.000038437167,0.000046575908,0.00010896883,0.0000340326],"domain_scores_gemma":[0.9993007,0.00022663202,0.0002730502,0.000034796536,0.00006153501,0.00010320192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005550571,0.00020473615,0.0003639856,0.00019302573,0.0002017732,0.00024809028,0.00018516448,0.00022729745,0.0014813303],"category_scores_gemma":[0.001206269,0.00014933548,0.00019981427,0.00015867403,0.00025742283,0.00022296947,0.00017621928,0.00025113337,0.00014787175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14731835,0.017415442,0.56665486,0.0009816856,0.00056456047,0.0008620872,0.0006498603,0.00048059752,0.14218695,0.00014531186,0.00036837062,0.12237191],"study_design_scores_gemma":[0.0020275617,0.17364436,0.8022976,0.000045145545,0.00031868965,0.0012479204,0.00035541772,0.00092887547,0.017882418,0.000053230684,0.00117581,0.000022905699],"about_ca_topic_score_codex":0.00070089515,"about_ca_topic_score_gemma":0.001378089,"teacher_disagreement_score":0.0014813303,"about_ca_system_score_codex":0.00022731413,"about_ca_system_score_gemma":0.00023115576,"threshold_uncertainty_score":0.00495553},"labels":[],"label_agreement":null},{"id":"W2007223681","doi":"10.2165/00044011-200020030-00003","title":"A Retrospective, Naturalistic Review Comparing Clinical Outcomes of In-Hospital Treatment with Risperidone and Olanzapine","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Hospital Edmonton","funders":"Janssen Pharmaceuticals","keywords":"Risperidone; Olanzapine; Medicine; Schizoaffective disorder; Schizophrenia (object-oriented programming); Antipsychotic; Atypical antipsychotic; Clozapine; Pharmacotherapy; Retrospective cohort study; Dopamine antagonist; Psychiatry; Pediatrics; Internal medicine; Anesthesia; Psychosis; Haloperidol","score_opus":0.05771796142956127,"score_gpt":0.3873884926423954,"score_spread":0.32967053121283413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007223681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9695026,0.025691582,0.00020805749,0.0000912408,0.00004692233,0.0003739553,0.0027346725,0.000009742399,0.0013412349],"genre_scores_gemma":[0.9895042,0.0061264057,0.00039516026,0.0003643344,0.000064062704,0.00030111257,0.002972875,0.000009190734,0.00026272723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995488,0.0010712038,0.001984233,0.00057424314,0.00066651433,0.00021593922],"domain_scores_gemma":[0.97928804,0.0068150824,0.0095839165,0.0006979988,0.0028910162,0.0007238594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020555826,0.00027463606,0.001275455,0.0025071227,0.00074428145,0.0012473245,0.0005994079,0.00056398596,0.001195552],"category_scores_gemma":[0.012413831,0.00036092743,0.00095410337,0.003634978,0.00069303723,0.0006596797,0.0005922791,0.0004067446,0.00025743758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006233366,0.00034854948,0.96116954,0.008198088,0.0022121458,0.0030604438,0.0013672232,0.000070783426,0.0012750546,0.00015203086,0.00098913,0.014923721],"study_design_scores_gemma":[0.00064475846,0.0036775582,0.97210497,0.0013707299,0.003665487,0.010224036,0.0021510313,0.0000716121,0.000811078,0.00005499772,0.00516118,0.000062550476],"about_ca_topic_score_codex":0.005571803,"about_ca_topic_score_gemma":0.008478357,"teacher_disagreement_score":0.005571803,"about_ca_system_score_codex":0.0019049639,"about_ca_system_score_gemma":0.0026087153,"threshold_uncertainty_score":0.013821542},"labels":[],"label_agreement":null},{"id":"W2009098521","doi":"10.2165/00044011-200019030-00007","title":"LIPI-WATCH, a Belgian/Luxembourg Survey on Achievement of European Atherosclerosis Society Lipid Goals","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"European Atherosclerosis Society","keywords":"Medicine; Body mass index; Internal medicine; Diabetes mellitus; Coronary heart disease; Lipid profile; Risk factor; Cholesterol; Endocrinology","score_opus":0.07260013807781045,"score_gpt":0.3247633831257585,"score_spread":0.252163245047948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009098521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84455436,0.0040947204,0.00061435945,0.001921619,0.00018181391,0.0002390904,0.1414085,0.000121098,0.0068644453],"genre_scores_gemma":[0.8795764,0.0019498493,0.0009642219,0.0011575696,0.00015492497,0.0004923407,0.10694417,0.0000747941,0.008685623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994073,0.00014753033,0.000066803696,0.000088523644,0.00011258507,0.00017723793],"domain_scores_gemma":[0.998706,0.00014650416,0.00040632195,0.000060013135,0.00028810755,0.0003930722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001131065,0.00043966834,0.00047117146,0.0017571152,0.00029287036,0.0007963326,0.00042336728,0.00064687774,0.0015976507],"category_scores_gemma":[0.0027196775,0.00024476572,0.00033113812,0.002718246,0.0001471134,0.00044030944,0.0006406942,0.00065731624,0.0005118686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040611622,0.00011060508,0.96448207,0.00012798932,0.00016229312,0.00013187519,0.0003575147,0.00022621242,0.000454425,0.00013625315,0.024563864,0.008840806],"study_design_scores_gemma":[0.00002154917,0.00004520384,0.99500126,0.00001537681,0.000027348284,0.000039502498,0.00014652498,0.00006237124,0.000036459183,0.000007032394,0.004594117,0.0000032302323],"about_ca_topic_score_codex":0.18649107,"about_ca_topic_score_gemma":0.16940768,"teacher_disagreement_score":0.18649107,"about_ca_system_score_codex":0.0017267624,"about_ca_system_score_gemma":0.0020289817,"threshold_uncertainty_score":0.37081116},"labels":[],"label_agreement":null},{"id":"W2021841808","doi":"10.2165/11537460-000000000-00000","title":"Mycophenolate Mofetil in the Treatment of Adults with Advanced Rheumatoid Arthritis","year":2010,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Mycophenolate; Rheumatoid arthritis; Internal medicine; Ciclosporin; Placebo; Adverse effect; Rheumatism; Mycophenolic acid; Gastroenterology; Refractory (planetary science); Transplantation; Pathology","score_opus":0.01971433525382949,"score_gpt":0.31069815578278737,"score_spread":0.2909838205289579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021841808","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4608657,0.51223016,0.0006588329,0.007882311,0.0011410284,0.00015325885,0.00042209923,0.00011876088,0.016527789],"genre_scores_gemma":[0.8699893,0.11889558,0.0015332748,0.003994257,0.0015055212,0.00010104993,0.00037810666,0.0000094701345,0.0035934176],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99974126,0.000102236634,0.000036499514,0.0000184196,0.000066501525,0.00003509903],"domain_scores_gemma":[0.99961096,0.00013382037,0.000086077875,0.000007442541,0.000039695537,0.00012208911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005000193,0.00024579096,0.0007357313,0.0003352961,0.0002530292,0.00021238557,0.00017914818,0.0005644172,0.0013561783],"category_scores_gemma":[0.00091780873,0.0000682658,0.00031079148,0.00034578107,0.00015669895,0.00022794245,0.00015972844,0.0010323604,0.00031553346],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026751975,0.0011298304,0.03693991,0.0019268208,0.00037860838,0.0028667292,0.0002177558,0.00031841142,0.009857592,0.00051506114,0.013327551,0.90576977],"study_design_scores_gemma":[0.033210345,0.07703395,0.5666967,0.0032982852,0.003169822,0.03147755,0.0007911001,0.0020354516,0.009958938,0.0016767111,0.2705369,0.000114227536],"about_ca_topic_score_codex":0.0013350626,"about_ca_topic_score_gemma":0.0037145265,"teacher_disagreement_score":0.0013561783,"about_ca_system_score_codex":0.00020775509,"about_ca_system_score_gemma":0.00048822438,"threshold_uncertainty_score":0.004536867},"labels":[],"label_agreement":null},{"id":"W2030320412","doi":"10.2165/11633550-000000000-00000","title":"Pharmacokinetics of a New Immediate-Release Methadone Tablet Formulation with Decreased In vitro Solubility","year":2012,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Paladin Labs (Canada)","funders":"","keywords":"Cmax; Pharmacokinetics; Bioavailability; Crossover study; Methadone; Pharmacology; Medicine; Solubility; Elimination rate constant; Bioequivalence; Chromatography; Chemistry; Volume of distribution","score_opus":0.06093009706750442,"score_gpt":0.3502869022208261,"score_spread":0.2893568051533217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030320412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968027,0.0014900138,0.00087562617,0.00009045462,0.000035725086,0.000057961603,0.00012353413,0.000028162422,0.00049584446],"genre_scores_gemma":[0.9964695,0.0008551408,0.0015239737,0.0000428237,0.000024413033,0.000021948723,0.0001791742,0.000012891772,0.0008699632],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99986625,0.000035091572,0.00000994853,0.000031990512,0.00003590799,0.000020900168],"domain_scores_gemma":[0.9998265,0.0000760561,0.00004396327,0.000012433165,0.000016210954,0.000024832214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023982767,0.00023406128,0.000369652,0.00011621086,0.0001418987,0.00028869175,0.00031709316,0.00028776212,0.0012790138],"category_scores_gemma":[0.00053801405,0.00020571318,0.00024535428,0.000094109455,0.00021491498,0.00034031447,0.000088697794,0.00065242994,0.00018531672],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017038997,0.0014399282,0.001134694,0.0002614877,0.000076727236,0.00061606726,0.00019970928,0.0009539629,0.9310021,0.00023247706,0.00054059725,0.04650341],"study_design_scores_gemma":[0.005824588,0.10459696,0.030728623,0.000039274833,0.00051451736,0.0046456684,0.00014730319,0.014213643,0.83026624,0.00009819069,0.008816257,0.00010870336],"about_ca_topic_score_codex":0.0010357556,"about_ca_topic_score_gemma":0.0013403728,"teacher_disagreement_score":0.0012790138,"about_ca_system_score_codex":0.00024106381,"about_ca_system_score_gemma":0.00030380354,"threshold_uncertainty_score":0.004278779},"labels":[],"label_agreement":null},{"id":"W2037415449","doi":"10.1007/s40261-013-0092-y","title":"Effectiveness and Tolerability of a Trandolapril-Based Antihypertensive Treatment Regimen over 12 months in Actual Clinical Care Across Canada","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Abbott (Canada); Hamilton Health Sciences","funders":"","keywords":"Medicine; Trandolapril; Tolerability; Regimen; Renal function; Internal medicine; Diabetes mellitus; Blood pressure; Adverse effect; ACE inhibitor; Angiotensin-converting enzyme; Endocrinology","score_opus":0.05152526555235366,"score_gpt":0.3504815952297871,"score_spread":0.29895632967743346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037415449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976895,0.0007558263,0.000019896019,0.00021256712,0.0000050740045,0.00003106504,0.00044729045,0.0000028017896,0.00083598617],"genre_scores_gemma":[0.99904984,0.0003839249,0.00006411906,0.00008615444,0.0000035763287,0.0000074241752,0.00022786098,0.0000015091357,0.00017549458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982157,0.00041774378,0.0001704866,0.00021777344,0.0005172507,0.00046108908],"domain_scores_gemma":[0.9938983,0.0006157077,0.0013234961,0.00012889208,0.0025728925,0.0014608555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013356056,0.00017549607,0.0004947928,0.0004812945,0.001815694,0.0012121127,0.0008732915,0.0003718164,0.0008760881],"category_scores_gemma":[0.0065532257,0.0002559476,0.000542294,0.0021293438,0.0008228237,0.0004608545,0.0004894907,0.00072561024,0.0000736077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002775212,0.0005116468,0.97326916,0.00018477185,0.00031429314,0.00011685901,0.0022962764,0.0004239311,0.0004822706,0.00013470158,0.001008634,0.018482227],"study_design_scores_gemma":[0.00012935154,0.0005937414,0.99705803,0.000039352555,0.00012452186,0.000036560057,0.0012768438,0.000229761,0.000097983866,0.000009648322,0.00038713572,0.000017117634],"about_ca_topic_score_codex":0.9856741,"about_ca_topic_score_gemma":0.9913823,"teacher_disagreement_score":0.033970166,"about_ca_system_score_codex":0.033970166,"about_ca_system_score_gemma":0.02917894,"threshold_uncertainty_score":0.24647194},"labels":[],"label_agreement":null},{"id":"W2040543869","doi":"10.2165/00044011-200121040-00007","title":"Bioequivalence Study of Two Formulations (Sachet and Tablet) of Cefixime after Single Oral Doses of 200mg in Healthy Male Volunteers","year":2001,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Bioequivalence; Cmax; Cefixime; Medicine; Bioavailability; Pharmacokinetics; Pharmacology; Crossover study; Confidence interval; Tolerability; Dosage form; Internal medicine; Adverse effect; Chemistry; Antibiotics; Cephalosporin; Placebo","score_opus":0.09374060141338489,"score_gpt":0.40408994518102703,"score_spread":0.3103493437676421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040543869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99762684,0.0006006552,0.00056346157,0.00006523923,0.00010346012,0.00029719423,0.00022587038,0.000039334358,0.00047801077],"genre_scores_gemma":[0.9959202,0.00035164066,0.0010082263,0.0001482174,0.00014808543,0.00041111,0.00033189193,0.00002192169,0.001658641],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9985267,0.0006924653,0.000093766204,0.00039408324,0.0001759972,0.00011693858],"domain_scores_gemma":[0.99843293,0.0005613242,0.00024299393,0.0002419748,0.00023210759,0.00028857097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021451132,0.0012247966,0.0025746673,0.000448143,0.00060331397,0.0007171807,0.00047400472,0.0019529262,0.003762392],"category_scores_gemma":[0.0035581142,0.0011120818,0.0010797915,0.00034639196,0.0011285444,0.0010681413,0.00031603262,0.001705724,0.0010159096],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84960175,0.021572316,0.0058116876,0.00060187746,0.0007753211,0.00021191915,0.0012739954,0.0006248209,0.08632087,0.00046411145,0.00072148873,0.032019895],"study_design_scores_gemma":[0.091369085,0.7677201,0.09610861,0.000054591936,0.0026736748,0.00078323856,0.00068178604,0.005785981,0.030697161,0.0004053867,0.003508763,0.00021157278],"about_ca_topic_score_codex":0.0012880316,"about_ca_topic_score_gemma":0.0007971449,"teacher_disagreement_score":0.003762392,"about_ca_system_score_codex":0.00039505438,"about_ca_system_score_gemma":0.000541757,"threshold_uncertainty_score":0.012586474},"labels":[],"label_agreement":null},{"id":"W2059248961","doi":"10.2165/11599870-000000000-00000","title":"Randomized Open-Label Drug-Drug Interaction Trial of Dextromethorphan/Quinidine and Paroxetine in Healthy Volunteers","year":2012,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Respiratory and Cough-Related Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Dextromethorphan; Paroxetine; CYP2D6; Medicine; Pharmacokinetics; Pharmacology; Quinidine; Drug interaction; Randomized controlled trial; Crossover study; Anesthesia; Internal medicine; Placebo; Cytochrome P450; Serotonin","score_opus":0.1980616557976609,"score_gpt":0.4780799159940573,"score_spread":0.2800182601963964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059248961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944224,0.0010646745,0.00046947808,0.00034512515,0.00045308424,0.001579058,0.00061039784,0.00009710399,0.0009587592],"genre_scores_gemma":[0.9924608,0.000681611,0.0010421033,0.0006896568,0.0005280012,0.0017102738,0.00074038724,0.000029550878,0.002117652],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981938,0.0009184551,0.000109401706,0.00044367713,0.00010320289,0.0002315089],"domain_scores_gemma":[0.9975624,0.00076893304,0.0004382241,0.0002775817,0.00020429994,0.00074856635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024638753,0.0027015796,0.0061997287,0.0005760232,0.0012402441,0.0012519307,0.001376505,0.0030011896,0.007621192],"category_scores_gemma":[0.0037527634,0.0016451267,0.0023789734,0.00042210467,0.0023844785,0.0021291715,0.0007734251,0.003775277,0.0015812222],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99156874,0.0037855208,0.00043354605,0.000088959525,0.0005091187,0.000030527568,0.000027312613,0.00007545031,0.001164229,0.00002835743,0.00018144229,0.0021068873],"study_design_scores_gemma":[0.9174161,0.077378824,0.0031742137,0.000009646053,0.000739058,0.000041271825,0.00003335776,0.00040239462,0.00036245852,0.00009507038,0.00032198324,0.000025663116],"about_ca_topic_score_codex":0.002584604,"about_ca_topic_score_gemma":0.0044270707,"teacher_disagreement_score":0.007621192,"about_ca_system_score_codex":0.0013272788,"about_ca_system_score_gemma":0.0012924112,"threshold_uncertainty_score":0.02549547},"labels":[],"label_agreement":null},{"id":"W2059623829","doi":"10.1007/bf03261913","title":"Effect of Ketoconazole on the Pharmacokinetic Profile of Buprenorphine following Administration of a Once-Weekly Buprenorphine Transdermal System","year":2012,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"Ketoconazole; Medicine; Buprenorphine; Cmax; Pharmacokinetics; Placebo; Crossover study; Pharmacology; Confidence interval; Transdermal; Area under the curve; Anesthesia; Internal medicine; Opioid","score_opus":0.10642077970965888,"score_gpt":0.43825656655936307,"score_spread":0.33183578684970416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059623829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991999,0.00021109649,0.00015192678,0.000044644166,0.000030304618,0.000014317592,0.000055052846,0.000020513815,0.0002722751],"genre_scores_gemma":[0.9993856,0.000086094085,0.00011170682,0.00003030629,0.000016932992,0.0000039757633,0.000059711663,0.0000069085945,0.00029877393],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999607,0.00014914296,0.000031848078,0.000046504745,0.00007430934,0.000091213704],"domain_scores_gemma":[0.99862003,0.0006803475,0.00023134043,0.00015295102,0.00009179227,0.00022355984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047144256,0.00029676463,0.00072033604,0.00016694654,0.00023960027,0.0005303141,0.00024178794,0.00046364454,0.001550991],"category_scores_gemma":[0.0030947425,0.00020208705,0.00045694356,0.00023201335,0.00050789793,0.0006198546,0.00012376884,0.0011653512,0.00025867464],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5091217,0.0053779604,0.020933669,0.00016503046,0.0004491239,0.0013657962,0.0006016135,0.0016543474,0.3686666,0.00019544565,0.0007249322,0.09074381],"study_design_scores_gemma":[0.005811643,0.20001708,0.35495463,0.000034340563,0.001149774,0.0035653242,0.00057833595,0.01772391,0.41268855,0.00019590068,0.0031457366,0.00013479294],"about_ca_topic_score_codex":0.002706439,"about_ca_topic_score_gemma":0.0033064303,"teacher_disagreement_score":0.002706439,"about_ca_system_score_codex":0.00039873543,"about_ca_system_score_gemma":0.00056236703,"threshold_uncertainty_score":0.0053814054},"labels":[],"label_agreement":null},{"id":"W2059944626","doi":"10.1007/s40261-013-0079-8","title":"Pharmacokinetics and Dose Proportionality of Fentanyl Sublingual Spray: a Single-Dose 5-Way Crossover Study","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AXYS Technologies (Canada)","funders":"","keywords":"Fentanyl; Medicine; Crossover study; Sublingual administration; Pharmacokinetics; Anesthesia; Adverse effect; Bioavailability; Pharmacology; Placebo","score_opus":0.08705137726059048,"score_gpt":0.3785797956719751,"score_spread":0.2915284184113846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059944626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936319,0.00060619327,0.0025349306,0.00010774235,0.00021638576,0.0016455554,0.00055829005,0.00016026886,0.00053867174],"genre_scores_gemma":[0.99192023,0.000577687,0.0025181798,0.00027467724,0.00036780216,0.0012559239,0.00049098587,0.00020636317,0.0023882189],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99092114,0.004354997,0.00062320486,0.0019402918,0.0012736077,0.000886698],"domain_scores_gemma":[0.9903792,0.0032445015,0.0021321238,0.0022624042,0.00072271726,0.0012591569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072447467,0.0026232067,0.0068500233,0.0012938374,0.0010546353,0.0021938828,0.0025054954,0.0025344952,0.0056966734],"category_scores_gemma":[0.010446604,0.002704868,0.0039093364,0.0012711702,0.0039753537,0.0039237626,0.0008130605,0.0052784816,0.001518759],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9126674,0.032989644,0.0023604368,0.00029609134,0.0011346888,0.00010174045,0.00058760087,0.0011881427,0.03163909,0.00023229442,0.00052651967,0.0162763],"study_design_scores_gemma":[0.31183803,0.6292238,0.031068316,0.000035845387,0.0016916409,0.00040693537,0.0001812006,0.0060077487,0.017116804,0.000529316,0.0016554857,0.00024480556],"about_ca_topic_score_codex":0.001961694,"about_ca_topic_score_gemma":0.0011743216,"teacher_disagreement_score":0.0072447467,"about_ca_system_score_codex":0.0016908959,"about_ca_system_score_gemma":0.002568496,"threshold_uncertainty_score":0.038314342},"labels":[],"label_agreement":null},{"id":"W2062703060","doi":"10.2165/00044011-200222030-00008","title":"Stevens-Johnson Syndrome Associated with Codeine in a Child","year":2002,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Codeine; Medicine; Pharmacotherapy; Pediatrics; Psychiatry; Pharmacology; Morphine","score_opus":0.07096297443176268,"score_gpt":0.3095869458347072,"score_spread":0.2386239714029445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062703060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769607,0.0021866052,0.0010152347,0.003350899,0.0003222496,0.0001931125,0.00034402654,0.0001833512,0.015443814],"genre_scores_gemma":[0.9958646,0.0010383447,0.0007350562,0.00086873554,0.00015024218,0.000024086225,0.00009560143,0.000024624704,0.0011987241],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9994968,0.00006789401,0.00006500958,0.000057342317,0.00012121067,0.0001916704],"domain_scores_gemma":[0.9984328,0.00043525442,0.00036157365,0.00008751994,0.00013679948,0.0005460756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025079073,0.00093615305,0.00085391424,0.0013596353,0.0018973146,0.0008380321,0.00076867413,0.0028642372,0.0017657998],"category_scores_gemma":[0.0025748056,0.000538022,0.0010478097,0.0007745008,0.001196097,0.00091616437,0.0007111019,0.0033037849,0.00042601253],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006144929,0.00010528321,0.013311558,0.000046036825,0.000011787782,0.98312646,0.00019372728,0.00006153544,0.001071666,0.0002417177,0.00046493593,0.0013038617],"study_design_scores_gemma":[0.000026700975,0.0004625207,0.031017004,0.00003391469,0.00003835455,0.9650081,0.00030644966,0.00031534868,0.0012742812,0.00009148587,0.0014116945,0.000014174061],"about_ca_topic_score_codex":0.009130981,"about_ca_topic_score_gemma":0.01335185,"teacher_disagreement_score":0.009130981,"about_ca_system_score_codex":0.0017491616,"about_ca_system_score_gemma":0.001473508,"threshold_uncertainty_score":0.018155694},"labels":[],"label_agreement":null},{"id":"W2063846810","doi":"10.2165/00044011-200019040-00003","title":"Theoretical Basis for Loxapine Augmentation in Risperidone Partial Responders","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Riverview Hospital; University of British Columbia","funders":"","keywords":"Risperidone; Medicine; Pharmacology; Antipsychotic; Pharmacodynamics; Dopamine receptor D2; Atypical antipsychotic; Pharmacokinetics; Schizophrenia (object-oriented programming); Internal medicine; Dopamine; Psychiatry","score_opus":0.06441166863861404,"score_gpt":0.400540279129865,"score_spread":0.336128610491251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063846810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38312632,0.0059377146,0.1746063,0.17773317,0.0012607065,0.00091827614,0.0012219623,0.0009554915,0.25424007],"genre_scores_gemma":[0.98638886,0.0004927022,0.0077935876,0.0024288984,0.00026863962,0.00020495364,0.00009666315,0.000018120736,0.0023075081],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99900913,0.00041439256,0.000064359665,0.00018721524,0.00018916141,0.00013584201],"domain_scores_gemma":[0.99660456,0.002528749,0.00024898042,0.0002020985,0.00019115169,0.00022439194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021968747,0.00049397565,0.0006310879,0.0011657926,0.0008812341,0.0020114502,0.001120308,0.0021133118,0.009751425],"category_scores_gemma":[0.0074659633,0.0003683922,0.00083335064,0.00028581836,0.002434354,0.0015644529,0.0013076732,0.0017159521,0.00094824133],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028401392,0.0010355014,0.011208078,0.0003943921,0.00012220611,0.0013574229,0.00059866265,0.011368886,0.005885559,0.8739994,0.0069472147,0.08424254],"study_design_scores_gemma":[0.0017023904,0.0019600785,0.009764349,0.0002071868,0.00025249823,0.0042045773,0.0007029315,0.07268656,0.0044239177,0.8899004,0.014103227,0.00009188993],"about_ca_topic_score_codex":0.0010106681,"about_ca_topic_score_gemma":0.0011589763,"teacher_disagreement_score":0.009751425,"about_ca_system_score_codex":0.0019693119,"about_ca_system_score_gemma":0.0028162731,"threshold_uncertainty_score":0.0326218},"labels":[],"label_agreement":null},{"id":"W2069015817","doi":"10.2165/00044011-200424020-00003","title":"Oxybutynin Extended Release and Tolterodine Immediate Release","year":2004,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Radiation Oncology; McGill University; Royal Victoria Hospital","funders":"","keywords":"Oxybutynin; Tolterodine; Overactive bladder; Medicine; Urology; Extended release; Pharmacology","score_opus":0.060921529881403896,"score_gpt":0.3717230359503727,"score_spread":0.31080150606896884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069015817","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95631003,0.032776535,0.0020950418,0.00052263733,0.0003264909,0.00022812182,0.00037675115,0.00009068246,0.007273668],"genre_scores_gemma":[0.9823186,0.006270727,0.0016119664,0.00026345326,0.00022198787,0.00008922114,0.00036954024,0.000021708109,0.008832771],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997477,0.000058042555,0.000023435348,0.00004795615,0.0000568083,0.000065923676],"domain_scores_gemma":[0.99963486,0.00014274084,0.00007300501,0.00004397803,0.000018374867,0.000086994005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047360524,0.0002458193,0.0005475941,0.00020337422,0.0001258861,0.00037089046,0.00044486078,0.0004813261,0.0029022568],"category_scores_gemma":[0.0008523067,0.00010849238,0.0003800682,0.00015840963,0.00042465562,0.00051056006,0.0002113702,0.00089194777,0.0003755061],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18630013,0.0027013198,0.0094553875,0.0012598302,0.00028575314,0.0041582943,0.0003965973,0.0005922355,0.27419576,0.0020516454,0.0013760973,0.51722693],"study_design_scores_gemma":[0.063754775,0.31928593,0.25192636,0.0005164584,0.0013236575,0.02727593,0.00088906597,0.0028487346,0.2595021,0.0014856841,0.0709636,0.00022778206],"about_ca_topic_score_codex":0.00046954438,"about_ca_topic_score_gemma":0.0011088125,"teacher_disagreement_score":0.0029022568,"about_ca_system_score_codex":0.00030978126,"about_ca_system_score_gemma":0.000332461,"threshold_uncertainty_score":0.00970906},"labels":[],"label_agreement":null},{"id":"W2073529780","doi":"10.1007/s40261-013-0088-7","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Tolerability; Pharmacodynamics; Pharmacokinetics; Crossover study; Dosing; Adverse effect; Ipratropium bromide; Placebo; Anesthesia; COPD; Tiotropium bromide; Pharmacology; Bronchodilator; Internal medicine; Asthma; Lung","score_opus":0.0649579216921815,"score_gpt":0.4054841485212134,"score_spread":0.3405262268290319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073529780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401605,0.0021370808,0.0008427459,0.00014130534,0.00008920495,0.0017858574,0.000464122,0.000059806553,0.00046377775],"genre_scores_gemma":[0.9923592,0.001394913,0.0017367523,0.0003867015,0.00029881747,0.0019237134,0.0007425337,0.000030430901,0.0011269567],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949603,0.0031589642,0.00044343784,0.00067924906,0.0003423269,0.00041567403],"domain_scores_gemma":[0.9932372,0.0027863474,0.0018205458,0.0009275233,0.0004073017,0.0008210884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057559335,0.00224061,0.0047007673,0.00064955367,0.0008253554,0.0011977536,0.0016204857,0.0031165709,0.0040725507],"category_scores_gemma":[0.0066155773,0.0013659748,0.0036008253,0.000750186,0.0029234888,0.001651658,0.00075216417,0.0026470881,0.00072013255],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9840316,0.0049236165,0.0012683233,0.00019792932,0.0009871662,0.000028827822,0.00005331648,0.00014541627,0.0023178228,0.000025044996,0.00008637603,0.0059345257],"study_design_scores_gemma":[0.78947234,0.19875363,0.007545268,0.000021253501,0.0018868182,0.00006918719,0.000046908244,0.00032726393,0.0013680507,0.000099997465,0.00036218495,0.000047077785],"about_ca_topic_score_codex":0.0012917792,"about_ca_topic_score_gemma":0.0015255888,"teacher_disagreement_score":0.0057559335,"about_ca_system_score_codex":0.0012366028,"about_ca_system_score_gemma":0.0011824431,"threshold_uncertainty_score":0.030440629},"labels":[],"label_agreement":null},{"id":"W2073707487","doi":"10.2165/00044011-200020020-00007","title":"Pharmacokinetics of Estradiol Valerate 2mg + Dienogest 2mg (Climodien?? 2/2) after Single and Repeated Oral Administration in Healthy Postmenopausal Women","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Menopause: Health Impacts and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Dienogest; Estrone; Estradiol valerate; Pharmacokinetics; Tolerability; Medicine; Endocrinology; Estrogen; Internal medicine; Valerate; Sex hormone-binding globulin; Hormone; Oral administration; Area under the curve; Pharmacology; Adverse effect; Androgen; Chemistry; Endometriosis","score_opus":0.07500335401889527,"score_gpt":0.3791222907515989,"score_spread":0.3041189367327036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073707487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969528,0.0015559888,0.00028239674,0.00006155076,0.000048979968,0.00006876365,0.0003151256,0.00004529716,0.00066904887],"genre_scores_gemma":[0.9962907,0.00070483674,0.00033289084,0.00010772386,0.00009203203,0.000059167804,0.0003619804,0.0000280722,0.0020225665],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994949,0.00021181066,0.000026503225,0.000110637775,0.0000926611,0.0000634931],"domain_scores_gemma":[0.99914694,0.0003049407,0.00016166037,0.00009583807,0.000086885564,0.00020380998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065331074,0.00060399796,0.0012731447,0.0004223913,0.0003637291,0.00064026023,0.00033242043,0.00094919314,0.002611655],"category_scores_gemma":[0.0028616674,0.00073250406,0.0008328179,0.00037872564,0.0006236343,0.0007530216,0.00019437488,0.0010703014,0.0007515391],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7161678,0.005814512,0.04401914,0.00033328228,0.0012070063,0.0011393433,0.0010828335,0.0022072324,0.15291567,0.0002532776,0.0013238627,0.073536],"study_design_scores_gemma":[0.022678085,0.26802525,0.6092014,0.00006351095,0.0033627604,0.003328109,0.0011598271,0.011242603,0.07268156,0.0005027442,0.0074697547,0.0002843596],"about_ca_topic_score_codex":0.004152612,"about_ca_topic_score_gemma":0.0029304635,"teacher_disagreement_score":0.004152612,"about_ca_system_score_codex":0.0004744699,"about_ca_system_score_gemma":0.00062003394,"threshold_uncertainty_score":0.008736908},"labels":[],"label_agreement":null},{"id":"W2074097337","doi":"10.1007/s40261-013-0110-0","title":"Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Allergic Rhinitis and Sensitization","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"","keywords":"Medicine; Pharmacokinetics; Renal function; Antihistamine; Urology; Internal medicine; Pharmacology","score_opus":0.08899851646535378,"score_gpt":0.329584416136197,"score_spread":0.2405858996708432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074097337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99927205,0.00020914369,0.00019974928,0.00000845767,0.0000027750402,0.000057696798,0.000054254288,0.000009738712,0.00018616],"genre_scores_gemma":[0.999337,0.00007517063,0.000264477,0.000025758662,0.0000088775905,0.00005132385,0.00009422038,0.0000029012451,0.00014019047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996861,0.00011895329,0.00002302615,0.0000740579,0.000060967308,0.000036901176],"domain_scores_gemma":[0.99924123,0.00022506478,0.00022133598,0.00005677281,0.000089346584,0.00016630092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009370486,0.00035492933,0.00081271277,0.0002493547,0.00034225296,0.00034616073,0.00018623626,0.0003628911,0.0015652708],"category_scores_gemma":[0.001289063,0.00014478146,0.0002744366,0.00022590776,0.0002951746,0.00034318498,0.00019561836,0.00045289894,0.00028940054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14033386,0.009337671,0.6679612,0.0004092579,0.00068859645,0.001088511,0.0010446676,0.0015915286,0.11492948,0.00009246028,0.00047153697,0.062051274],"study_design_scores_gemma":[0.0026469484,0.13838647,0.8367213,0.000014076096,0.00041828473,0.0021897145,0.00031479922,0.0019507093,0.016019404,0.000065826986,0.0012463186,0.000026172234],"about_ca_topic_score_codex":0.00037252615,"about_ca_topic_score_gemma":0.00035185931,"teacher_disagreement_score":0.0015652708,"about_ca_system_score_codex":0.00026707866,"about_ca_system_score_gemma":0.0002738634,"threshold_uncertainty_score":0.0052363873},"labels":[],"label_agreement":null},{"id":"W2077423491","doi":"10.2165/11598940-000000000-00000","title":"Cost-Effectiveness and Cost-Utility of Beclomethasone/Formoterol versus Fluticasone Propionate/Salmeterol in Patients with Moderate to Severe Asthma","year":2012,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institute for Theoretical Astrophysics; Chiesi Farmaceutici","keywords":"Salmeterol; Fluticasone propionate; Medicine; Formoterol; Asthma; Exacerbation; Fluticasone; Quality-adjusted life year; Quality of life (healthcare); Pediatrics; Cost effectiveness; Emergency medicine; Budesonide; Internal medicine","score_opus":0.08262178632127089,"score_gpt":0.3634312461936802,"score_spread":0.28080945987240935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077423491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98736715,0.00954649,0.00020528238,0.00094451325,0.00008252231,0.000074136995,0.00037464005,0.0000083091245,0.001397012],"genre_scores_gemma":[0.9988593,0.00062622764,0.00013760758,0.00009469326,0.000038166392,0.000013453551,0.00014219251,0.0000010311354,0.00008723077],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9989054,0.00070938724,0.00008110137,0.0000662369,0.000103123915,0.00013477154],"domain_scores_gemma":[0.9980192,0.0014115382,0.0002179319,0.000047743208,0.00006398808,0.00023951942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013471113,0.0005527299,0.0016053122,0.00055360806,0.00025977942,0.00090934016,0.0004744396,0.0011137516,0.0023762656],"category_scores_gemma":[0.0058507593,0.00032081598,0.0032434326,0.00065074547,0.00046338432,0.00087595085,0.00045324836,0.0011285653,0.000116566225],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5908193,0.004164493,0.21588635,0.0020971994,0.012469325,0.0011088403,0.00025054236,0.043778934,0.0028433574,0.0017643305,0.0022717658,0.12254554],"study_design_scores_gemma":[0.082098596,0.07436783,0.69310254,0.0007871264,0.03460928,0.0021882898,0.001587613,0.10261843,0.0023114765,0.003680425,0.0023735669,0.00027487392],"about_ca_topic_score_codex":0.0067556584,"about_ca_topic_score_gemma":0.0069964174,"teacher_disagreement_score":0.0067556584,"about_ca_system_score_codex":0.0017257902,"about_ca_system_score_gemma":0.00085528835,"threshold_uncertainty_score":0.013432682},"labels":[],"label_agreement":null},{"id":"W2078098902","doi":"10.2165/00044011-200020020-00005","title":"Mammographic Density in Postmenopausal Women Treated with Tibolone, Estriol or Conventional Hormone Replacement Therapy","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Trois-Rivieres; Cegep de Thetford","funders":"","keywords":"Tibolone; Medicine; Estriol; Medroxyprogesterone acetate; Hormone replacement therapy (female-to-male); Menopause; Estrogen; Medroxyprogesterone; Internal medicine; Gynecology; Urology; Testosterone (patch)","score_opus":0.027944960573764242,"score_gpt":0.2974984960247114,"score_spread":0.2695535354509472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078098902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967449,0.001610031,0.00003059149,0.000095061885,0.000019906965,0.00001119548,0.00014739952,0.0000046516093,0.001336205],"genre_scores_gemma":[0.9989021,0.00051041064,0.000030780713,0.00007522546,0.000032819593,0.0000071256577,0.0001327472,0.0000012056884,0.00030760656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99982977,0.00005179129,0.00002221584,0.000018544475,0.0000447506,0.000032965345],"domain_scores_gemma":[0.9993741,0.00025295484,0.00013268852,0.000019780877,0.00005934611,0.00016117736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028126448,0.00019532854,0.00051056565,0.00077697646,0.00032853853,0.0003647971,0.00018492874,0.0005271173,0.0014567113],"category_scores_gemma":[0.002988916,0.00018496666,0.0003767697,0.0008372583,0.00023754196,0.00019941574,0.00017472485,0.00045716183,0.000171252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007303538,0.00026877044,0.98184115,0.000042392843,0.00012652832,0.0012255714,0.00018016879,0.000093097144,0.0015915527,0.000030447587,0.00016417248,0.0071327393],"study_design_scores_gemma":[0.0001727244,0.0014115403,0.995719,0.000011175001,0.00020949222,0.0014155379,0.00021422817,0.00017648822,0.00022510542,0.00002898771,0.0004096321,0.0000061001506],"about_ca_topic_score_codex":0.007977063,"about_ca_topic_score_gemma":0.0075711515,"teacher_disagreement_score":0.007977063,"about_ca_system_score_codex":0.00046683228,"about_ca_system_score_gemma":0.00035736238,"threshold_uncertainty_score":0.015861273},"labels":[],"label_agreement":null},{"id":"W2080870880","doi":"10.1007/s40261-014-0195-0","title":"Clinical Pharmacokinetics of the Nicotinic Channel Modulator Dexmecamylamine (TC-5214) in Subjects with Various Degrees of Renal Impairment","year":2014,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Nicotinic Acetylcholine Receptors Study","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Pharmacokinetics; Nicotinic agonist; Pharmacotherapy; Pharmacology; Internal medicine; Receptor","score_opus":0.02027199749577582,"score_gpt":0.3037944552337191,"score_spread":0.2835224577379433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080870880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985134,0.0005306422,0.00015441311,0.000027596547,0.00000606816,0.000016209471,0.00014093533,0.000014126115,0.00059658213],"genre_scores_gemma":[0.99904066,0.00018833538,0.00009673655,0.000047171532,0.000013323944,0.000009468323,0.0001786896,0.0000057279562,0.0004198607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999752,0.0000841048,0.000017619222,0.000068271875,0.00004583736,0.000032061434],"domain_scores_gemma":[0.9992268,0.00025069556,0.00016061844,0.00006477545,0.00008101689,0.00021615098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003784035,0.00032707566,0.00060443394,0.00040449726,0.00031231582,0.00043651828,0.00017980841,0.00050954224,0.0012385336],"category_scores_gemma":[0.0018002661,0.00029612958,0.0002871381,0.00036489867,0.00030308435,0.0003884303,0.00014465244,0.0005627466,0.00026423557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10131241,0.0016266814,0.79254997,0.0001201317,0.0008960747,0.0018741798,0.00053630257,0.0010042867,0.063757464,0.00021004137,0.00059844146,0.035514083],"study_design_scores_gemma":[0.00083628856,0.010437675,0.9800545,0.0000086864065,0.00031298574,0.0010781498,0.00018112049,0.0013647897,0.004956768,0.00008777027,0.0006525715,0.000028640618],"about_ca_topic_score_codex":0.0024161842,"about_ca_topic_score_gemma":0.0024237717,"teacher_disagreement_score":0.0024161842,"about_ca_system_score_codex":0.00036161212,"about_ca_system_score_gemma":0.0002979434,"threshold_uncertainty_score":0.0048042536},"labels":[],"label_agreement":null},{"id":"W2082548041","doi":"10.2165/00044011-200525010-00004","title":"Dose Conversion and Cost???Effectiveness of Erythropoietic???Therapies in Chemotherapy-Related Anaemia","year":2005,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Medicine; Darbepoetin alfa; Epoetin alfa; Dosing; Confidence interval; Internal medicine; Chemotherapy; Oncology","score_opus":0.033923485562995154,"score_gpt":0.34490357357782436,"score_spread":0.31098008801482924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082548041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9320061,0.051079117,0.0012532359,0.0024701552,0.00017023187,0.00018482373,0.0008046839,0.000043905853,0.011987721],"genre_scores_gemma":[0.994224,0.0036022724,0.00068431615,0.00033473488,0.000068147434,0.000021480815,0.0002527919,0.000012223489,0.000800044],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998019,0.0014259365,0.00012122598,0.00005956613,0.00030284465,0.00007145373],"domain_scores_gemma":[0.99403834,0.0042997506,0.00093636423,0.00032579206,0.00022187087,0.00017788679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019557416,0.00020315542,0.0006245286,0.00050990493,0.0001166295,0.00075440964,0.0004919509,0.0005966167,0.003781935],"category_scores_gemma":[0.011942234,0.00016474907,0.0012461245,0.000706312,0.0004664244,0.0006983941,0.00023698523,0.0011326483,0.000270819],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18772377,0.0038399752,0.072137,0.001509077,0.0044017425,0.00043751314,0.00020157057,0.018514924,0.0056313137,0.008576911,0.003938794,0.6930874],"study_design_scores_gemma":[0.027103039,0.085030705,0.7454618,0.0015342828,0.013459991,0.0067768176,0.0006284919,0.0387909,0.024423221,0.01650216,0.04003701,0.00025159764],"about_ca_topic_score_codex":0.0019487863,"about_ca_topic_score_gemma":0.0016585096,"teacher_disagreement_score":0.003781935,"about_ca_system_score_codex":0.0019906217,"about_ca_system_score_gemma":0.0005155745,"threshold_uncertainty_score":0.01444298},"labels":[],"label_agreement":null},{"id":"W2094140885","doi":"10.1007/s40261-013-0071-3","title":"Pharmacokinetic and Pharmacodynamic Profile of Rosuvastatin in Patients with End-Stage Renal Disease on Chronic Haemodialysis","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"AstraZeneca","keywords":"Rosuvastatin; Medicine; Pharmacokinetics; Pharmacodynamics; Rosuvastatin Calcium; End stage renal disease; Urology; Dialysis; Population; Area under the curve; Internal medicine; Kidney disease; Pharmacology; Hemodialysis","score_opus":0.017598463046620848,"score_gpt":0.29924447481007505,"score_spread":0.2816460117634542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094140885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989318,0.0005107801,0.00011998228,0.00006101026,0.00000868268,0.000009792121,0.00007874425,0.000008238089,0.00027096065],"genre_scores_gemma":[0.9994665,0.00011677603,0.00011649983,0.00006788347,0.000017521343,0.000007890223,0.0000946161,0.0000031078207,0.000109307955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996082,0.00015014426,0.000042820135,0.00006251898,0.000072427836,0.00006389345],"domain_scores_gemma":[0.99919444,0.000300703,0.00014959682,0.00005089076,0.000054354423,0.0002500716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041282744,0.0002926959,0.0012177229,0.00021791873,0.00032761178,0.00065729214,0.00015710155,0.0005299781,0.0006315226],"category_scores_gemma":[0.002228677,0.0001937127,0.0006406677,0.00031362002,0.000256015,0.0004398897,0.00021461092,0.00087016134,0.00015286174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13335085,0.0021547345,0.7665657,0.00026388853,0.0017807254,0.0016650711,0.00087281887,0.001713224,0.035104927,0.0002486516,0.000786291,0.055493217],"study_design_scores_gemma":[0.0017473549,0.01708365,0.9709024,0.00002552719,0.00076446065,0.0017340742,0.00036220226,0.0028425504,0.002969877,0.00018380978,0.0013345928,0.000049526447],"about_ca_topic_score_codex":0.0010789129,"about_ca_topic_score_gemma":0.0010834818,"teacher_disagreement_score":0.0012177229,"about_ca_system_score_codex":0.00033992165,"about_ca_system_score_gemma":0.0003533308,"threshold_uncertainty_score":0.002466321},"labels":[],"label_agreement":null},{"id":"W2096365365","doi":"10.1007/s40261-015-0302-x","title":"Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System","year":2015,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); Santé Montérégie; Thornhill Medical (Canada)","funders":"","keywords":"Lapatinib; Medicine; Trastuzumab emtansine; Capecitabine; Trastuzumab; Adverse effect; Oncology; Internal medicine; Breast cancer; Clinical trial; Metastatic breast cancer; Taxane; Cancer; Colorectal cancer","score_opus":0.08230834484887428,"score_gpt":0.41124979316270993,"score_spread":0.32894144831383565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096365365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730652,0.015492222,0.00023708332,0.0024646525,0.000051104296,0.000087531975,0.002749824,0.000009562069,0.0058427267],"genre_scores_gemma":[0.99736744,0.0014254262,0.00008978382,0.00020520305,0.00003277827,0.000008382897,0.0005575282,0.0000020411376,0.0003114629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985967,0.00041547325,0.00011679375,0.00009434112,0.00053457567,0.00024206506],"domain_scores_gemma":[0.99642,0.0010125745,0.0013312118,0.00007588854,0.0007020434,0.00045828972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001291123,0.00022563072,0.0005565958,0.0006912012,0.00040313974,0.0011654716,0.0005005567,0.00044098968,0.0021847403],"category_scores_gemma":[0.0068046954,0.0001517085,0.0018484831,0.0010885964,0.00028518413,0.00037176308,0.00032438082,0.0010035516,0.00009193189],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06861283,0.0010778109,0.6650617,0.0013677428,0.006753197,0.0014961539,0.00039272007,0.020425748,0.004067893,0.003005144,0.007580639,0.22015846],"study_design_scores_gemma":[0.0016411814,0.0052754213,0.9733018,0.00024327284,0.0032746918,0.0010012612,0.00044397262,0.009231546,0.00079720357,0.0005330322,0.004185885,0.00007085906],"about_ca_topic_score_codex":0.20074634,"about_ca_topic_score_gemma":0.3257331,"teacher_disagreement_score":0.9880109,"about_ca_system_score_codex":0.011989092,"about_ca_system_score_gemma":0.0063926894,"threshold_uncertainty_score":0.3991558},"labels":[],"label_agreement":null},{"id":"W2097671393","doi":"10.1007/s40261-013-0080-2","title":"Cross-Over, Open-Label Trial of the Effects of Gabapentin versus Pregabalin on Painful Peripheral Neuropathy and Health-Related Quality of Life in Haemodialysis Patients","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Dialysis and Renal Disease Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"McGill University","keywords":"Pregabalin; Gabapentin; Medicine; Neuropathic pain; Anesthesia; Peripheral neuropathy; Quality of life (healthcare); McGill Pain Questionnaire; Crossover study; Randomized controlled trial; Internal medicine; Visual analogue scale; Diabetes mellitus","score_opus":0.10081858985071827,"score_gpt":0.3959633070533829,"score_spread":0.2951447172026646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097671393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979691,0.0006531652,0.00010903526,0.00014366941,0.00016049125,0.00024701853,0.00023225344,0.000024592257,0.0004606438],"genre_scores_gemma":[0.9967289,0.00051531644,0.0003582672,0.0003554605,0.0002467671,0.00044363886,0.0004243806,0.00001102208,0.000916184],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999311,0.00027822028,0.00005125872,0.00018701445,0.00004004708,0.00013255037],"domain_scores_gemma":[0.99809915,0.00055690494,0.00027917436,0.00018882263,0.00010982345,0.00076614495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014868652,0.0018653929,0.0038961526,0.00038418785,0.0007369941,0.001454745,0.0011036173,0.0017957465,0.0050081215],"category_scores_gemma":[0.0021479516,0.0009698074,0.0017907541,0.0003894455,0.001834259,0.0018711882,0.0005948549,0.0042300727,0.0008619796],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9896746,0.005361387,0.00033057173,0.00008044369,0.0003268024,0.000017415447,0.000024126297,0.000112346366,0.0011061948,0.000025747322,0.000089014524,0.0028512736],"study_design_scores_gemma":[0.87132174,0.12280739,0.004085691,0.000020625046,0.000474265,0.000040759034,0.000042442956,0.00042250787,0.0004553669,0.00010297525,0.00020320441,0.000023072447],"about_ca_topic_score_codex":0.002156692,"about_ca_topic_score_gemma":0.0029204753,"teacher_disagreement_score":0.0050081215,"about_ca_system_score_codex":0.0013383509,"about_ca_system_score_gemma":0.0011126831,"threshold_uncertainty_score":0.016753852},"labels":[],"label_agreement":null},{"id":"W2123457220","doi":"10.2165/00044011-200525120-00006","title":"Famciclovir for the Management of??Genital Herpes Simplex in Patients??with Inadequate Response to??Aciclovir or Valaciclovir","year":2005,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of British Columbia","funders":"","keywords":"Valaciclovir; Famciclovir; Aciclovir; Medicine; Genital herpes; Herpes Genitalis; Herpes simplex virus; Penciclovir; Dermatology; Pharmacotherapy; Virology; Herpesviridae; Internal medicine; Virus; Viral disease","score_opus":0.04670342193287763,"score_gpt":0.35732742689386937,"score_spread":0.31062400496099174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123457220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85229045,0.08854983,0.0021270306,0.01634587,0.0014075455,0.00015475164,0.00017243192,0.00015582162,0.038796276],"genre_scores_gemma":[0.9904479,0.0058501437,0.00058321195,0.0016398343,0.00033564522,0.000011927425,0.000058610156,0.0000074027707,0.0010653461],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988055,0.000041189247,0.00001493199,0.000010228925,0.000017793567,0.00003537914],"domain_scores_gemma":[0.99980015,0.000077229226,0.000035915957,0.000008245574,0.000015052214,0.00006346496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002593335,0.0001846146,0.00044917516,0.00027022784,0.0003300344,0.0002047344,0.0001856825,0.00058631704,0.0016731676],"category_scores_gemma":[0.0011835232,0.00009269306,0.0002941868,0.00016642411,0.00021814302,0.000253738,0.00013086211,0.0008218282,0.0002707679],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025102254,0.001172708,0.12912042,0.0013763122,0.00044935461,0.088605456,0.00046711456,0.00090944656,0.02263714,0.0014841103,0.031374373,0.69730127],"study_design_scores_gemma":[0.007162493,0.021381145,0.37208018,0.0019197544,0.000990938,0.44137624,0.0016892744,0.007101521,0.022165952,0.00411305,0.119868465,0.00015098152],"about_ca_topic_score_codex":0.00073861965,"about_ca_topic_score_gemma":0.0015280538,"teacher_disagreement_score":0.0016731676,"about_ca_system_score_codex":0.00029747564,"about_ca_system_score_gemma":0.00026355046,"threshold_uncertainty_score":0.0055972934},"labels":[],"label_agreement":null},{"id":"W2150339979","doi":"10.2165/11595370-000000000-00000","title":"Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus","year":2011,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo; McGill University","keywords":"Medicine; Type 2 Diabetes Mellitus; Pharmacotherapy; Diabetes mellitus; Secretion; Internal medicine; Type 2 diabetes; Gastroenterology; Pharmacology; Intensive care medicine; Endocrinology","score_opus":0.2086526985467771,"score_gpt":0.3294358003476996,"score_spread":0.1207831018009225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150339979","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041346747,0.9982407,0.00022349624,0.00024766868,0.00014229432,0.0000101493515,0.00001931641,0.000008817287,0.00069413485],"genre_scores_gemma":[0.002335065,0.996029,0.0005073528,0.0003744638,0.00020643196,0.000018670153,0.000042585834,0.0000016100718,0.00048486263],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998746,0.000025855605,0.00002547622,0.000020134408,0.00003961172,0.0000142680265],"domain_scores_gemma":[0.9998047,0.00010363002,0.00004268013,0.0000046380233,0.000029445737,0.000014969125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005200848,0.00090079766,0.0020307377,0.0014494861,0.0001411683,0.00059665996,0.0006479415,0.0007188168,0.0030689891],"category_scores_gemma":[0.00047800076,0.000232725,0.0007483991,0.0009780425,0.0003170587,0.00078463973,0.0004433659,0.0017529114,0.0009542756],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041485348,0.00024347335,0.0002338838,0.014009875,0.00024079633,0.00023009093,0.000027413384,0.00020243021,0.0024817127,0.0009353242,0.008822365,0.97215784],"study_design_scores_gemma":[0.0011701032,0.0017537695,0.005402709,0.008805309,0.0021424294,0.0034966045,0.00011883647,0.0005278069,0.0028675203,0.0028214701,0.9708203,0.00007313919],"about_ca_topic_score_codex":0.00051672006,"about_ca_topic_score_gemma":0.0016919441,"teacher_disagreement_score":0.0030689891,"about_ca_system_score_codex":0.00027581872,"about_ca_system_score_gemma":0.00049291714,"threshold_uncertainty_score":0.010266781},"labels":[],"label_agreement":null},{"id":"W2161313492","doi":"10.1007/s40261-014-0266-2","title":"Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks","year":2015,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"ViiV Healthcare; GlaxoSmithKline","keywords":"Darunavir; Dolutegravir; Raltegravir; Efavirenz; Medicine; Ritonavir; Integrase inhibitor; Pharmacology; Pharmacotherapy; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Internal medicine; Viral load","score_opus":0.15773271120190108,"score_gpt":0.42962761527089716,"score_spread":0.2718949040689961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161313492","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994018,0.00025195064,0.000018525774,0.000013874595,0.0000047514054,0.00002415302,0.0000964346,0.0000021683884,0.0001863204],"genre_scores_gemma":[0.9993697,0.00012354601,0.00008229327,0.00004202051,0.000010391862,0.000029340723,0.00022582218,9.853752e-7,0.00011598418],"study_design_codex":"randomized_trial","study_design_gemma":"systematic_review","domain_scores_codex":[0.9996184,0.00015117264,0.000048635335,0.00007115778,0.000060026843,0.000050568648],"domain_scores_gemma":[0.9991972,0.0002316203,0.00024478917,0.000039506853,0.00007760336,0.00020922496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009176566,0.0002853533,0.0009646951,0.0003045581,0.00020444374,0.00047068752,0.00018681283,0.00053179066,0.0010342401],"category_scores_gemma":[0.0013501476,0.00020524667,0.00056402304,0.00044169146,0.0002423294,0.00045405142,0.00018549987,0.00061814196,0.00015261865],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5690191,0.011232653,0.3335129,0.00049748784,0.0026329104,0.0006588576,0.00073465204,0.0012944575,0.031343106,0.00014090743,0.0005838677,0.048349146],"study_design_scores_gemma":[0.015356592,0.15372212,0.8216896,0.000044453398,0.0013906911,0.0004797059,0.00042199425,0.0018484328,0.003989593,0.0001206655,0.00089279196,0.00004345802],"about_ca_topic_score_codex":0.0007033505,"about_ca_topic_score_gemma":0.0010327076,"teacher_disagreement_score":0.0010342401,"about_ca_system_score_codex":0.00031414969,"about_ca_system_score_gemma":0.00022819272,"threshold_uncertainty_score":0.00485307},"labels":[],"label_agreement":null},{"id":"W2176476316","doi":"10.2165/00044011-200525120-00003","title":"Antihypertensive Effect of Irbesartan and Predictors of Response in Obesity-Associated Hypertension","year":2005,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton General Hospital; McMaster University","funders":"Sanofi","keywords":"Medicine; Irbesartan; Internal medicine; Blood pressure; Hydrochlorothiazide; Overweight; Tolerability; Body mass index; Diabetes mellitus; Obesity; Diastole; Nephropathy; Cardiology; Adverse effect; Endocrinology","score_opus":0.03470090359067777,"score_gpt":0.3112170291442123,"score_spread":0.2765161255535345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2176476316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977229,0.001397765,0.000055449607,0.000060599836,0.000021685488,0.000010190843,0.00009988232,0.00000476272,0.0006267622],"genre_scores_gemma":[0.9988213,0.00053486804,0.00009063468,0.00006332318,0.00008814515,0.00001132462,0.00015879676,0.000002840618,0.00022877465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989058,0.0006690374,0.00008954986,0.00008508591,0.00014995664,0.00010059512],"domain_scores_gemma":[0.99520856,0.002537088,0.00076803664,0.0002850261,0.00023437737,0.0009668634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002597111,0.00047464162,0.001063868,0.0005110031,0.0003583309,0.0007286019,0.00034628267,0.0006763158,0.0009862023],"category_scores_gemma":[0.004109428,0.00034692767,0.00089845626,0.0007721083,0.00034748923,0.00064476655,0.00027701596,0.0016261842,0.00021807919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054640718,0.002404519,0.9221254,0.00014953487,0.0020670677,0.00019866665,0.00020161437,0.0002861198,0.00305332,0.000093390736,0.00023994414,0.01453965],"study_design_scores_gemma":[0.0007380457,0.004145543,0.9928576,0.000014931151,0.0008426123,0.00013625633,0.00009248863,0.00041044306,0.00043116204,0.000044049335,0.00026966457,0.000017341396],"about_ca_topic_score_codex":0.0014145445,"about_ca_topic_score_gemma":0.0017494862,"teacher_disagreement_score":0.002597111,"about_ca_system_score_codex":0.00025941114,"about_ca_system_score_gemma":0.00039478144,"threshold_uncertainty_score":0.013734996},"labels":[],"label_agreement":null},{"id":"W2179646396","doi":"10.1007/s40261-015-0336-0","title":"Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe","year":2015,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Guanfacine; Atomoxetine; Medicine; Stimulant; Methylphenidate; Dopamine; Context (archaeology); Attention deficit hyperactivity disorder; Monoaminergic; Pharmacology; Norepinephrine; Pharmacotherapy; Neuroscience; Psychiatry; Psychology; Clonidine; Receptor; Internal medicine","score_opus":0.39677855011462093,"score_gpt":0.5193796967377047,"score_spread":0.12260114662308375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2179646396","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011779241,0.9553876,0.0013190111,0.008238114,0.00085297995,0.000037992464,0.00027967905,0.00010253584,0.022002714],"genre_scores_gemma":[0.068598755,0.89787585,0.005661222,0.013065553,0.0019136441,0.00008255329,0.0008834965,0.00005138566,0.0118675735],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998379,0.000030627158,0.00003311484,0.00003669935,0.000037833703,0.00002391224],"domain_scores_gemma":[0.9998159,0.000049910734,0.000060032406,0.0000059848308,0.000030659216,0.000037603953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004885284,0.00029308934,0.0005574392,0.0004867878,0.00016899225,0.00054689357,0.00031014622,0.00084370404,0.00440215],"category_scores_gemma":[0.0003417279,0.000088760244,0.00047561806,0.00041062402,0.00026532818,0.00080130476,0.00047263163,0.0013141487,0.0010855058],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005020412,0.00018207889,0.0012910027,0.0025880616,0.00011012733,0.0013357069,0.000070213,0.00025207672,0.0049231937,0.0052961074,0.019850068,0.96359944],"study_design_scores_gemma":[0.0005095117,0.0011223402,0.011219749,0.0034362401,0.00021398762,0.010656902,0.000109078326,0.00031270768,0.0014238324,0.0028150992,0.9681369,0.000043581902],"about_ca_topic_score_codex":0.00066708174,"about_ca_topic_score_gemma":0.0015562848,"teacher_disagreement_score":0.00440215,"about_ca_system_score_codex":0.00040060957,"about_ca_system_score_gemma":0.0005917941,"threshold_uncertainty_score":0.014726698},"labels":[],"label_agreement":null},{"id":"W2287107829","doi":"10.1007/s40261-016-0381-3","title":"The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA","year":2016,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Eating Disorders and Behaviors","field":"Psychology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Binge-eating disorder; Binge eating; Pharmacotherapy; Medicine; Psychiatry; Bulimia nervosa; Stimulant; Eating disorders","score_opus":0.09954238075549586,"score_gpt":0.4170827267776626,"score_spread":0.31754034602216674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287107829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9102953,0.0601465,0.0078122076,0.008283291,0.00025916813,0.0010194327,0.0041069053,0.00009352538,0.007983714],"genre_scores_gemma":[0.99282527,0.004604099,0.0013049911,0.0004999716,0.000035795834,0.00015758492,0.00036482987,0.000003624313,0.00020385499],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9963534,0.0029037206,0.00015764814,0.0001553031,0.00030022743,0.00012966126],"domain_scores_gemma":[0.99093515,0.007263202,0.0012825932,0.00009293378,0.00020394946,0.00022210088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063048783,0.00046078113,0.0010115684,0.00078570965,0.000177496,0.001009336,0.0005080069,0.0009817497,0.002515581],"category_scores_gemma":[0.019836076,0.00033401547,0.003108952,0.0005986631,0.00038287326,0.0006790034,0.000658829,0.0009981779,0.00008397322],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082249746,0.0024338858,0.124225475,0.009837867,0.020248983,0.00082580175,0.00018470005,0.4567665,0.0019488012,0.012191169,0.0076763644,0.2814107],"study_design_scores_gemma":[0.023606883,0.03577584,0.1690095,0.007610448,0.029523363,0.0015406274,0.00046318898,0.6990748,0.0029186436,0.018593067,0.011618462,0.00026520967],"about_ca_topic_score_codex":0.008462494,"about_ca_topic_score_gemma":0.008681766,"teacher_disagreement_score":0.008462494,"about_ca_system_score_codex":0.0034471422,"about_ca_system_score_gemma":0.0025115388,"threshold_uncertainty_score":0.033343792},"labels":[],"label_agreement":null},{"id":"W2327894690","doi":"10.1007/s40261-016-0397-8","title":"Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995","year":2016,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Simon Fraser University; Centre for Addiction and Mental Health","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Harm; Benzodiazepine; Narrative review; Psychiatry; Pharmacotherapy; Population; Intensive care medicine; Psychology; Environmental health; Internal medicine; Social psychology","score_opus":0.37809996263737117,"score_gpt":0.4652990289311206,"score_spread":0.0871990662937494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327894690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004448494,0.99876934,0.0000105528725,0.00021293423,0.00002391926,0.000007687144,0.00030039597,0.0000015249699,0.00022874352],"genre_scores_gemma":[0.002595019,0.9969404,0.00007125639,0.0001697841,0.000018939152,0.0000067432643,0.00012330672,5.486238e-7,0.00007408121],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99902856,0.00010674371,0.00022822234,0.000112810405,0.00042881892,0.0000948193],"domain_scores_gemma":[0.99691075,0.0010905201,0.00082554703,0.00003281805,0.00097023475,0.00017013971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015443969,0.0007032114,0.0019986674,0.0056414804,0.0008122467,0.0019684753,0.0010122288,0.0007663311,0.0016944823],"category_scores_gemma":[0.0043326784,0.00038318674,0.0015218409,0.013670768,0.00076103676,0.0007225037,0.000902659,0.0010530666,0.00013459842],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005007175,0.00007069425,0.013821023,0.3153045,0.0029774392,0.0004631779,0.0010322711,0.00046604953,0.00048578694,0.0016052601,0.034183815,0.6290893],"study_design_scores_gemma":[0.00014752711,0.00023627185,0.11461031,0.33126995,0.01699121,0.0019028817,0.0021241766,0.00026177964,0.00045345965,0.0009787142,0.5308187,0.00020495457],"about_ca_topic_score_codex":0.70920676,"about_ca_topic_score_gemma":0.9005632,"teacher_disagreement_score":0.29079324,"about_ca_system_score_codex":0.012408629,"about_ca_system_score_gemma":0.056991722,"threshold_uncertainty_score":0.58501154},"labels":[],"label_agreement":null},{"id":"W2460337359","doi":"10.1007/s40261-016-0437-4","title":"Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers","year":2016,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Takeda Pharmaceuticals U.S.A.","keywords":"Vedolizumab; Medicine; Pharmacokinetics; Tolerability; Pharmacodynamics; Adverse effect; Placebo; Ulcerative colitis; Pharmacology; Area under the curve; Internal medicine; Gastroenterology; Cmax; Disease; Pathology","score_opus":0.023301745145831988,"score_gpt":0.32872720095539415,"score_spread":0.30542545580956215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2460337359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989409,0.00020465563,0.00025151187,0.000016782951,0.000012135966,0.000076081116,0.000099045814,0.000020164527,0.00037865376],"genre_scores_gemma":[0.9985415,0.00013313712,0.0002654435,0.000050005856,0.000023147612,0.000064015825,0.00016122116,0.000008030834,0.0007536343],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997843,0.00005938185,0.000011848518,0.00006572922,0.00003070231,0.000048103935],"domain_scores_gemma":[0.9997285,0.00006544721,0.00005269253,0.000038767168,0.000026477332,0.000088077926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039978893,0.00038743622,0.0006082046,0.00016099344,0.00028311872,0.00035550876,0.0001506836,0.00046175878,0.0014020329],"category_scores_gemma":[0.0009076418,0.0002952835,0.00025862138,0.00013190947,0.00047781123,0.0004291778,0.000118472024,0.0008225192,0.00039706432],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4806958,0.01249872,0.03558976,0.0001999763,0.0003007407,0.00086557376,0.000989466,0.0011697784,0.34598365,0.00017910142,0.0012530469,0.120274395],"study_design_scores_gemma":[0.01670049,0.50786173,0.34990796,0.00003659679,0.0006297424,0.0019268949,0.00052190945,0.0047014677,0.1143768,0.00033597756,0.0028953978,0.00010497698],"about_ca_topic_score_codex":0.0010587515,"about_ca_topic_score_gemma":0.0011402147,"teacher_disagreement_score":0.0014020329,"about_ca_system_score_codex":0.00019255071,"about_ca_system_score_gemma":0.00024769557,"threshold_uncertainty_score":0.00469023},"labels":[],"label_agreement":null},{"id":"W2492967488","doi":"10.1007/s40261-016-0443-6","title":"Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study","year":2016,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Bedaquiline; Medicine; Regimen; Tuberculosis; Cohort; Internal medicine; Mycobacterium tuberculosis; Pathology","score_opus":0.07280175794311688,"score_gpt":0.4181055599369192,"score_spread":0.34530380199380234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492967488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962148,0.0003327401,0.0017636364,0.00030030936,0.000017365386,0.00013666466,0.00035256482,0.000017631099,0.0008643199],"genre_scores_gemma":[0.998372,0.00015593253,0.0007664176,0.00007025274,0.000010870631,0.00011365568,0.00027193927,0.000004571095,0.00023433485],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9971341,0.002069656,0.00012381669,0.00021161085,0.000113219394,0.000347612],"domain_scores_gemma":[0.94934255,0.04537373,0.0019766765,0.0007796357,0.0007920747,0.0017353431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065274327,0.0010698971,0.0024857433,0.0007513733,0.00056850276,0.0010742929,0.0015510619,0.001895662,0.0041137664],"category_scores_gemma":[0.01834989,0.00070620194,0.0032311114,0.0005512071,0.0007512394,0.0012219015,0.00090743124,0.0019074687,0.0002443383],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07838227,0.010377568,0.04900601,0.00048115163,0.0040398175,0.0004908036,0.00039850635,0.8359915,0.0012940353,0.004681111,0.0010493904,0.01380781],"study_design_scores_gemma":[0.014489891,0.02821961,0.016115595,0.00010307499,0.002366374,0.00020779962,0.00041768368,0.9336977,0.0009053708,0.0028931154,0.00047629746,0.0001074337],"about_ca_topic_score_codex":0.015135498,"about_ca_topic_score_gemma":0.0074802306,"teacher_disagreement_score":0.015135498,"about_ca_system_score_codex":0.0027622734,"about_ca_system_score_gemma":0.0025122869,"threshold_uncertainty_score":0.034520805},"labels":[],"label_agreement":null},{"id":"W2494421376","doi":"10.1007/s40261-016-0442-7","title":"A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol Dependence","year":2016,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"demographic modeling and climate adaptation","field":"Decision Sciences","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Centre for Addiction and Mental Health","funders":"H. Lundbeck A/S","keywords":"Alcohol consumption; Alcohol; Microsimulation; Markov chain; Alcohol dependence; Medicine; Reduction (mathematics); Heavy drinking; Markov model; Consumption (sociology); Econometrics; Pharmacotherapy; Alcohol use disorder; Psychiatry; Statistics; Economics; Mathematics; Engineering","score_opus":0.42368096994878446,"score_gpt":0.46640618105823356,"score_spread":0.0427252111094491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2494421376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8967809,0.00051025423,0.09450279,0.001941648,0.00015052292,0.00015039463,0.00072113046,0.00020481796,0.00503757],"genre_scores_gemma":[0.9877225,0.00019677966,0.010677925,0.00014171939,0.000030415355,0.000106746316,0.00026764328,0.000022395056,0.0008339107],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99919087,0.0005144779,0.000032803575,0.0000937411,0.000044446097,0.00012375585],"domain_scores_gemma":[0.9756438,0.021563124,0.0009212984,0.00041952086,0.0006151398,0.00083710195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039736456,0.00071394024,0.0013241891,0.0010457021,0.0005836188,0.0010907758,0.0021044381,0.0022157023,0.0031587877],"category_scores_gemma":[0.015219506,0.000699036,0.0015064527,0.0007053374,0.0009956667,0.0012331095,0.0010399999,0.0015048089,0.00014710907],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015192232,0.000075544274,0.001394678,0.000017658247,0.00003751855,0.00000871252,0.000024414461,0.9949239,0.00004492383,0.002066696,0.00008756155,0.0011664534],"study_design_scores_gemma":[0.000038287282,0.00003855851,0.00028504716,0.0000037987102,0.000017049497,0.000002709131,0.000016726699,0.99861944,0.000028812421,0.00089974015,0.00004408525,0.0000056871963],"about_ca_topic_score_codex":0.065447144,"about_ca_topic_score_gemma":0.034303747,"teacher_disagreement_score":0.065447144,"about_ca_system_score_codex":0.0020041952,"about_ca_system_score_gemma":0.0030292328,"threshold_uncertainty_score":0.13013244},"labels":[],"label_agreement":null},{"id":"W2515349100","doi":"10.1007/s40261-016-0457-0","title":"Antiepileptic Drug Removal by Continuous Renal Replacement Therapy: A Review of the Literature","year":2016,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Levetiracetam; Renal replacement therapy; Carbamazepine; Lacosamide; Phenytoin; Valproic Acid; Dosing; Intensive care medicine; Intensive care unit; Acute kidney injury; Gabapentin; Topiramate; Pharmacology; Epilepsy; Internal medicine","score_opus":0.06827889689270568,"score_gpt":0.40966517506328576,"score_spread":0.3413862781705801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515349100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015997911,0.9995184,0.000030042305,0.00006480535,0.000029049823,0.000004689419,0.000024472438,0.000001653498,0.00016690623],"genre_scores_gemma":[0.0006852047,0.999042,0.00010868506,0.00006370428,0.000034229644,0.0000033090957,0.000014528564,3.497594e-7,0.00004790658],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996165,0.000055920074,0.0001505194,0.00006230469,0.00009739008,0.000017406779],"domain_scores_gemma":[0.9988863,0.0006717101,0.000267712,0.000015930862,0.00012516764,0.00003323198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008100711,0.00092026446,0.002517999,0.004513579,0.00028863587,0.0011628546,0.0009458858,0.0008177855,0.0036585373],"category_scores_gemma":[0.0014037811,0.00037792025,0.0012380176,0.004638135,0.0004444308,0.0015611731,0.0006329737,0.00086001924,0.0004940124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028812914,0.00013180322,0.00088742835,0.26925287,0.00085773726,0.0006697325,0.00014981595,0.00028568236,0.0016060717,0.0010082182,0.00973459,0.7151279],"study_design_scores_gemma":[0.00020021568,0.0006208811,0.010557761,0.14985576,0.008689797,0.010902208,0.00076843635,0.00038081213,0.0015970321,0.002396477,0.81390333,0.00012724177],"about_ca_topic_score_codex":0.0015080443,"about_ca_topic_score_gemma":0.0040687365,"teacher_disagreement_score":0.004513579,"about_ca_system_score_codex":0.0004716066,"about_ca_system_score_gemma":0.0016323631,"threshold_uncertainty_score":0.012239039},"labels":[],"label_agreement":null},{"id":"W2737067199","doi":"10.1007/s40261-017-0556-6","title":"Prescription Drug Price Paradox: Cost Analysis of Canadian Online Pharmacies versus US Medicare Beneficiaries for the Top 100 Drugs","year":2017,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Medical prescription; Medicine; Medicare Part D; Prescription drug; Beneficiary; Drug; Family medicine; Drug prices; Emergency medicine; Business; Pharmacology; Finance","score_opus":0.20812412305971914,"score_gpt":0.43406334927737134,"score_spread":0.2259392262176522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737067199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829081,0.0037352494,0.00020691448,0.0027726346,0.000037974136,0.0000884545,0.006351129,0.000025586212,0.0038739736],"genre_scores_gemma":[0.997364,0.00030313694,0.0001494309,0.0003195898,0.000023023966,0.000009246703,0.0015197253,0.0000065082754,0.00030536944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976972,0.0007007712,0.00014173752,0.00024040564,0.0007561169,0.00046375167],"domain_scores_gemma":[0.9825805,0.009407137,0.0034324692,0.0007444773,0.0024055538,0.0014298749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003188587,0.00046480793,0.0012718842,0.002159889,0.0010877486,0.002736501,0.0021227319,0.0012278782,0.005172219],"category_scores_gemma":[0.029151572,0.00038744602,0.0019985416,0.0064042094,0.0008994502,0.001581256,0.00094572135,0.0017806075,0.0001440968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012465404,0.001070322,0.9155689,0.0005415574,0.0036600158,0.00046370298,0.00039297124,0.0144052915,0.00034863153,0.006795431,0.0139390575,0.030348806],"study_design_scores_gemma":[0.00079520076,0.00057016633,0.9517785,0.00010638632,0.0024657308,0.00043591444,0.001851422,0.03631667,0.00024475728,0.0021189475,0.0032106272,0.00010570106],"about_ca_topic_score_codex":0.84803456,"about_ca_topic_score_gemma":0.82721364,"teacher_disagreement_score":0.15196544,"about_ca_system_score_codex":0.021451721,"about_ca_system_score_gemma":0.011880642,"threshold_uncertainty_score":0.30572075},"labels":[],"label_agreement":null},{"id":"W2747687728","doi":"10.2165/11530800-000000000-00000","title":"Subjective Effects and Safety of Whole and Tampered Morphine Sulfate and Naltrexone Hydrochloride (ALO-01) Extended-Release Capsules versus Morphine Solution and Placebo in Experienced Non-Dependent Opioid Users","year":2009,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Johnson and Johnson","keywords":"Morphine; Placebo; Euphoriant; Medicine; Anesthesia; Visual analogue scale; Opioid; Oxycodone; Naltrexone; Crossover study; Heroin; Pharmacology; Internal medicine; Drug; Psychiatry","score_opus":0.017257573873969017,"score_gpt":0.29826670053137955,"score_spread":0.2810091266574105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747687728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995303,0.00013646252,0.000038199276,0.000009139002,0.000006330378,0.000016630738,0.00005045191,0.0000026923276,0.00020981512],"genre_scores_gemma":[0.9991999,0.00011277898,0.00008144085,0.000021420015,0.000018824194,0.000012636532,0.0000504248,0.0000013247878,0.0005012583],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99969983,0.00014843863,0.000034360186,0.000031159263,0.000047607457,0.00003866946],"domain_scores_gemma":[0.99856806,0.0005911674,0.00029604652,0.000080135236,0.000097963304,0.0003665512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062713306,0.0003897777,0.0004900731,0.00017596423,0.00020173397,0.00029231748,0.00023602846,0.00039749756,0.0031732756],"category_scores_gemma":[0.002019352,0.00027814656,0.0004582052,0.0001509875,0.000404651,0.0005623199,0.00017134004,0.00060045853,0.0002818967],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.653271,0.024856986,0.09981814,0.0007454525,0.00082951254,0.00075670355,0.001577497,0.00108852,0.13745081,0.00023561224,0.00047058117,0.07889917],"study_design_scores_gemma":[0.018517291,0.43036783,0.52447265,0.00003708371,0.00067297864,0.00085041655,0.0010829174,0.0025674992,0.02050918,0.00011253072,0.0007091726,0.000100399884],"about_ca_topic_score_codex":0.00073587854,"about_ca_topic_score_gemma":0.0012184648,"teacher_disagreement_score":0.0031732756,"about_ca_system_score_codex":0.0001581585,"about_ca_system_score_gemma":0.00015367269,"threshold_uncertainty_score":0.010615647},"labels":[],"label_agreement":null},{"id":"W2757607441","doi":"10.1007/s40261-017-0561-9","title":"In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations","year":2017,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Opioid; Pharmacology; Oxycodone; Immediate release; Medicine; Drug; Dosage form; Chromatography; Chemistry; Internal medicine","score_opus":0.08471633368849583,"score_gpt":0.40042209201315004,"score_spread":0.3157057583246542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757607441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880839,0.0064978213,0.002715417,0.00008035439,0.000051931875,0.0002463139,0.00051088125,0.00003631156,0.0017769121],"genre_scores_gemma":[0.9752773,0.010025428,0.009953568,0.00010025212,0.00005354607,0.0002152181,0.00093682914,0.000040206287,0.0033974922],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994199,0.00014934075,0.00008236517,0.0000989209,0.00019414855,0.000055322733],"domain_scores_gemma":[0.99906725,0.0003311194,0.0003062751,0.000083743085,0.00016060153,0.0000510625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006753149,0.0005905035,0.0005766892,0.00040672216,0.0002489722,0.00045887096,0.00026961765,0.0004205145,0.0013584398],"category_scores_gemma":[0.0010469964,0.00027015005,0.00068714714,0.0005061093,0.00032655062,0.0006066817,0.00028583116,0.00068699947,0.00023639982],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013396025,0.0005556619,0.001026913,0.00063897105,0.000068579306,0.00025396555,0.00024509823,0.00065366103,0.9855354,0.00009251432,0.00011611224,0.009473599],"study_design_scores_gemma":[0.0001599025,0.018836634,0.01388979,0.000060377635,0.0002654886,0.00076844025,0.00021278198,0.002806121,0.95914036,0.00004120288,0.0037781217,0.000040703395],"about_ca_topic_score_codex":0.0013163133,"about_ca_topic_score_gemma":0.0016855563,"teacher_disagreement_score":0.0013584398,"about_ca_system_score_codex":0.00026686562,"about_ca_system_score_gemma":0.0003147373,"threshold_uncertainty_score":0.004544437},"labels":[],"label_agreement":null},{"id":"W2765390494","doi":"10.1007/s40261-017-0581-5","title":"Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study","year":2017,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"GlaxoSmithKline","keywords":"Medicine; Quality of life (healthcare); Rash; Cohort; Observational study; Postherpetic neuralgia; Prospective cohort study; Neuralgia; Cohort study; Physical therapy; Brief Pain Inventory; McGill Pain Questionnaire; Pediatrics; Internal medicine; Neuropathic pain; Chronic pain; Anesthesia; Visual analogue scale","score_opus":0.12188452375459266,"score_gpt":0.4224204255638445,"score_spread":0.3005359018092518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765390494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992654,0.00023212859,0.00002324468,0.000016658612,0.000004570205,0.000011902558,0.00033419344,7.560024e-7,0.00011118602],"genre_scores_gemma":[0.9991437,0.00016722997,0.0000388429,0.000029137413,0.000007876227,0.00001690895,0.00053600315,7.706474e-7,0.00005955261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99950254,0.000107579,0.00007752602,0.00012467701,0.00008617201,0.00010151125],"domain_scores_gemma":[0.99893767,0.00009564071,0.00045219908,0.00009632264,0.00016194017,0.0002562262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010553639,0.0003778374,0.0005437365,0.00063392817,0.00051722856,0.00068226166,0.00033479018,0.0004848327,0.0005976585],"category_scores_gemma":[0.0014359936,0.00035595437,0.00093537517,0.0011042131,0.00025367245,0.00048455637,0.00061527506,0.0005284476,0.000119543845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097115815,0.000034585733,0.9992399,0.000011653247,0.00010249349,0.000032847198,0.00007267911,0.000009201824,0.00007136274,0.000002445616,0.00003286036,0.00029283902],"study_design_scores_gemma":[0.000008431194,0.000058793164,0.99965084,0.0000025558566,0.000043867018,0.000043655473,0.00012035754,0.000026969945,0.0000059123586,0.0000016029691,0.00003525503,0.0000018284811],"about_ca_topic_score_codex":0.013810983,"about_ca_topic_score_gemma":0.016129278,"teacher_disagreement_score":0.013810983,"about_ca_system_score_codex":0.00034068522,"about_ca_system_score_gemma":0.00038589415,"threshold_uncertainty_score":0.02746123},"labels":[],"label_agreement":null},{"id":"W2771385809","doi":"10.1007/s40261-017-0610-4","title":"Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects","year":2017,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; Mallinckrodt Pharmaceuticals","keywords":"Pharmacokinetics; Medicine; Acetaminophen; Morphine; Dosing; Pharmacology; Bioavailability; Oral administration; Opioid; Anesthesia; Analgesic; Internal medicine","score_opus":0.06099708031379279,"score_gpt":0.3626744945745505,"score_spread":0.30167741426075767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771385809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994048,0.00028497493,0.0001379394,0.000006931522,0.000005430216,0.000028176893,0.000036455855,0.0000056393947,0.000089555644],"genre_scores_gemma":[0.9989267,0.00019869379,0.00036323455,0.000047162823,0.000022298756,0.000053292842,0.00011294357,0.0000028080342,0.00027276372],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996376,0.0001233292,0.000025378456,0.00008993035,0.0000746646,0.000049034465],"domain_scores_gemma":[0.9996063,0.00009110445,0.00010756093,0.000036977068,0.000043563945,0.00011440589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040940585,0.00037747054,0.0006310446,0.00017164879,0.00024016979,0.00027130693,0.00010797458,0.00040713119,0.0005124555],"category_scores_gemma":[0.0009657016,0.0003073062,0.00018948801,0.0001328533,0.00034768553,0.00027222,0.00012625143,0.00035537712,0.00020752188],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21421108,0.015342135,0.3488133,0.00035060383,0.0007626476,0.0014165745,0.0011857495,0.0010554666,0.34129858,0.00016373371,0.0007482413,0.07465183],"study_design_scores_gemma":[0.0029656447,0.1968499,0.78083724,0.000009836758,0.0002840626,0.0017132298,0.00024583828,0.0013082642,0.014541156,0.00006414005,0.0011397516,0.000041010342],"about_ca_topic_score_codex":0.0009137034,"about_ca_topic_score_gemma":0.0008177018,"teacher_disagreement_score":0.0009137034,"about_ca_system_score_codex":0.00021917022,"about_ca_system_score_gemma":0.00027536467,"threshold_uncertainty_score":0.0021651983},"labels":[],"label_agreement":null},{"id":"W2771762421","doi":"10.1007/s40261-017-0598-9","title":"Lithium Toxicity in Older Adults: a Systematic Review of Case Reports","year":2017,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"China Scholarship Council","keywords":"Medicine; Polypharmacy; Lithium (medication); Toxicity; Internal medicine; Comorbidity","score_opus":0.11636072012543469,"score_gpt":0.4331381137862295,"score_spread":0.3167773936607948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771762421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009685743,0.99842876,0.000056512712,0.00008043927,0.00003803304,0.000059934824,0.00025144214,0.0000032797427,0.00011297645],"genre_scores_gemma":[0.008663093,0.9901918,0.00036271536,0.00041477333,0.000051642735,0.000069241716,0.0001825921,0.000002820231,0.000061262326],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9964295,0.0004884516,0.0022142588,0.00032185228,0.00046150063,0.000084445615],"domain_scores_gemma":[0.98859125,0.006680854,0.0036972002,0.00018032888,0.0007191769,0.00013116702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002752733,0.0011610991,0.0050714714,0.008023903,0.00052124634,0.0017205708,0.0016045865,0.001488235,0.0032768284],"category_scores_gemma":[0.014023465,0.0006699351,0.0048855026,0.0090248585,0.0006823325,0.0021009413,0.001416659,0.0008390169,0.00020889305],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037142908,0.000034523437,0.0041559977,0.8911073,0.010323256,0.00072471204,0.00033451896,0.00013655468,0.0004309008,0.00021945089,0.003277642,0.088883705],"study_design_scores_gemma":[0.0004522827,0.0003304994,0.021405067,0.7730079,0.13150814,0.007138266,0.0008650328,0.00011429305,0.0004396989,0.0006159403,0.06398149,0.00014141372],"about_ca_topic_score_codex":0.0042212163,"about_ca_topic_score_gemma":0.018432077,"teacher_disagreement_score":0.008023903,"about_ca_system_score_codex":0.0013130346,"about_ca_system_score_gemma":0.004039821,"threshold_uncertainty_score":0.014558017},"labels":[],"label_agreement":null},{"id":"W2789269735","doi":"10.1007/s40261-018-0626-4","title":"Antipsychotic Prescribing and Safety Monitoring Practices in Children and Youth: A Population-Based Study in Alberta, Canada","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Pharmacotherapy; Antipsychotic; Population; Psychiatry; Family medicine; Environmental health; Schizophrenia (object-oriented programming)","score_opus":0.07601212069905343,"score_gpt":0.376873753978564,"score_spread":0.30086163327951054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789269735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99697876,0.00046384794,0.000088930734,0.00021369291,0.000009390506,0.000035399036,0.0010088215,0.000008483706,0.0011926264],"genre_scores_gemma":[0.9978042,0.0004719979,0.0002443486,0.00014922323,0.0000052094947,0.000016935472,0.0005202291,0.00000678341,0.00078099885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979937,0.00017658262,0.00015024496,0.00028293973,0.0007575407,0.0006390896],"domain_scores_gemma":[0.9966402,0.0002372705,0.00071909616,0.00009269741,0.0014900438,0.0008205689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000963284,0.0005859899,0.00073795236,0.001953245,0.0044912663,0.0022684378,0.0021746443,0.000999657,0.0017451206],"category_scores_gemma":[0.0024672353,0.00081096624,0.0008788393,0.0061343927,0.0013867167,0.0006765034,0.0011675507,0.0012720247,0.00028266103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051850424,0.00007413156,0.9949897,0.000028072087,0.00004868918,0.00016105438,0.0018600901,0.00008274011,0.0001312278,0.000082774364,0.00046434693,0.0020253554],"study_design_scores_gemma":[0.000009484855,0.000036820893,0.99524385,0.0000411781,0.0000338028,0.00010744803,0.0038604974,0.0002472638,0.00004475889,0.00001662886,0.0003458165,0.000012388351],"about_ca_topic_score_codex":0.9955835,"about_ca_topic_score_gemma":0.99747497,"teacher_disagreement_score":0.0387221,"about_ca_system_score_codex":0.0387221,"about_ca_system_score_gemma":0.035644624,"threshold_uncertainty_score":0.28094977},"labels":[],"label_agreement":null},{"id":"W2795474249","doi":"10.1007/s40261-018-0648-y","title":"Translating Benzodiazepine Utilization Data into Meaningful Population Exposure: Integration of Two Metrics for Improved Reporting","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Sleep and related disorders","field":"Psychology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Manitoba Health; University of Manitoba","funders":"","keywords":"Defined daily dose; Zopiclone; Medicine; Zolpidem; Benzodiazepine; Metric (unit); Population; Consumption (sociology); Pharmacology; Drug; Statistics; Environmental health; Hypnotic; Internal medicine; Mathematics; Operations management; Insomnia; Engineering","score_opus":0.2832879371559091,"score_gpt":0.47366443236735567,"score_spread":0.19037649521144656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795474249","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4031414,0.0086121755,0.47308147,0.012082215,0.0016545842,0.00488569,0.056823593,0.004643623,0.035075247],"genre_scores_gemma":[0.7181897,0.001619773,0.25758824,0.0015248645,0.00047990552,0.0028181993,0.01619309,0.00026429375,0.0013220726],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9375396,0.02582338,0.017195143,0.0038032592,0.01455868,0.0010800685],"domain_scores_gemma":[0.8232593,0.06348654,0.03587797,0.019739898,0.055121038,0.0025153079],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.05082851,0.0010951954,0.002033578,0.007897467,0.0007368971,0.0053942166,0.0017236517,0.0013445825,0.0012547295],"category_scores_gemma":[0.14915115,0.00044869355,0.0013792628,0.0066693104,0.000690764,0.0036602619,0.0041592508,0.0020095855,0.00052362395],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005930537,0.00037459002,0.7291038,0.0012191258,0.0009591507,0.00006374748,0.0013464597,0.0027782442,0.0019727128,0.005249519,0.011982087,0.24435756],"study_design_scores_gemma":[0.0001387693,0.0017282598,0.8919798,0.000976357,0.0012596846,0.0005899475,0.0018094907,0.028550027,0.019165214,0.010614434,0.042899832,0.00028814524],"about_ca_topic_score_codex":0.0055216635,"about_ca_topic_score_gemma":0.0070348876,"teacher_disagreement_score":0.9491715,"about_ca_system_score_codex":0.002204169,"about_ca_system_score_gemma":0.0043178727,"threshold_uncertainty_score":0.26881003},"labels":[],"label_agreement":null},{"id":"W2800927037","doi":"10.1007/s40261-018-0653-1","title":"Acetazolamide and Cardiac Failure","year":2018,"lang":"en","type":"letter","venue":"Clinical Drug Investigation","topic":"Eicosanoids and Hypertension Pharmacology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Acetazolamide; Medicine; Pharmacotherapy; Heart failure; Cardiology; Intensive care medicine; Internal medicine","score_opus":0.032390212415900024,"score_gpt":0.31501771566473136,"score_spread":0.28262750324883135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800927037","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011882402,0.012194885,0.0002789144,0.93345207,0.020646363,0.0000375356,0.00007216901,0.000050410537,0.021385346],"genre_scores_gemma":[0.16200696,0.013857172,0.0008107488,0.57661337,0.22966787,0.00009105445,0.00011860471,0.000034875542,0.016799446],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99944717,0.0002067656,0.00006819369,0.00006740145,0.00011841366,0.00009208636],"domain_scores_gemma":[0.99773943,0.0014047095,0.00020140129,0.000108282504,0.00017997422,0.00036625526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008475702,0.0005323962,0.0007712793,0.0005797523,0.0012745315,0.0013579057,0.0006518432,0.014021368,0.003717496],"category_scores_gemma":[0.007822695,0.0002934534,0.00059769646,0.0004105508,0.0015100827,0.001221072,0.00061027176,0.012055671,0.0016147998],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009269799,0.0004047511,0.012709297,0.00024896904,0.00012080588,0.29990223,0.00025324486,0.00026756548,0.0022415936,0.015833836,0.60434616,0.0627446],"study_design_scores_gemma":[0.0017718093,0.0007508869,0.024898564,0.00096203113,0.00024819677,0.19982848,0.0005825034,0.0023784956,0.0019142614,0.044440176,0.7220983,0.00012636674],"about_ca_topic_score_codex":0.0010563199,"about_ca_topic_score_gemma":0.002131657,"teacher_disagreement_score":0.014021368,"about_ca_system_score_codex":0.0017335014,"about_ca_system_score_gemma":0.00114362,"threshold_uncertainty_score":0.012577474},"labels":[],"label_agreement":null},{"id":"W2807503561","doi":"10.1007/s40261-018-0660-2","title":"Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Amino Acid Enzymes and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim","keywords":"Pharmacokinetics; Tolerability; Medicine; Adverse effect; Placebo; Pharmacology; Morning; Evening; Dosing; Internal medicine","score_opus":0.055154740894502265,"score_gpt":0.380198570377732,"score_spread":0.32504382948322974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807503561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556893,0.0012152488,0.00045781882,0.00010967613,0.00008786818,0.0016597038,0.00035183123,0.000077001685,0.00047198727],"genre_scores_gemma":[0.9896954,0.0017417624,0.0016123776,0.0005741116,0.0002750179,0.0030728295,0.00067128765,0.000027493174,0.00232976],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99927133,0.00033956478,0.00005660606,0.00014991713,0.000063998494,0.0001186313],"domain_scores_gemma":[0.99916184,0.0001493009,0.00017539579,0.00006854306,0.000070602684,0.00037422692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016867251,0.001709072,0.0029072713,0.0006121767,0.0005510821,0.0006923322,0.00078924303,0.0015577585,0.0029505854],"category_scores_gemma":[0.0012929462,0.0011201911,0.0008905478,0.00046953454,0.0012588984,0.0009484035,0.00045036926,0.0017550639,0.0007641879],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92309964,0.027357806,0.0013035225,0.00030006215,0.00042735902,0.0000886571,0.00014035265,0.00029515132,0.030747332,0.000042296117,0.00044000198,0.015757754],"study_design_scores_gemma":[0.3736803,0.61572874,0.0066541736,0.0000142829185,0.00036711583,0.0000799252,0.000054707714,0.00038179028,0.0024003298,0.000054029624,0.000554739,0.000029870707],"about_ca_topic_score_codex":0.0011661524,"about_ca_topic_score_gemma":0.0022124755,"teacher_disagreement_score":0.0029505854,"about_ca_system_score_codex":0.00053210906,"about_ca_system_score_gemma":0.0012544875,"threshold_uncertainty_score":0.009870648},"labels":[],"label_agreement":null},{"id":"W2883630601","doi":"10.1007/s40261-018-0672-y","title":"The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol–Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Veterinary Pharmacology and Anesthesia","field":"Veterinary","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BioPhage Pharma (Canada); Innovaderm (Canada)","funders":"Esteve Pharmaceuticals","keywords":"Celecoxib; Medicine; Cmax; Tramadol; Bioavailability; Pharmacokinetics; Crossover study; Pharmacology; Oral administration; Bioequivalence; Analgesic; Placebo","score_opus":0.14055741941731265,"score_gpt":0.44165498609137444,"score_spread":0.3010975666740618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883630601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983468,0.00047757215,0.00017708195,0.000046095745,0.00008466807,0.00045084767,0.0001510106,0.000021551201,0.00024444907],"genre_scores_gemma":[0.99582833,0.0006206571,0.000705163,0.00015316348,0.00019394961,0.00058770954,0.00033919787,0.000020309051,0.0015515932],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99910873,0.00031802242,0.00006905354,0.00022539018,0.0001171396,0.00016157498],"domain_scores_gemma":[0.998242,0.00051703944,0.00035903289,0.00018110921,0.00016502783,0.0005357465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011707926,0.0012296219,0.0024185784,0.00039761903,0.0005846897,0.00075471954,0.0005356332,0.0016731062,0.0031834927],"category_scores_gemma":[0.0023344117,0.001148936,0.0013431937,0.00035518015,0.001433182,0.0010466289,0.00050223974,0.0019959395,0.0006896533],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9241831,0.025105953,0.0009349734,0.00028256862,0.00025647032,0.000092493494,0.0001576926,0.00015442062,0.039231773,0.00003749087,0.00017929032,0.0093838945],"study_design_scores_gemma":[0.097994156,0.8785219,0.014532331,0.000013977119,0.00042163092,0.000103685394,0.00007350762,0.00046903559,0.0072133616,0.00005995559,0.0005520758,0.000044431858],"about_ca_topic_score_codex":0.0010699517,"about_ca_topic_score_gemma":0.0014273728,"teacher_disagreement_score":0.0031834927,"about_ca_system_score_codex":0.00045036792,"about_ca_system_score_gemma":0.0008488533,"threshold_uncertainty_score":0.0106498},"labels":[],"label_agreement":null},{"id":"W2891851132","doi":"10.1007/s40261-018-0694-5","title":"Regression and Genomic Analyses on the Association Between Dose-Normalized Mycophenolic Acid Exposure and Absolute Neutrophil Count in Steroid-Free, De Novo Kidney Transplant Recipients","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; University of Alberta","funders":"Vancouver Coastal Health Research Institute; University of British Columbia; F. Hoffmann-La Roche","keywords":"Medicine; Absolute neutrophil count; Mycophenolic acid; Neutropenia; Internal medicine; UGT2B7; Creatinine; Tacrolimus; Gastroenterology; Single-nucleotide polymorphism; Population; Immunology; Transplantation; Toxicity; Genotype; Biology","score_opus":0.0895704304835811,"score_gpt":0.373520759183502,"score_spread":0.28395032869992093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891851132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595815,0.0005643293,0.0012494673,0.000184094,0.000026916738,0.000006882899,0.0012631892,0.00005193892,0.0006950077],"genre_scores_gemma":[0.9977477,0.00014375732,0.0005045421,0.000044375935,0.000029569062,0.000010449939,0.0006830498,0.00002061841,0.00081576145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987588,0.00060050975,0.000074332434,0.00029742674,0.000113694085,0.00015533293],"domain_scores_gemma":[0.9953165,0.0028613652,0.0008228944,0.0005658443,0.00017638659,0.0002570042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014695066,0.000539798,0.00051760586,0.00065941125,0.00025666362,0.0007401814,0.00061877765,0.00045876158,0.004673954],"category_scores_gemma":[0.00522312,0.00023768014,0.0016431457,0.000937839,0.00028758193,0.00047392637,0.00048264174,0.0011323991,0.00048646543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039308146,0.00014234206,0.9762441,0.000049494585,0.002734949,0.00028142234,0.00008891082,0.0012875523,0.0032069052,0.0003834921,0.0006253153,0.011024726],"study_design_scores_gemma":[0.00009158852,0.00064336095,0.98521394,0.000016544549,0.0016237248,0.0006161781,0.0001959096,0.008516335,0.0010670387,0.00053423725,0.0014641284,0.000017121525],"about_ca_topic_score_codex":0.0071381982,"about_ca_topic_score_gemma":0.0046819155,"teacher_disagreement_score":0.0071381982,"about_ca_system_score_codex":0.0002787569,"about_ca_system_score_gemma":0.00063704094,"threshold_uncertainty_score":0.015635967},"labels":[],"label_agreement":null},{"id":"W2893335845","doi":"10.1007/s40261-018-0705-6","title":"Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier universitaire de Québec; University of Alberta; McGill University Health Centre; University of Ottawa; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary; Sunnybrook Hospital; Queen Elizabeth II Health Sciences Centre; University of British Columbia; University of Toronto; Dalhousie University; McMaster University","funders":"Fonds de Recherche du Québec - Santé; Canadian Centre for Applied Research in Cancer Control","keywords":"Pazopanib; Sunitinib; Medicine; Renal cell carcinoma; Internal medicine; Oncology; Cost effectiveness; Intensive care medicine","score_opus":0.3289610242284381,"score_gpt":0.4109753416940739,"score_spread":0.08201431746563581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893335845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85816216,0.06842841,0.0015481027,0.013997899,0.00029584885,0.000733569,0.040493507,0.00008638078,0.016254175],"genre_scores_gemma":[0.9871257,0.0067655444,0.00075276237,0.0004568603,0.000048056747,0.000046659643,0.004276641,0.000011689913,0.00051615294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682546,0.0011344906,0.0003110681,0.00030326526,0.00084580865,0.0005798645],"domain_scores_gemma":[0.9891221,0.0046439436,0.0019348327,0.00023713685,0.00285387,0.0012082121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036774832,0.00077062246,0.0014194193,0.0019396334,0.00080323586,0.0031874962,0.001514942,0.00094197225,0.0034006194],"category_scores_gemma":[0.02700711,0.00037228776,0.0031910874,0.004821119,0.0010465847,0.0012878274,0.0009348847,0.0017423467,0.00013646066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0269089,0.0007613357,0.68240917,0.007927469,0.018946026,0.0009341646,0.0003705549,0.13483348,0.00042654513,0.008271999,0.02348402,0.09472638],"study_design_scores_gemma":[0.0083812745,0.002838932,0.7538456,0.0054435628,0.032750152,0.00093896664,0.0024233167,0.15541394,0.00091967365,0.0067606852,0.029887147,0.00039680468],"about_ca_topic_score_codex":0.95353764,"about_ca_topic_score_gemma":0.9670415,"teacher_disagreement_score":0.07067843,"about_ca_system_score_codex":0.07067843,"about_ca_system_score_gemma":0.055864222,"threshold_uncertainty_score":0.5128103},"labels":[],"label_agreement":null},{"id":"W2898173867","doi":"10.1007/s40261-018-0719-0","title":"Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials","year":2018,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Neratinib; Medicine; Oncology; Internal medicine; Adverse effect; Diarrhea; Breast cancer; Clinical trial; Hazard ratio; Nausea; Cancer; Trastuzumab; Confidence interval","score_opus":0.5943309892068062,"score_gpt":0.6027997922926437,"score_spread":0.008468803085837528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898173867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009012305,0.98933125,0.0004689522,0.00014549174,0.000080841,0.00014796483,0.0005760429,0.000016321776,0.00022077287],"genre_scores_gemma":[0.27257362,0.72089094,0.002610993,0.0013719992,0.00019990305,0.00042988698,0.0014398413,0.00004214803,0.00044063324],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99250305,0.00271635,0.0027926778,0.00095517683,0.0007942374,0.00023846218],"domain_scores_gemma":[0.98630434,0.009554429,0.0026922044,0.0005562915,0.00071093685,0.0001817627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0101698255,0.0021157658,0.013810306,0.0033341676,0.00050443475,0.002433383,0.0019742881,0.0016286985,0.0033630193],"category_scores_gemma":[0.020355262,0.0011584796,0.024622018,0.0055019143,0.0008032768,0.001822496,0.0013941117,0.001711828,0.0003226219],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003675297,0.000039418297,0.0069916635,0.26007214,0.7112171,0.00016019269,0.00010086465,0.00047141954,0.0004077822,0.0001289835,0.00066239847,0.016072739],"study_design_scores_gemma":[0.0008437406,0.0002020606,0.004977574,0.007491328,0.98419225,0.00013145262,0.000051426705,0.0000869662,0.00011748597,0.00016123556,0.0017192947,0.000025209267],"about_ca_topic_score_codex":0.0028420622,"about_ca_topic_score_gemma":0.010375004,"teacher_disagreement_score":0.013810306,"about_ca_system_score_codex":0.0016252185,"about_ca_system_score_gemma":0.0025367301,"threshold_uncertainty_score":0.053783774},"labels":[],"label_agreement":null},{"id":"W2900661293","doi":"10.1007/s40261-018-0726-1","title":"Drugs that Can Kill a Toddler with One Tablet or Teaspoonful: A 2018 Updated List","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Toddler; Drug; Accidental; Intensive care medicine; Pharmacotherapy; Pediatrics; Pharmacology; Psychiatry","score_opus":0.20738916300126933,"score_gpt":0.41880932038576707,"score_spread":0.21142015738449774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900661293","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022840172,0.90106463,0.0010035438,0.018700013,0.007592248,0.00027375904,0.011127005,0.00040660062,0.057548176],"genre_scores_gemma":[0.0056359516,0.9372625,0.0034936168,0.0109506445,0.004855192,0.000238584,0.010127599,0.00008490416,0.027351057],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987087,0.00012544925,0.00043072406,0.00010786294,0.00050884415,0.000118321885],"domain_scores_gemma":[0.99360186,0.0021337897,0.0017332118,0.00017780122,0.0016973558,0.00065601355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009642559,0.0010185131,0.0018122507,0.0056858584,0.00055348856,0.002099738,0.00077933446,0.0018154338,0.03327417],"category_scores_gemma":[0.0049552713,0.00044435027,0.0018039511,0.0042753494,0.00043921088,0.0030170986,0.0012254431,0.0028642388,0.011371279],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028744474,0.00013398309,0.0016133657,0.007759385,0.000105326624,0.00056994095,0.00005394122,0.000059390935,0.0009493904,0.0009406023,0.33673888,0.65078825],"study_design_scores_gemma":[0.000117421936,0.00012273306,0.00547756,0.00503047,0.0002908927,0.0013937845,0.00004709483,0.00003406296,0.00035094153,0.0002727758,0.98683447,0.000027899838],"about_ca_topic_score_codex":0.003344159,"about_ca_topic_score_gemma":0.010778053,"teacher_disagreement_score":0.03327417,"about_ca_system_score_codex":0.0011572063,"about_ca_system_score_gemma":0.004224555,"threshold_uncertainty_score":0.111313224},"labels":[],"label_agreement":null},{"id":"W2904095541","doi":"10.1007/s40261-018-0721-6","title":"A Literature Review of Psychotropic Medications and Alcohol as Risk Factors for Falls in Community Dwelling Older Adults","year":2018,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Balance, Gait, and Falls Prevention","field":"Health Professions","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Regional Municipality of Waterloo; University of Waterloo","funders":"University of Waterloo","keywords":"Medicine; Psychiatry; CINAHL; Psychotropic drug; Benzodiazepine; Poison control; Drug; Internal medicine; Psychological intervention; Emergency medicine","score_opus":0.12728007257417165,"score_gpt":0.49230984268360256,"score_spread":0.36502977010943094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904095541","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039090932,0.9991493,0.000031182823,0.00013281945,0.000064255226,0.000014243679,0.00008397342,0.000002050422,0.0001312305],"genre_scores_gemma":[0.0015642581,0.9979359,0.0001466855,0.00019502833,0.00005214072,0.000012883844,0.000047915004,4.3564617e-7,0.000044785815],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.999283,0.00009977478,0.00032123335,0.00009859713,0.00015960349,0.000037768594],"domain_scores_gemma":[0.99762195,0.0015926063,0.00045223447,0.000028474384,0.00024988956,0.00005487116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012210179,0.0008596654,0.002336175,0.0058883717,0.00048383226,0.0012742007,0.0011068169,0.0013140974,0.0031084719],"category_scores_gemma":[0.0041814377,0.00046849283,0.0030077826,0.006455328,0.00042625543,0.0012635805,0.00083845307,0.00092525705,0.0002483667],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019783522,0.00012436125,0.005053184,0.5620165,0.0035486093,0.0005567959,0.00042328253,0.00018220118,0.000360349,0.00064207363,0.012783218,0.4141116],"study_design_scores_gemma":[0.0002085789,0.00038795907,0.034915987,0.6947902,0.046607126,0.0040644333,0.0012596317,0.00018947366,0.00032865867,0.0012838811,0.21582669,0.00013731584],"about_ca_topic_score_codex":0.00980053,"about_ca_topic_score_gemma":0.024335004,"teacher_disagreement_score":0.00980053,"about_ca_system_score_codex":0.00080628303,"about_ca_system_score_gemma":0.004136185,"threshold_uncertainty_score":0.019486964},"labels":[],"label_agreement":null},{"id":"W2908559747","doi":"10.1007/s40261-018-00744-7","title":"Opioid Use and Pain Control in the Elderly After Elective or Urgent Orthopaedic Surgery: A Retrospective Cohort Study","year":2019,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Delirium; Retrospective cohort study; Opioid; Morphine; Cohort; Adverse effect; Orthopedic surgery; Anesthesia; Incidence (geometry); Confidence interval; Elective surgery; Surgery; Internal medicine; Intensive care medicine","score_opus":0.028575331215768246,"score_gpt":0.3071452122697988,"score_spread":0.2785698810540306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908559747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999453,0.00014012694,0.000031109237,0.000012839208,0.0000049046425,0.0000066601942,0.00019151419,8.8407296e-7,0.00015893037],"genre_scores_gemma":[0.9993923,0.00013792492,0.0000412689,0.000033020508,0.000011792859,0.000007126021,0.0002327695,0.000001121406,0.00014269246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995784,0.000071005066,0.000060231567,0.00011386489,0.00006544051,0.000111160196],"domain_scores_gemma":[0.9990965,0.00010725457,0.00040587928,0.00008830458,0.000092925424,0.00020909998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045730788,0.00032975574,0.00042259047,0.00070436636,0.00064358534,0.0007866743,0.00031718597,0.0005187503,0.0013553016],"category_scores_gemma":[0.0011527082,0.0004942373,0.00079109415,0.0010807913,0.00030648345,0.0006551423,0.00048472616,0.00073828007,0.00023112404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001340399,0.000057599947,0.99920577,0.0000048492434,0.000059464484,0.00009280114,0.000052632895,0.000008261705,0.00010476549,0.0000064887877,0.000032273536,0.00024100463],"study_design_scores_gemma":[0.000011661258,0.00018350554,0.99883455,0.0000047045382,0.000049955128,0.00035334806,0.00037338526,0.000065459695,0.00002556517,0.000009416819,0.00008366691,0.000004785606],"about_ca_topic_score_codex":0.01035537,"about_ca_topic_score_gemma":0.012237827,"teacher_disagreement_score":0.01035537,"about_ca_system_score_codex":0.00037142067,"about_ca_system_score_gemma":0.00050991273,"threshold_uncertainty_score":0.020590246},"labels":[],"label_agreement":null},{"id":"W2909165413","doi":"10.1007/s40261-018-00743-8","title":"Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review","year":2019,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre; Mediprobe Research (Canada)","funders":"","keywords":"Medicine; Hair loss; Hair growth; Dermatology; Latanoprost; Placebo; Hair follicle; Randomized controlled trial; Internal medicine; Surgery; Alternative medicine; Physiology; Pathology","score_opus":0.22350001816306975,"score_gpt":0.4640909259438874,"score_spread":0.24059090778081765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909165413","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012041542,0.999526,0.000033393313,0.00006174424,0.0000442992,0.00000453706,0.000017767661,0.0000025651186,0.00018929412],"genre_scores_gemma":[0.00080004317,0.9987256,0.00012265837,0.00015524855,0.000063145075,0.000004905693,0.000023699173,7.4902937e-7,0.000103952574],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9997428,0.000046695597,0.00006169035,0.000051490617,0.00008074171,0.000016628055],"domain_scores_gemma":[0.9990907,0.00060812425,0.00014371709,0.00001533485,0.0001061362,0.000035976624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081212394,0.00076051295,0.0021102189,0.0026687991,0.00020759687,0.0010809149,0.0010228519,0.00095508154,0.0039285105],"category_scores_gemma":[0.00126705,0.00027221013,0.0011806655,0.0019511572,0.00042071694,0.00093309017,0.00049503625,0.0012728422,0.00060976157],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033091335,0.00013375834,0.00026988485,0.07265808,0.00050584687,0.00021770253,0.000057899382,0.00023298609,0.0014702815,0.0008462923,0.01142189,0.9118545],"study_design_scores_gemma":[0.00045650074,0.0011193078,0.0057812287,0.05643533,0.0050513167,0.0042992053,0.00026637994,0.00040391096,0.0014254294,0.0020309086,0.9226255,0.0001049278],"about_ca_topic_score_codex":0.0011045692,"about_ca_topic_score_gemma":0.0026170237,"teacher_disagreement_score":0.0039285105,"about_ca_system_score_codex":0.0004089364,"about_ca_system_score_gemma":0.0010300811,"threshold_uncertainty_score":0.0131421685},"labels":[],"label_agreement":null},{"id":"W2913271953","doi":"10.1007/s40261-019-00752-1","title":"Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects","year":2019,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"","keywords":"Abiraterone acetate; Pharmacokinetics; Cmax; Pharmacology; Abiraterone; Bioanalysis; Chemistry; Metabolite; Medicine; Chromatography; Oral administration; Internal medicine; Cancer; Prostate cancer","score_opus":0.1339849863886814,"score_gpt":0.4217515987455929,"score_spread":0.28776661235691153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913271953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99674004,0.0010308229,0.00082607026,0.000039991963,0.00003387112,0.000098060766,0.00027679588,0.000063881744,0.0008904958],"genre_scores_gemma":[0.9979114,0.0002885253,0.00036984426,0.00006132459,0.000030535106,0.00003890711,0.00019582474,0.000016500126,0.0010870976],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995208,0.0001448124,0.000020664746,0.00011345468,0.00014878319,0.000051579136],"domain_scores_gemma":[0.9992229,0.00023658424,0.00014782349,0.000099460216,0.0000970961,0.00019615168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047258427,0.00044162388,0.0008455737,0.00036588148,0.0005401781,0.0006379797,0.00026353262,0.0005271123,0.0014773689],"category_scores_gemma":[0.0022950233,0.00042047878,0.00040217128,0.0003593308,0.00047303204,0.00046168792,0.00015088431,0.000886907,0.00039968773],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3111525,0.0056605227,0.24385962,0.00040785252,0.0013387338,0.002281568,0.0024712277,0.0027757918,0.29190972,0.00039114838,0.0017153097,0.13603607],"study_design_scores_gemma":[0.004227415,0.07605345,0.84360015,0.000026099537,0.00090633024,0.004479399,0.0009367337,0.00907871,0.05590336,0.00037956223,0.004301966,0.000106769854],"about_ca_topic_score_codex":0.0073587447,"about_ca_topic_score_gemma":0.0046422514,"teacher_disagreement_score":0.0073587447,"about_ca_system_score_codex":0.0004859931,"about_ca_system_score_gemma":0.00093471986,"threshold_uncertainty_score":0.014631808},"labels":[],"label_agreement":null},{"id":"W3005447570","doi":"10.1007/s40261-020-00893-8","title":"Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Queen's University","funders":"Boehringer Ingelheim","keywords":"Pharmacotherapy; Randomized controlled trial; Schizophrenia (object-oriented programming); Medicine; Cognition; Physical therapy; Double blind; Psychiatry; Internal medicine; Placebo; Alternative medicine","score_opus":0.35070056278581757,"score_gpt":0.4565512925816959,"score_spread":0.10585072979587834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005447570","genre_codex":"protocol","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4692762,0.002472893,0.0138647165,0.0011868019,0.0020376877,0.5038404,0.0020736502,0.0005136522,0.0047340514],"genre_scores_gemma":[0.42208216,0.0012735036,0.03833874,0.001690033,0.0011831482,0.5309491,0.0010386931,0.00008268291,0.0033620386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9804535,0.014980242,0.0013652998,0.001221481,0.0011432284,0.0008363232],"domain_scores_gemma":[0.9904283,0.0030889548,0.002280042,0.001626348,0.0012410147,0.0013353041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02511413,0.004075784,0.0063952645,0.0014484271,0.0014370512,0.0017012171,0.0018655297,0.004223065,0.008981629],"category_scores_gemma":[0.01770043,0.0018969409,0.004161991,0.0013100116,0.0029292698,0.0022073153,0.0014108568,0.0035510648,0.0019517053],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98111075,0.009202076,0.0003095744,0.00035948367,0.0005139774,0.0000117102545,0.0000472451,0.0003300208,0.0009741078,0.00016073148,0.00025852543,0.006721736],"study_design_scores_gemma":[0.9572694,0.04110392,0.0004077732,0.000023407378,0.00022367675,0.0000050485232,0.00000781425,0.00038222596,0.00017316954,0.00012646696,0.00026499195,0.000012230303],"about_ca_topic_score_codex":0.0010411509,"about_ca_topic_score_gemma":0.0016753003,"teacher_disagreement_score":0.02511413,"about_ca_system_score_codex":0.0016798491,"about_ca_system_score_gemma":0.0039834883,"threshold_uncertainty_score":0.1328178},"labels":[],"label_agreement":null},{"id":"W3006624590","doi":"10.1007/s40261-020-00894-7","title":"Mechanisms of Cannabinoids and Potential Applicability to Skin Diseases","year":2020,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Synthetic cannabinoids; Cannabis; Acne; Pharmacology; Cannabinoid; Bioinformatics; Dermatology; Psychiatry; Biology; Receptor; Internal medicine","score_opus":0.05416861842926524,"score_gpt":0.3990094038006741,"score_spread":0.3448407853714089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006624590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000102704784,0.9986002,0.000080899714,0.00011602227,0.00008108633,0.000004953034,0.000021526841,0.0000037098314,0.0009888965],"genre_scores_gemma":[0.00065479125,0.9984824,0.00014650937,0.00010121595,0.00008842393,0.000004691761,0.000022630598,6.059596e-7,0.00049880444],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999845,0.000025605314,0.000021555874,0.000028594119,0.00006160576,0.000017499433],"domain_scores_gemma":[0.9997557,0.0001298769,0.00003759595,0.0000073778774,0.000051391202,0.000018151628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049348525,0.0008066184,0.001372308,0.0027680763,0.0002508252,0.0011777232,0.0006691202,0.00094845454,0.00556125],"category_scores_gemma":[0.00075737236,0.00024950714,0.00052838644,0.0024014383,0.00045725706,0.0010003309,0.0006942053,0.0012906147,0.0014598311],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016579028,0.00009276483,0.00021092618,0.030505145,0.000121171855,0.0002521475,0.00005478436,0.00039885502,0.0031413678,0.004709779,0.014132657,0.9462145],"study_design_scores_gemma":[0.000048534548,0.00012804894,0.0014414446,0.0073681497,0.0003464487,0.001314079,0.000095999305,0.00017679048,0.00088058674,0.003960529,0.9842079,0.000031422627],"about_ca_topic_score_codex":0.0019066145,"about_ca_topic_score_gemma":0.0039062835,"teacher_disagreement_score":0.00556125,"about_ca_system_score_codex":0.0006972436,"about_ca_system_score_gemma":0.0014039623,"threshold_uncertainty_score":0.018604279},"labels":[],"label_agreement":null},{"id":"W307221476","doi":"10.2165/00044011-200424030-00004","title":"Depression during Pregnancy","year":2004,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Maternal Mental Health During Pregnancy and Postpartum","field":"Medicine","cited_by":313,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Pregnancy; Depression (economics); Epidemiology; Observational study; Psychiatry; Dosing; Antidepressant; Pharmacotherapy; Intensive care medicine; Anxiety; Internal medicine","score_opus":0.05335177734112267,"score_gpt":0.36465486671468483,"score_spread":0.31130308937356216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W307221476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8934889,0.042792916,0.0002862143,0.0057114116,0.00041312215,0.00014833188,0.0014094345,0.000016433607,0.055733185],"genre_scores_gemma":[0.9802382,0.0146054905,0.00015234305,0.00082173396,0.000116999465,0.00004363969,0.00033537424,0.0000024177257,0.0036837712],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996536,0.000096633004,0.00003498394,0.000036140256,0.0000634516,0.000115252136],"domain_scores_gemma":[0.99954695,0.000116768395,0.00012423092,0.000021870273,0.00006721214,0.00012294717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027754682,0.00011589293,0.00018399954,0.0004985789,0.0006686265,0.00053848146,0.00017273174,0.0003384168,0.001729537],"category_scores_gemma":[0.0023673668,0.00013251144,0.00016811393,0.00068872917,0.00013029668,0.00022326176,0.00030848832,0.00050294015,0.00025875928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005884664,0.0002771213,0.8169364,0.00027837683,0.00007411975,0.0042427774,0.0029385593,0.000055051612,0.0012982192,0.0011088965,0.0064650285,0.16573714],"study_design_scores_gemma":[0.000021032965,0.00018047579,0.9790596,0.00021007918,0.000055024684,0.00600755,0.001599955,0.000046528094,0.00024116632,0.00028091038,0.012287994,0.0000097094335],"about_ca_topic_score_codex":0.017062822,"about_ca_topic_score_gemma":0.0257398,"teacher_disagreement_score":0.017062822,"about_ca_system_score_codex":0.0010410919,"about_ca_system_score_gemma":0.0009457646,"threshold_uncertainty_score":0.033926964},"labels":[],"label_agreement":null},{"id":"W3152873057","doi":"10.1007/s40261-021-01033-6","title":"Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma","year":2021,"lang":"en","type":"letter","venue":"Clinical Drug Investigation","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Manchester Biomedical Research Centre; Novartis Pharma; National Institute for Health and Care Research; Novartis","keywords":"Indacaterol; Mometasone furoate; Medicine; Lung function; Asthma; Anesthesia; Pharmacology; Lung; Internal medicine; Corticosteroid","score_opus":0.02132686585436193,"score_gpt":0.26729580283147597,"score_spread":0.24596893697711403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152873057","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030193431,0.01887709,0.0005331361,0.8955456,0.018519653,0.00007516592,0.00023333254,0.00013123917,0.03589148],"genre_scores_gemma":[0.34340265,0.013141989,0.0009867101,0.53442883,0.090789735,0.00010619185,0.000324074,0.000069165224,0.016750641],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990458,0.00038905026,0.00012739039,0.00007239661,0.00023561381,0.00012978284],"domain_scores_gemma":[0.99720854,0.0016766787,0.00019705202,0.00013425753,0.00037930158,0.00040414027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013836123,0.0003281432,0.0008238688,0.0005019112,0.001136169,0.00077004766,0.0008180357,0.009145558,0.0023570983],"category_scores_gemma":[0.008240617,0.00021627086,0.00068630616,0.0006164126,0.0009710824,0.0007509216,0.00026445033,0.00505127,0.0019735703],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013958509,0.00033475162,0.028517598,0.00029548968,0.00010677032,0.17523651,0.0003170072,0.00041461285,0.0024327363,0.0036547605,0.71001244,0.07728156],"study_design_scores_gemma":[0.0022558747,0.0018080557,0.100995906,0.002277166,0.00030790237,0.3940643,0.00094418257,0.0065277023,0.002684059,0.022183618,0.4657835,0.00016779553],"about_ca_topic_score_codex":0.0035958295,"about_ca_topic_score_gemma":0.006420365,"teacher_disagreement_score":0.009145558,"about_ca_system_score_codex":0.001772709,"about_ca_system_score_gemma":0.001126266,"threshold_uncertainty_score":0.0128619075},"labels":[],"label_agreement":null},{"id":"W3183348330","doi":"10.1007/s40261-021-01059-w","title":"Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada","year":2021,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Migraine; Discontinuation; Tolerability; Chronic Migraine; Concomitant; Internal medicine; Pediatrics; Adverse effect","score_opus":0.04766454268181435,"score_gpt":0.31495744755964744,"score_spread":0.2672929048778331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183348330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996956,0.00051856274,0.000044169537,0.00041045694,0.0000089968335,0.000022973167,0.00031323565,0.000002710035,0.0017228744],"genre_scores_gemma":[0.99888414,0.00027175795,0.00008061054,0.000167224,0.000011851608,0.000003890129,0.00016557222,0.000002235618,0.000412734],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9994765,0.0000631805,0.000042510284,0.00006982701,0.00013137993,0.0002166157],"domain_scores_gemma":[0.9991196,0.00014364888,0.00018746071,0.000036698806,0.00027920777,0.00023347378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035064883,0.00023106122,0.0003220786,0.0007087093,0.0019925504,0.0009355743,0.0005869866,0.00064208434,0.0013920055],"category_scores_gemma":[0.001493566,0.00014804442,0.00022631802,0.001091294,0.00070858607,0.00025457476,0.00037762712,0.0005604172,0.00014600062],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022704843,0.00013448147,0.95286024,0.000056431516,0.00005762437,0.034635205,0.003061984,0.00011932079,0.0013669463,0.00015858699,0.0013418286,0.0059802607],"study_design_scores_gemma":[0.000022532082,0.00013779913,0.9622858,0.000048449278,0.00005465762,0.026249167,0.008106666,0.00036758732,0.00020090403,0.00004868239,0.00245266,0.000025051206],"about_ca_topic_score_codex":0.82460225,"about_ca_topic_score_gemma":0.905809,"teacher_disagreement_score":0.17539775,"about_ca_system_score_codex":0.0102430405,"about_ca_system_score_gemma":0.005915156,"threshold_uncertainty_score":0.3528614},"labels":[],"label_agreement":null},{"id":"W4212935414","doi":"10.1007/s40261-022-01121-1","title":"Significant Correlations between p-Cresol Sulfate and Mycophenolic Acid Plasma Concentrations in Adult Kidney Transplant Recipients","year":2022,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta Hospital; Alberta Hospital Edmonton; University of Alberta","funders":"","keywords":"Thymoglobulin; Medicine; Basiliximab; Mycophenolic acid; Tacrolimus; Internal medicine; Renal function; Kidney transplantation; Transplantation; Urology; Gastroenterology","score_opus":0.05223121414555955,"score_gpt":0.3257007181582811,"score_spread":0.2734695040127216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212935414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99860805,0.00053697074,0.00008255554,0.00007007594,0.000008564004,0.000003326871,0.00007983379,0.000003999104,0.000606678],"genre_scores_gemma":[0.9995272,0.00013183494,0.00007034449,0.000032118056,0.00001751903,0.0000019579456,0.00006014944,8.6750924e-7,0.00015796868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996798,0.000083360355,0.000050378338,0.00004087485,0.00007002295,0.000075532924],"domain_scores_gemma":[0.99751425,0.00074593804,0.0011114365,0.00007807641,0.00019740195,0.00035282815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045486822,0.00022922328,0.00024119989,0.00058661355,0.00022109089,0.00069668196,0.00016136983,0.0003889016,0.0016049554],"category_scores_gemma":[0.002771987,0.00015511144,0.00030982087,0.00057959487,0.0002352217,0.00030594165,0.0002668745,0.0005705876,0.00020659929],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041356636,0.000043322394,0.99619436,0.000010197029,0.000053146774,0.00022139294,0.00003461679,0.000027596778,0.0007838297,0.000028258952,0.000047609297,0.0021422582],"study_design_scores_gemma":[0.000008346466,0.00021049866,0.9983038,0.000005497906,0.00004859482,0.0004984549,0.000119889686,0.00020793201,0.00040709853,0.000035874553,0.00015129267,0.0000028423322],"about_ca_topic_score_codex":0.0009977492,"about_ca_topic_score_gemma":0.0014126726,"teacher_disagreement_score":0.0016049554,"about_ca_system_score_codex":0.00020843963,"about_ca_system_score_gemma":0.00041391625,"threshold_uncertainty_score":0.005369067},"labels":[],"label_agreement":null},{"id":"W4220663751","doi":"10.1007/s40261-022-01129-7","title":"Multiple Sclerosis Relapses Following Cessation of Fingolimod","year":2022,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"National Health and Medical Research Council; Grifols; Multiple Sclerosis Society; Multiple Sclerosis International Federation; Acorda Therapeutics; Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques; Teva Pharmaceutical Industries; Biogen; Celgene; Fondazione Italiana Sclerosi Multipla; Sanofi Genzyme; University of Melbourne; Sanofi","keywords":"Fingolimod; Medicine; Smoking cessation; Multiple sclerosis; Internal medicine; Pharmacotherapy; Disease; Physical therapy; Psychiatry; Pathology","score_opus":0.19720931043894974,"score_gpt":0.3747379330857507,"score_spread":0.17752862264680097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220663751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925598,0.0033346687,0.00019417089,0.00027436833,0.00002025081,0.000034512996,0.0015648808,0.00003483109,0.001982516],"genre_scores_gemma":[0.9975587,0.00087862666,0.00008522006,0.0000881384,0.00005000807,0.000015782343,0.0011233601,0.000005682603,0.00019440969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804026,0.0004170371,0.00030936082,0.00034064255,0.0006713205,0.00022136321],"domain_scores_gemma":[0.9906109,0.0018998669,0.0064497846,0.000359301,0.00039489035,0.0002851861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017823584,0.00016764746,0.00064142316,0.0008004935,0.00027051038,0.0006818469,0.0003612255,0.00032386693,0.0025249082],"category_scores_gemma":[0.008216972,0.00015065343,0.0008050231,0.0009927928,0.00019294696,0.00037718276,0.00045197236,0.00071472244,0.00041097606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057476247,0.00005000058,0.98087615,0.00017266077,0.0002762452,0.00043211135,0.0001382865,0.00013339733,0.0002721321,0.000041950643,0.00086149934,0.016170755],"study_design_scores_gemma":[0.00001396593,0.00009493327,0.99745554,0.00007563812,0.000079756326,0.001328546,0.00005924817,0.00015879617,0.00013146435,0.00005296127,0.0005437144,0.0000054363027],"about_ca_topic_score_codex":0.002174153,"about_ca_topic_score_gemma":0.002218656,"teacher_disagreement_score":0.0025249082,"about_ca_system_score_codex":0.00047405448,"about_ca_system_score_gemma":0.0003303637,"threshold_uncertainty_score":0.009426117},"labels":[],"label_agreement":null},{"id":"W4246989892","doi":"10.1007/s40261-013-0114-9","title":"Italian Perspective on Psoriasis, Spondyloarthritis, Rheumatoid Arthritis and Juvenile Idiopathic Arthritis: Immunopathology and Role of Etanercept","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph's Hospital","funders":"Pfizer","keywords":"Etanercept; Medicine; Rheumatoid arthritis; Psoriasis; Arthritis; Dermatology; Juvenile rheumatoid arthritis; Antirheumatic Agents; Psoriatic arthritis; Immunopathology; Pharmacotherapy; Immunology; Internal medicine","score_opus":0.017533638634001536,"score_gpt":0.29929788868104024,"score_spread":0.2817642500470387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246989892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00048377496,0.8756798,0.000083609346,0.09781447,0.013050576,0.000006929703,0.00017633833,0.000022903629,0.01268164],"genre_scores_gemma":[0.010477451,0.7867718,0.00049802236,0.08840459,0.098027155,0.00004290927,0.0002296797,0.000023597253,0.015524747],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99922013,0.0002623641,0.00008185465,0.000096029275,0.0001817688,0.00015786699],"domain_scores_gemma":[0.9980585,0.0005932706,0.00038993012,0.000049035974,0.00041960957,0.00048967346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002234375,0.0011695136,0.0009936175,0.0017727037,0.00051904755,0.0019665472,0.00054154196,0.0037653188,0.012901039],"category_scores_gemma":[0.0017293419,0.00030411477,0.0006931178,0.00211222,0.0010089423,0.0018216633,0.00091386406,0.003542192,0.0034829457],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000687216,0.00011895819,0.0013962614,0.0030741135,0.00008205418,0.0006890174,0.00012714413,0.00019799768,0.0013545612,0.008729381,0.7998855,0.1836578],"study_design_scores_gemma":[0.00007835189,0.00008832769,0.003734434,0.0009275463,0.000057443372,0.0007658766,0.000045692228,0.000033518503,0.000042562435,0.00074810046,0.99346644,0.000011718888],"about_ca_topic_score_codex":0.0036947764,"about_ca_topic_score_gemma":0.009578063,"teacher_disagreement_score":0.012901039,"about_ca_system_score_codex":0.0021299182,"about_ca_system_score_gemma":0.003179053,"threshold_uncertainty_score":0.043158293},"labels":[],"label_agreement":null},{"id":"W4289918702","doi":"10.1007/s40261-022-01182-2","title":"Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective","year":2022,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Regione Autonoma della Sardegna; Università degli Studi di Cagliari","keywords":"Major depressive disorder; Cost-effectiveness analysis; CYP2C19; Medicine; Psychiatry; Quality-adjusted life year; Cost effectiveness; Cost–utility analysis; Clinical psychology; Risk analysis (engineering); Internal medicine","score_opus":0.3473253564150627,"score_gpt":0.532487651890823,"score_spread":0.18516229547576035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289918702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9458125,0.0025416387,0.03957378,0.0020983545,0.000041918247,0.00042694187,0.0016473314,0.0000575056,0.0077999434],"genre_scores_gemma":[0.99582434,0.00040007939,0.0028978589,0.00007589845,0.0000129871705,0.00008137592,0.00028642794,0.000006239769,0.00041476788],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9961416,0.0030608482,0.00007306702,0.00021995169,0.00021299325,0.0002915212],"domain_scores_gemma":[0.9757505,0.022048669,0.0010994296,0.00043460808,0.00041942592,0.00024733174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00810648,0.0011997769,0.0009912031,0.0013588993,0.0002629105,0.0014566885,0.0010410888,0.0011466241,0.0024115704],"category_scores_gemma":[0.020242989,0.00052475766,0.0026127768,0.0010322935,0.000692676,0.00092780736,0.0010554267,0.001066831,0.00009034696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061049045,0.000112239424,0.014181832,0.00012700818,0.00040074796,0.00019607731,0.000045500925,0.97231627,0.00024428967,0.0058399253,0.00031800606,0.005607568],"study_design_scores_gemma":[0.00013753763,0.00063439086,0.014221407,0.00008202001,0.00057768717,0.00019493663,0.00010661159,0.9770905,0.0002806667,0.006126394,0.00050537253,0.00004250052],"about_ca_topic_score_codex":0.012944223,"about_ca_topic_score_gemma":0.005888165,"teacher_disagreement_score":0.012944223,"about_ca_system_score_codex":0.0056644827,"about_ca_system_score_gemma":0.0022631665,"threshold_uncertainty_score":0.042871714},"labels":[],"label_agreement":null},{"id":"W4303649374","doi":"10.1007/s40261-022-01209-8","title":"The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Hartstichting; Medical Research Council; ZonMw; Teva Pharmaceutical Industries","keywords":"Medicine; Colchicine; Renal function; Internal medicine; Creatinine; Creatine kinase; Blood urea nitrogen; Placebo; Liver function; Liver function tests; Bilirubin; Gastroenterology; Coronary artery disease; Endocrinology; Pathology","score_opus":0.0128010725083666,"score_gpt":0.2588416079498216,"score_spread":0.246040535441455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303649374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682769,0.027514435,0.000216878,0.0007224667,0.00013137453,0.0001754522,0.00089871197,0.000013053037,0.002050713],"genre_scores_gemma":[0.99450594,0.003583073,0.00016396033,0.00047806412,0.00013741506,0.0001215263,0.00059365714,0.0000041457856,0.00041222217],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99916947,0.00056802714,0.000057892154,0.000071027,0.00006736127,0.000066172],"domain_scores_gemma":[0.9982998,0.00060093537,0.00064554997,0.00009299321,0.00013235162,0.00022844462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016386313,0.00031321845,0.00087960623,0.00013391301,0.00021230275,0.0006788504,0.00022447051,0.0005586743,0.0017089369],"category_scores_gemma":[0.001893042,0.00009297058,0.00070409087,0.00026660494,0.00033187418,0.0002340954,0.00023069295,0.00079982786,0.00020352358],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76775956,0.0023751145,0.08433284,0.005786822,0.009752387,0.00022389156,0.00024359096,0.00080157595,0.014814006,0.00031956434,0.005324026,0.108266674],"study_design_scores_gemma":[0.24849758,0.23857267,0.4634327,0.0013523055,0.015711507,0.0009709477,0.00041128142,0.0013957693,0.006916841,0.0007769267,0.021827316,0.00013410149],"about_ca_topic_score_codex":0.00055263954,"about_ca_topic_score_gemma":0.0020618113,"teacher_disagreement_score":0.0017089369,"about_ca_system_score_codex":0.0004414412,"about_ca_system_score_gemma":0.00037654597,"threshold_uncertainty_score":0.0086660385},"labels":[],"label_agreement":null},{"id":"W4319302860","doi":"10.1007/s40261-022-01241-8","title":"A Single- and Multiple-Dose Pharmacokinetic Study of Oral Perampanel in Healthy Chinese Subjects","year":2023,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai","keywords":"Perampanel; Pharmacokinetics; Tolerability; Cmax; Medicine; Area under the curve; Pharmacology; Epilepsy; Anesthesia; Gastroenterology; Adverse effect","score_opus":0.14763831980539976,"score_gpt":0.4407086908938581,"score_spread":0.29307037108845835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319302860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999114,0.00019582808,0.00020302033,0.000017269007,0.0000053010913,0.00013241573,0.00009342698,0.000010092605,0.00022850951],"genre_scores_gemma":[0.9983596,0.0001841381,0.0003898222,0.00011428021,0.0000173866,0.00012853675,0.0002135343,0.0000040481013,0.00058867916],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99968934,0.000086972854,0.000020469952,0.00010237953,0.000055205706,0.00004571466],"domain_scores_gemma":[0.99972683,0.00004036588,0.00004766621,0.000032645174,0.000046233876,0.00010619649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009032277,0.00066490093,0.0010362279,0.0002924694,0.00054942473,0.00027426422,0.00025196778,0.0004609606,0.0014012441],"category_scores_gemma":[0.0005795021,0.00034377028,0.00037433748,0.00030339396,0.00045078437,0.0004701268,0.00021260194,0.000515205,0.00032751652],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13340355,0.024470996,0.28457293,0.0011606398,0.0019756407,0.0023093384,0.00440613,0.0014701856,0.4176553,0.0003525556,0.0025252497,0.12569752],"study_design_scores_gemma":[0.010948292,0.23179819,0.7312187,0.000019401212,0.0011085136,0.0021667345,0.00065785577,0.002830629,0.014636486,0.00016541622,0.0043172664,0.00013254453],"about_ca_topic_score_codex":0.00255041,"about_ca_topic_score_gemma":0.0030321144,"teacher_disagreement_score":0.00255041,"about_ca_system_score_codex":0.00042637833,"about_ca_system_score_gemma":0.00076561247,"threshold_uncertainty_score":0.005071163},"labels":[],"label_agreement":null},{"id":"W4381598306","doi":"10.1007/s40261-023-01278-3","title":"Safety, Tolerability, Bioavailability, and Biological Activity of Inhaled Interferon-α2b in Healthy Adults: The IN2COVID Phase I Randomized Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Tolerability; Medicine; Placebo; Adverse effect; Vital signs; Internal medicine; Bioavailability; Cohort; Randomized controlled trial; Pharmacology; Anesthesia; Pathology","score_opus":0.07083239280995628,"score_gpt":0.37751660517047075,"score_spread":0.30668421236051446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381598306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900405,0.0041353656,0.0005898299,0.00044614976,0.0002769586,0.0016833751,0.0012747265,0.000052180512,0.0015009075],"genre_scores_gemma":[0.9887278,0.0023212256,0.0009896418,0.0010185603,0.00041306746,0.0017404495,0.0020572941,0.000026212143,0.0027057186],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990375,0.0005146506,0.000055950128,0.00017345614,0.00007487754,0.0001435118],"domain_scores_gemma":[0.9986253,0.0003900264,0.00035762647,0.00015092024,0.000092439666,0.00038372335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002054067,0.0018037047,0.003203957,0.0003120554,0.00048585027,0.0013750226,0.00085957116,0.0020204585,0.0055443775],"category_scores_gemma":[0.0020604762,0.00071855413,0.0020943796,0.00039190784,0.0013111725,0.0009823542,0.000430802,0.0031694542,0.0009943424],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9847584,0.002956177,0.0012835214,0.00020103171,0.000820959,0.000023994706,0.00002935903,0.00015737966,0.0018612352,0.000057508405,0.00037366888,0.007476767],"study_design_scores_gemma":[0.9137403,0.0799383,0.0038506603,0.000030740026,0.0007799044,0.00004213585,0.0000265213,0.00025212625,0.0005409561,0.00012876157,0.00065303623,0.00001661981],"about_ca_topic_score_codex":0.0010433875,"about_ca_topic_score_gemma":0.0013785622,"teacher_disagreement_score":0.0055443775,"about_ca_system_score_codex":0.0010645544,"about_ca_system_score_gemma":0.0010843034,"threshold_uncertainty_score":0.018547773},"labels":[],"label_agreement":null},{"id":"W4384820193","doi":"10.1007/s40261-023-01287-2","title":"Elevations in Creatine Kinase are Not Related to the Choice or Dose of Statins in Patients Taking Colchicine 0.5 mg Daily: Insights from the LoDoCo2 Trial","year":2023,"lang":"en","type":"letter","venue":"Clinical Drug Investigation","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Medical Research Council; ZonMw; Teva Pharmaceutical Industries","keywords":"Medicine; Colchicine; Creatine kinase; Pharmacotherapy; Pharmacology; Simvastatin; Internal medicine; Intensive care medicine","score_opus":0.09666996585426156,"score_gpt":0.36331875718599727,"score_spread":0.2666487913317357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384820193","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06369626,0.015048188,0.00025183495,0.8768676,0.010086183,0.000053323445,0.0022738497,0.000060203536,0.031662572],"genre_scores_gemma":[0.2795517,0.0081372745,0.0006875919,0.6579914,0.04063967,0.00014180118,0.001102932,0.00006217332,0.011685431],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849224,0.0008324172,0.00015889408,0.000116761374,0.0002625686,0.0001370683],"domain_scores_gemma":[0.99311465,0.004861006,0.0006240828,0.00020194371,0.00051525177,0.000683187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025317483,0.00037473417,0.0012379445,0.00027743305,0.00083037454,0.001451876,0.00063003897,0.0077664647,0.0029382622],"category_scores_gemma":[0.012703245,0.00022369261,0.00057871966,0.0006722926,0.00075375097,0.00064581353,0.00029065672,0.0060659195,0.0021460862],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019507015,0.00041573486,0.079644226,0.00047853362,0.0007152486,0.013990534,0.00043084112,0.00033708627,0.0029939818,0.003245899,0.7827774,0.09546344],"study_design_scores_gemma":[0.018971926,0.0047597946,0.2450117,0.0017820791,0.0021061148,0.026557656,0.0014312787,0.0036123947,0.002785864,0.023447014,0.66917616,0.00035804426],"about_ca_topic_score_codex":0.003992976,"about_ca_topic_score_gemma":0.009728875,"teacher_disagreement_score":0.0077664647,"about_ca_system_score_codex":0.0012830684,"about_ca_system_score_gemma":0.0011781316,"threshold_uncertainty_score":0.013389349},"labels":[],"label_agreement":null},{"id":"W4386501607","doi":"10.1007/s40261-023-01282-7","title":"Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis","year":2023,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"Merck Sharp and Dohme","keywords":"Posaconazole; Voriconazole; Medicine; Aspergillosis; Pharmacokinetics; Population; Clinical endpoint; Internal medicine; Adverse effect; Quartile; Randomized controlled trial; Confidence interval; Antifungal; Immunology","score_opus":0.11925961162710076,"score_gpt":0.41330703928924056,"score_spread":0.2940474276621398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386501607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821093,0.0013920923,0.0053874296,0.0002454885,0.00028116239,0.008412386,0.0006458836,0.00016116844,0.001364982],"genre_scores_gemma":[0.98375064,0.0005697886,0.0057799425,0.00043387205,0.0003203802,0.007373648,0.00057840504,0.000047534235,0.0011457729],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9832496,0.013591052,0.0006509917,0.0008768885,0.00097418594,0.0006573144],"domain_scores_gemma":[0.98822045,0.0057192165,0.002409349,0.0015279589,0.0008126487,0.0013104501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016756037,0.0017391657,0.0040255706,0.0008080216,0.0005469908,0.0010948761,0.00097098254,0.0020452149,0.003094257],"category_scores_gemma":[0.014670876,0.0010760045,0.0031967044,0.0006482348,0.001816298,0.0015066743,0.0005937628,0.0029527112,0.00046554444],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9730249,0.010879719,0.00089408376,0.00020539496,0.0009303582,0.000025611142,0.000058437825,0.0008460443,0.0038081235,0.00012933137,0.00019202715,0.009006056],"study_design_scores_gemma":[0.6354734,0.34682336,0.008458594,0.000023529086,0.0009748696,0.00005590474,0.00002419195,0.00463963,0.0020494517,0.00053117325,0.0008951867,0.00005070059],"about_ca_topic_score_codex":0.00037399703,"about_ca_topic_score_gemma":0.00060639204,"teacher_disagreement_score":0.016756037,"about_ca_system_score_codex":0.0009951162,"about_ca_system_score_gemma":0.0022904093,"threshold_uncertainty_score":0.08861548},"labels":[],"label_agreement":null},{"id":"W4387326964","doi":"10.1007/s40261-023-01303-5","title":"Acthar® Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence","year":2023,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Polymyositis; Dermatomyositis; Mallinckrodt; Rheumatoid arthritis; Etanercept; Rituximab; Immunology; Dermatology; Lymphoma","score_opus":0.22788604157527756,"score_gpt":0.4625133993624705,"score_spread":0.23462735778719293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387326964","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022810439,0.99702114,0.00012808084,0.0015007305,0.00034148505,0.0000055346463,0.000017455102,0.000004246402,0.0007531477],"genre_scores_gemma":[0.0020905992,0.99428046,0.00039539556,0.0016973338,0.0013030781,0.000012671536,0.00002827196,0.0000030462077,0.0001890822],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991518,0.00021782037,0.00026354133,0.00014117587,0.00019398915,0.00003161885],"domain_scores_gemma":[0.9957681,0.0026504411,0.00045072453,0.00007384479,0.0008967122,0.00016025263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023165836,0.0006717393,0.0012360505,0.0035918443,0.0006152543,0.0015888988,0.0007312639,0.0014251841,0.0018472774],"category_scores_gemma":[0.0049540303,0.00034623925,0.00090039906,0.0023891008,0.0012222001,0.0028285943,0.00067821506,0.0029669448,0.0006908657],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031740512,0.000102407066,0.001986644,0.03867747,0.00033611243,0.000948798,0.00045734918,0.00027061068,0.001792202,0.010134868,0.04068237,0.9042938],"study_design_scores_gemma":[0.00005990291,0.00035462494,0.0037526116,0.030547878,0.00083124026,0.006578249,0.0003579495,0.00019127187,0.0008919029,0.004255309,0.9520975,0.00008152672],"about_ca_topic_score_codex":0.0009618514,"about_ca_topic_score_gemma":0.0018734622,"teacher_disagreement_score":0.0035918443,"about_ca_system_score_codex":0.0010262888,"about_ca_system_score_gemma":0.0015588313,"threshold_uncertainty_score":0.012251377},"labels":[],"label_agreement":null},{"id":"W4390618444","doi":"10.1007/s40261-023-01329-9","title":"Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches","year":2024,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Imatinib; Health care; Tyrosine kinase; Tyrosine-kinase inhibitor; Life expectancy; Intensive care medicine; Tolerability; Pharmacology; Cancer research; Internal medicine; Cancer; Environmental health; Population; Adverse effect","score_opus":0.15196433801219633,"score_gpt":0.3743277414487546,"score_spread":0.22236340343655825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390618444","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025167086,0.99821967,0.0002197167,0.0007208903,0.000038603335,0.0000057098973,0.00003291119,0.0000020880927,0.0005086573],"genre_scores_gemma":[0.0029079395,0.9963025,0.0004478431,0.00015551526,0.00007852605,0.000008647991,0.000019489682,9.575855e-7,0.0000785683],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995054,0.00019350246,0.0000679691,0.000056624882,0.00014126961,0.000035278117],"domain_scores_gemma":[0.9980835,0.001374333,0.00028284432,0.000014933097,0.00021300871,0.00003143695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016485174,0.0010399033,0.0018906019,0.0016694942,0.00015628473,0.0016907074,0.0010193828,0.0010333237,0.0026417421],"category_scores_gemma":[0.0036840388,0.00028621373,0.0013552686,0.0026010864,0.00033478154,0.0010731565,0.0005109931,0.0016272826,0.0002987233],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021478324,0.00013168786,0.00085656496,0.03410214,0.0015761651,0.00007196424,0.000030388896,0.008162448,0.00033526425,0.019569047,0.012938366,0.9220112],"study_design_scores_gemma":[0.0004956072,0.0010823776,0.018075384,0.15091178,0.010378036,0.0014965445,0.0005455276,0.015465912,0.0014075047,0.05972153,0.7401883,0.00023144398],"about_ca_topic_score_codex":0.004758613,"about_ca_topic_score_gemma":0.009994034,"teacher_disagreement_score":0.004758613,"about_ca_system_score_codex":0.0017546312,"about_ca_system_score_gemma":0.003118167,"threshold_uncertainty_score":0.012730777},"labels":[],"label_agreement":null},{"id":"W4391391181","doi":"10.1007/s40261-024-01341-7","title":"Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance","year":2024,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Etanercept; Medicine; Adalimumab; Biosimilar; Rheumatoid arthritis; Internal medicine; Infliximab; Observational study; Disease; Arthritis","score_opus":0.041359489177806366,"score_gpt":0.3287282879898965,"score_spread":0.28736879881209015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391391181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99924624,0.0003647207,0.00010169449,0.000018170553,0.0000058687233,0.0000072286625,0.000086973036,0.0000020063358,0.00016707847],"genre_scores_gemma":[0.9997112,0.000049351518,0.000050786242,0.000007214791,0.0000083410805,0.0000062513045,0.0001240994,6.3691283e-7,0.000042246702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866426,0.00048033346,0.00021078462,0.00023149898,0.0002674096,0.00014564022],"domain_scores_gemma":[0.9935489,0.0011932988,0.003951941,0.00022510313,0.00033495514,0.00074568123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019248896,0.00030875934,0.0005368487,0.00054744823,0.0003168351,0.00065717683,0.00020954176,0.0004963746,0.00076976116],"category_scores_gemma":[0.0039882073,0.00014263857,0.0006640298,0.0005847541,0.00025843628,0.00053857645,0.0004120356,0.0006856423,0.00021423637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028906874,0.00011001275,0.99346465,0.000024025063,0.000074799784,0.00008175406,0.000097767515,0.00009438929,0.00045413335,0.000009959094,0.000035478985,0.0026621348],"study_design_scores_gemma":[0.000058516274,0.0022492546,0.9960603,0.000010376284,0.00009953859,0.00038732452,0.00009218518,0.000479318,0.0003192232,0.000027043268,0.00020662221,0.000010321548],"about_ca_topic_score_codex":0.00046831937,"about_ca_topic_score_gemma":0.00034946273,"teacher_disagreement_score":0.0019248896,"about_ca_system_score_codex":0.00030007,"about_ca_system_score_gemma":0.0002054413,"threshold_uncertainty_score":0.010179877},"labels":[],"label_agreement":null},{"id":"W4401794058","doi":"10.1007/s40261-024-01368-w","title":"Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2024,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Universidad Autónoma de Madrid","keywords":"Roflumilast; Medicine; Psoriasis; Randomized controlled trial; Adverse effect; Food and drug administration; Dermatology; Meta-analysis; Safety profile; Intensive care medicine; Pharmacology; Internal medicine; Pulmonary disease","score_opus":0.19724499704418705,"score_gpt":0.41843696655347923,"score_spread":0.22119196950929218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401794058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002676054,0.9958253,0.00034830612,0.00014777621,0.000108617016,0.00032034324,0.00034307636,0.000017355336,0.00021327984],"genre_scores_gemma":[0.09175104,0.90263075,0.0020064425,0.0009249749,0.0002435332,0.0013660149,0.00075478014,0.000030999327,0.000291505],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9877101,0.005450911,0.0040324954,0.0011171356,0.0014156491,0.00027377548],"domain_scores_gemma":[0.97899526,0.014800562,0.0037822465,0.0005555257,0.0016254818,0.00024083655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014983462,0.0027420018,0.02169782,0.0064978325,0.0006569817,0.0035078228,0.002189596,0.0020927058,0.0038659135],"category_scores_gemma":[0.032481737,0.0013695518,0.03303984,0.007532148,0.0008436679,0.0018708986,0.0013493598,0.0019347435,0.0003578158],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002364094,0.00003340792,0.0015807559,0.5415479,0.4389226,0.00008720269,0.00007626618,0.00037738102,0.00022856367,0.00013594945,0.0006127123,0.014033115],"study_design_scores_gemma":[0.0010383014,0.00025734553,0.002062738,0.041074343,0.9531045,0.00007812414,0.00004341596,0.0001541042,0.00013088086,0.00019118114,0.0018400893,0.000025070933],"about_ca_topic_score_codex":0.0049341656,"about_ca_topic_score_gemma":0.010908771,"teacher_disagreement_score":0.02169782,"about_ca_system_score_codex":0.0028619503,"about_ca_system_score_gemma":0.0041144383,"threshold_uncertainty_score":0.07924104},"labels":[],"label_agreement":null},{"id":"W4407859078","doi":"10.1007/s40261-025-01426-x","title":"Economic Model of Uridine Triacetate Versus Supportive Care for the Treatment of Patients with Life-Threatening Early-Onset Severe Toxicity","year":2025,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Toxicity; Pharmacotherapy; Intensive care medicine; Pediatrics; Internal medicine","score_opus":0.05931122926178046,"score_gpt":0.34798245632751945,"score_spread":0.288671227065739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407859078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8264464,0.0033486239,0.11073833,0.007828645,0.00037373774,0.0010915787,0.009380411,0.00023744417,0.040554706],"genre_scores_gemma":[0.97866577,0.0009290954,0.009158511,0.00038105587,0.00006567925,0.0006074022,0.0014248092,0.000019405607,0.008748202],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9983071,0.0010541664,0.000035393034,0.00018244759,0.000104144536,0.00031675398],"domain_scores_gemma":[0.99497,0.0038444307,0.0003952634,0.000041618518,0.00034842722,0.0004002584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031113413,0.001579112,0.0020225006,0.0017881801,0.0008025603,0.0026395444,0.0023508416,0.0030456465,0.009821723],"category_scores_gemma":[0.0062348093,0.0008210435,0.0022133484,0.0016104685,0.0008861616,0.0013711485,0.0011214915,0.0023303684,0.00052624027],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003750445,0.00011382486,0.0025705793,0.00006802383,0.00008024879,0.00016475642,0.000021506277,0.98949754,0.00007739045,0.004594925,0.0006835946,0.0017525424],"study_design_scores_gemma":[0.00013426742,0.00018070622,0.0007808798,0.000030143188,0.000095136355,0.000045091758,0.00004315878,0.9959971,0.000035056597,0.002194691,0.0004506603,0.00001317356],"about_ca_topic_score_codex":0.039689697,"about_ca_topic_score_gemma":0.019527052,"teacher_disagreement_score":0.039689697,"about_ca_system_score_codex":0.00642318,"about_ca_system_score_gemma":0.00476589,"threshold_uncertainty_score":0.078917325},"labels":[],"label_agreement":null},{"id":"W4414016326","doi":"10.1007/s40261-025-01476-1","title":"Off-Label Prescription of Benzodiazepines: A Retrospective Cohort Study of Prescribing Prevalence in Primary Care","year":2025,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Sleep and related disorders","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Medical prescription; Benzodiazepine; Off-label use; Pharmacy; Pharmacoepidemiology; Pharmacotherapy; Psychiatry; Pediatrics; Family medicine; Internal medicine; Pharmacology","score_opus":0.03358103271673089,"score_gpt":0.34480058428255417,"score_spread":0.31121955156582326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414016326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99897325,0.00015033262,0.000071395974,0.000026491187,0.000005765609,0.000015521797,0.00049961207,0.0000032505586,0.0002544868],"genre_scores_gemma":[0.99910396,0.000104980434,0.00008987001,0.000056064102,0.000009710645,0.000013714252,0.00045236797,0.0000041642743,0.0001651341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981316,0.0004824722,0.0002431955,0.0005658419,0.0002720779,0.00030478602],"domain_scores_gemma":[0.99534434,0.00073411997,0.0019339657,0.00058644963,0.00058685424,0.0008142956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009684717,0.00045143586,0.00061676285,0.0015380856,0.0014300538,0.0017228312,0.0007502918,0.0011318151,0.0023263143],"category_scores_gemma":[0.003587833,0.0011707736,0.0010708016,0.002249634,0.00061564875,0.001475114,0.0010858186,0.0013929934,0.0006609367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054495777,0.000060728256,0.9993482,0.000004453131,0.000046986228,0.00005635541,0.0001234322,0.0000065047266,0.00008558692,0.000005598966,0.00003662433,0.0001711346],"study_design_scores_gemma":[0.0000061396913,0.000112399146,0.9990175,0.0000046960217,0.000026510379,0.00022371153,0.00046517453,0.000062028084,0.000020106501,0.00000589208,0.000051534535,0.0000042256356],"about_ca_topic_score_codex":0.035091173,"about_ca_topic_score_gemma":0.03769985,"teacher_disagreement_score":0.035091173,"about_ca_system_score_codex":0.00084693683,"about_ca_system_score_gemma":0.0010159841,"threshold_uncertainty_score":0.06977379},"labels":[],"label_agreement":null},{"id":"W4414443146","doi":"10.1007/s40261-025-01478-z","title":"Mucous Membrane Pemphigoid Outcome Measurement in Clinical Research: A Scoping Review","year":2025,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Outcome (game theory); Critical appraisal; Patient-reported outcome; MEDLINE; Pharmacotherapy; Perspective (graphical); Pemphigoid","score_opus":0.6380473468550989,"score_gpt":0.6038945010449779,"score_spread":0.03415284581012101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414443146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006096075,0.99965394,0.000034318065,0.00007105961,0.000050088787,0.000021563597,0.000028042143,0.0000016640911,0.00007833654],"genre_scores_gemma":[0.0010146925,0.99844366,0.00018060295,0.00019718474,0.00004443696,0.000044000844,0.000034317894,0.0000012195455,0.000039851162],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99396026,0.0017284277,0.0022925683,0.0006034122,0.0011786711,0.00023673428],"domain_scores_gemma":[0.97151595,0.022825975,0.0034791431,0.0003264974,0.001587457,0.0002649913],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01282119,0.00161285,0.0099206185,0.009753041,0.0006851664,0.0051135714,0.002211358,0.0035225647,0.004848892],"category_scores_gemma":[0.02747557,0.0011653345,0.0053794957,0.010604519,0.0015714959,0.003179195,0.0026471661,0.0023824559,0.00053533056],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022824234,0.000055341738,0.0007416591,0.74452996,0.004439666,0.00012679888,0.00019632553,0.0001740692,0.0002610829,0.0009027276,0.0051622265,0.24318191],"study_design_scores_gemma":[0.00021310092,0.00013868566,0.0027517804,0.8916922,0.028047815,0.00039423862,0.00027390715,0.00012232456,0.00016766632,0.0009990326,0.07514028,0.000058907237],"about_ca_topic_score_codex":0.005746303,"about_ca_topic_score_gemma":0.013106287,"teacher_disagreement_score":0.9871788,"about_ca_system_score_codex":0.0029782024,"about_ca_system_score_gemma":0.009402525,"threshold_uncertainty_score":0.06780571},"labels":[],"label_agreement":null},{"id":"W4414755693","doi":"10.1007/s40261-025-01487-y","title":"Intra-arterial Injection of OTR4132, a Novel Neuroprotector in Acute Ischemic Stroke: The MaTRISS Trial","year":2025,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Horizon 2020 Framework Programme; European Commission","keywords":"Clinical trial; Pharmacotherapy; Randomized controlled trial; Adverse effect; Drug","score_opus":0.034105945531067786,"score_gpt":0.3325746821015559,"score_spread":0.2984687365704881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414755693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884916,0.007175153,0.0003742487,0.0005228981,0.00014808579,0.0005845227,0.00047745797,0.000070062604,0.0017985211],"genre_scores_gemma":[0.9859081,0.0061099883,0.0012192446,0.0010815618,0.0006291895,0.0013850937,0.0015077092,0.000024301118,0.0021349601],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996916,0.00014253224,0.000029248242,0.000045258155,0.00004812306,0.000043340027],"domain_scores_gemma":[0.99969816,0.000043879303,0.00011327155,0.000039233426,0.000029202112,0.00007639831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009553063,0.0010626313,0.0013538852,0.0002554203,0.00022421723,0.0006813717,0.0004510068,0.0009836532,0.0018112487],"category_scores_gemma":[0.00055878423,0.000193977,0.0009858983,0.00033029504,0.00046499135,0.0004717696,0.00025673996,0.0015056933,0.00045622303],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80902845,0.010859964,0.0059640068,0.0026328904,0.0024730344,0.00035523754,0.00020590202,0.0012987813,0.02621443,0.0007282963,0.0049698967,0.1352691],"study_design_scores_gemma":[0.58337456,0.36888966,0.02499963,0.0003140142,0.00257076,0.0008927749,0.00008284529,0.0023112781,0.008305803,0.0007585077,0.007431009,0.000069150956],"about_ca_topic_score_codex":0.00019391616,"about_ca_topic_score_gemma":0.00041792728,"teacher_disagreement_score":0.0018112487,"about_ca_system_score_codex":0.00030243548,"about_ca_system_score_gemma":0.00060679356,"threshold_uncertainty_score":0.00605917},"labels":[],"label_agreement":null},{"id":"W4415229655","doi":"10.1007/s40261-025-01474-3","title":"Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies in Healthy Adults","year":2025,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"Neuraxpharm","keywords":"Bioequivalence; Methylphenidate; Crossover study; Bioavailability; Suspension (topology); Drug; Dosage form","score_opus":0.18074646386597096,"score_gpt":0.46231584406963544,"score_spread":0.2815693802036645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415229655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932441,0.0027427208,0.00048780965,0.00013586655,0.00020677639,0.0022096583,0.000411093,0.00004644367,0.00051558285],"genre_scores_gemma":[0.99105597,0.001952387,0.001799596,0.00022545818,0.00036610643,0.0027537101,0.0004582342,0.00002268098,0.0013658007],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99788326,0.0011242211,0.00023543977,0.00035565367,0.00022149985,0.00017998557],"domain_scores_gemma":[0.9976411,0.0007894209,0.00069497706,0.00018603845,0.00023302538,0.0004555172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035786477,0.00161668,0.004326292,0.00067401514,0.00046078398,0.00095243164,0.0010447212,0.0026691812,0.004350632],"category_scores_gemma":[0.0039472696,0.0015167508,0.0021714682,0.00047184335,0.0013979365,0.001882901,0.0006059795,0.0021362964,0.0006940432],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9624791,0.012852398,0.0004056603,0.0005972388,0.00067754736,0.00004054474,0.00010789238,0.00014786996,0.012557385,0.00004385839,0.00018435543,0.009906184],"study_design_scores_gemma":[0.4475499,0.5432647,0.0041916943,0.000029653347,0.0009079378,0.000051060444,0.000036622936,0.00037023355,0.0030665586,0.00010139215,0.0003927816,0.000037366095],"about_ca_topic_score_codex":0.00067889085,"about_ca_topic_score_gemma":0.0011071496,"teacher_disagreement_score":0.004350632,"about_ca_system_score_codex":0.0005727357,"about_ca_system_score_gemma":0.0010749942,"threshold_uncertainty_score":0.018925905},"labels":[],"label_agreement":null},{"id":"W4415567623","doi":"10.1007/s40261-025-01489-w","title":"Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia","year":2025,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Melbourne; International Society of Oncology Pharmacy Practitioners","keywords":"Reimbursement; DPYD; Genotyping; Standard of care; Pharmacotherapy; Health care; Pharmacogenetics; Health economics","score_opus":0.21893161215604237,"score_gpt":0.5177472132587021,"score_spread":0.2988156011026597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415567623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98779047,0.002343016,0.0038134789,0.0020463478,0.00003729978,0.0002853938,0.0009001531,0.00004316727,0.0027406192],"genre_scores_gemma":[0.99804074,0.00031628195,0.00094524986,0.00014491506,0.0000059821296,0.000056114626,0.00021317923,0.000003578455,0.00027398558],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9968202,0.0023595009,0.00012793417,0.0002890987,0.0001729202,0.00023033006],"domain_scores_gemma":[0.99076664,0.0070237746,0.0011131204,0.0001877865,0.0004472592,0.00046135092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059727435,0.0005402633,0.0012303976,0.000533283,0.00024892212,0.0012650453,0.0010765725,0.00085312413,0.0026861492],"category_scores_gemma":[0.02799405,0.0004589969,0.0024786675,0.0004740926,0.00063931633,0.001060658,0.001329807,0.0012289259,0.00011401894],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008617868,0.00066829333,0.10603195,0.0009182942,0.0017195428,0.0004149985,0.00024230934,0.83745956,0.00048468873,0.003853353,0.0013076266,0.038281474],"study_design_scores_gemma":[0.0018081375,0.0060818745,0.08015993,0.0005688885,0.0018936348,0.00033168384,0.00027282527,0.90111566,0.0007571921,0.005554424,0.0013736971,0.00008208412],"about_ca_topic_score_codex":0.075976886,"about_ca_topic_score_gemma":0.034215223,"teacher_disagreement_score":0.075976886,"about_ca_system_score_codex":0.0073882565,"about_ca_system_score_gemma":0.004585666,"threshold_uncertainty_score":0.15106928},"labels":[],"label_agreement":null},{"id":"W4416626155","doi":"10.1007/s40261-025-01504-0","title":"Treatment of Non-severe COVID-19 with Molnupiravir: A Systematic Review with Meta-analysis and Trial Sequential Analysis of the Evidence from Randomized Controlled Trials","year":2025,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Randomized controlled trial; Pharmacotherapy; Coronavirus disease 2019 (COVID-19); MEDLINE; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Severe acute respiratory syndrome; Meta-analysis; Coronavirus; Systematic review","score_opus":0.2447877601629181,"score_gpt":0.48226276946680274,"score_spread":0.23747500930388465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416626155","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013391598,0.9830308,0.0013550506,0.00023388125,0.00035393809,0.00069759815,0.00056104973,0.000054819968,0.0003211745],"genre_scores_gemma":[0.42631713,0.56139725,0.0065601873,0.0017645715,0.0003732683,0.0018209124,0.001119066,0.000090507616,0.0005571518],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9860388,0.007372063,0.0037359872,0.0014283466,0.0010081371,0.0004166811],"domain_scores_gemma":[0.98053104,0.013907675,0.0036065076,0.0008117495,0.0008351419,0.0003079003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016840737,0.0032228306,0.024715107,0.003361845,0.0006148355,0.003582855,0.002199371,0.002616567,0.0038632315],"category_scores_gemma":[0.03492472,0.0019573877,0.04333803,0.0044039893,0.001095308,0.0025808674,0.0017269169,0.0030591004,0.0003234695],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008823834,0.000039136426,0.0020367003,0.19254811,0.7877337,0.000065528126,0.00006221699,0.00041564574,0.0002020278,0.00009275061,0.0002887081,0.0076916297],"study_design_scores_gemma":[0.003548866,0.0003768468,0.001687923,0.007904741,0.9851623,0.00004023534,0.000033256787,0.00018644508,0.00007824529,0.00020073363,0.0007561248,0.000024209],"about_ca_topic_score_codex":0.0050568567,"about_ca_topic_score_gemma":0.011460388,"teacher_disagreement_score":0.024715107,"about_ca_system_score_codex":0.0027071545,"about_ca_system_score_gemma":0.0031901803,"threshold_uncertainty_score":0.089063406},"labels":[],"label_agreement":null},{"id":"W44331634","doi":"10.2165/11588810-000000000-00000","title":"Identifying Amnestic Mild Cognitive Impairment in Primary Care","year":2011,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Eisai; Pfizer","keywords":"Clinical Dementia Rating; Dementia; Medicine; Cognition; Montreal Cognitive Assessment; Cognitive impairment; Rating scale; Disease; Recall; Clinical psychology; Audiology; Psychiatry; Psychology; Internal medicine; Cognitive psychology; Developmental psychology","score_opus":0.12943722046456144,"score_gpt":0.3926775700269315,"score_spread":0.2632403495623701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W44331634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888603,0.006264629,0.00010044017,0.00087125646,0.000060491177,0.000094474744,0.00020234208,0.000011839051,0.0035341913],"genre_scores_gemma":[0.9967687,0.001630795,0.00048189226,0.0005284274,0.00010500049,0.00002566577,0.0001533574,0.0000018768553,0.0003042581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982685,0.00056164945,0.0003409501,0.00015419954,0.0003817389,0.00029290273],"domain_scores_gemma":[0.9950276,0.0017070438,0.0012930146,0.00012219114,0.0010709751,0.0007791517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001985235,0.00050386577,0.0010092561,0.0023258307,0.001227902,0.0017962073,0.00067171274,0.0011839388,0.001360529],"category_scores_gemma":[0.010677688,0.0004309786,0.0005171746,0.0013156922,0.0004504289,0.001042976,0.0009283517,0.0011491325,0.00038599534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030921426,0.00031659537,0.98758566,0.00012207596,0.000036685535,0.00094092963,0.00033657637,0.000023324927,0.00028665224,0.000023238646,0.0005039309,0.009515123],"study_design_scores_gemma":[0.000053512656,0.0007688096,0.99373686,0.00011673801,0.00013124594,0.002617924,0.0011491823,0.00026145467,0.00024259485,0.000091444264,0.0008186515,0.000011536736],"about_ca_topic_score_codex":0.021372424,"about_ca_topic_score_gemma":0.045016926,"teacher_disagreement_score":0.021372424,"about_ca_system_score_codex":0.0012647682,"about_ca_system_score_gemma":0.0026565315,"threshold_uncertainty_score":0.042496085},"labels":[],"label_agreement":null},{"id":"W47119266","doi":"10.2165/00044011-200222100-00005","title":"Antidepressant Selection, Healthcare Resource Consumption and Costs in a Large Workplace Environment","year":2002,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Mental Health Treatment and Access","field":"Psychology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Medical prescription; Antidepressant; Psychiatry; Depression (economics); Health care; Major depressive disorder; Psychotropic drug; Emergency medicine; Drug; Anxiety; Pharmacology; Mood","score_opus":0.08901846562884352,"score_gpt":0.38935892432678504,"score_spread":0.3003404586979415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W47119266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99943036,0.000064107095,0.00003719619,0.00014003627,0.000003795245,0.0000035806945,0.000054041848,0.0000016607972,0.00026521628],"genre_scores_gemma":[0.99964976,0.000044723554,0.000047924113,0.000046065103,0.000012040143,0.000003470651,0.000039769115,0.0000014638313,0.00015482343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992186,0.00040128917,0.00003946138,0.000073614814,0.00007829608,0.0001888245],"domain_scores_gemma":[0.9965167,0.0009141982,0.00069553906,0.00013960565,0.00021769782,0.0015162413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006320035,0.00018204954,0.00032996235,0.00062915805,0.0017081301,0.0013846167,0.00040471173,0.00081907585,0.0021951413],"category_scores_gemma":[0.0028713795,0.00033742504,0.00030241068,0.00057312316,0.0005283703,0.0007903761,0.0009949607,0.00072687113,0.00039082716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005547831,0.00071383815,0.9908428,0.000009412847,0.000055727298,0.0013667044,0.0004654838,0.0003115062,0.0004477569,0.00007029115,0.00045126976,0.004710418],"study_design_scores_gemma":[0.000045315846,0.00075302523,0.9916147,0.00000926934,0.00003917913,0.0010389069,0.0043765632,0.0015274392,0.000113131944,0.00018329461,0.00027901796,0.000020178637],"about_ca_topic_score_codex":0.012373815,"about_ca_topic_score_gemma":0.038246945,"teacher_disagreement_score":0.012373815,"about_ca_system_score_codex":0.00072874804,"about_ca_system_score_gemma":0.00068724994,"threshold_uncertainty_score":0.024603546},"labels":[],"label_agreement":null},{"id":"W4765708","doi":"10.2165/00044011-200929050-00003","title":"Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4 mg/day to Solifenacin Treatment","year":2009,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bayer Canada; Astellas Pharma; GlaxoSmithKline; Pfizer","keywords":"Tolterodine; Overactive bladder; Solifenacin; Medicine; Tolerability; Urology; Adverse effect; Nocturia; Urinary urgency; Internal medicine; Urinary system","score_opus":0.03128411834866037,"score_gpt":0.3371129593835576,"score_spread":0.30582884103489727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4765708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99889696,0.0003015423,0.000025486092,0.000044501125,0.000010764611,0.000010025973,0.00021556219,0.000002036799,0.0004932158],"genre_scores_gemma":[0.99949586,0.00008544257,0.000030403286,0.000032333308,0.00000927676,0.000007661034,0.0002639037,6.468257e-7,0.000074485884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943775,0.00018718379,0.00010758188,0.00006351551,0.000111112546,0.00009273969],"domain_scores_gemma":[0.9966383,0.0010459285,0.0013532817,0.00012217261,0.0002600936,0.000580261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008370242,0.00019610298,0.00086711184,0.00050351146,0.00032511243,0.00065824215,0.00025768904,0.0004687584,0.0011705223],"category_scores_gemma":[0.0056741894,0.00013386016,0.0008401509,0.0006754349,0.00017017622,0.00063246285,0.00035900055,0.0007790126,0.00012954643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004693397,0.00038026262,0.9829652,0.00009055083,0.00051881996,0.00017709692,0.00025294427,0.00028026244,0.0004295581,0.000026773489,0.0002462934,0.009938787],"study_design_scores_gemma":[0.0001720934,0.001505163,0.9969079,0.000012605477,0.00018465039,0.00025827505,0.00019909757,0.00047906727,0.00008962416,0.000023672132,0.00015545444,0.000012465037],"about_ca_topic_score_codex":0.0016916068,"about_ca_topic_score_gemma":0.002058196,"teacher_disagreement_score":0.0016916068,"about_ca_system_score_codex":0.00032715235,"about_ca_system_score_gemma":0.00027667498,"threshold_uncertainty_score":0.004426658},"labels":[],"label_agreement":null},{"id":"W645710337","doi":"10.1007/s40261-015-0300-z","title":"Recombinant Human C1 Esterase Inhibitor in the Management of Hereditary Angioedema","year":2015,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Valeant Pharmaceuticals International; CSL Behring; BioCryst; Viropharma","keywords":"Hereditary angioedema; Medicine; Danazol; Pharmacology; C1-inhibitor; Population; Angioedema; Pharmacokinetics; Gastroenterology; Internal medicine; Immunology","score_opus":0.19398339833349348,"score_gpt":0.441416956826433,"score_spread":0.24743355849293952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W645710337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45855105,0.5220653,0.003385416,0.002417266,0.00084903557,0.00067275524,0.00023551696,0.00025026407,0.011573422],"genre_scores_gemma":[0.9203341,0.07189907,0.0031855372,0.0011778381,0.0007454851,0.00026305456,0.00034502352,0.000016849664,0.0020331072],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997682,0.00011005611,0.000017654564,0.000024574925,0.000059957223,0.000019542564],"domain_scores_gemma":[0.9998159,0.00008631963,0.000036251662,0.000008304979,0.000016130774,0.000037147463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062154146,0.00027269588,0.00067475135,0.00032848155,0.00013452978,0.00020179206,0.00031684505,0.0005059044,0.0010242118],"category_scores_gemma":[0.00064369786,0.00006753323,0.0003155551,0.00025067697,0.00017205368,0.00018223173,0.00013116305,0.00097213767,0.00017741969],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019954035,0.0029206139,0.0025170592,0.0034426665,0.00058675295,0.002046531,0.00018649416,0.0011983804,0.05490711,0.0009856917,0.0077507445,0.90350395],"study_design_scores_gemma":[0.097461514,0.25358137,0.17026003,0.0040640277,0.0031209453,0.03609423,0.0003541525,0.006775917,0.08138269,0.0025866663,0.3441032,0.00021515728],"about_ca_topic_score_codex":0.0005963657,"about_ca_topic_score_gemma":0.0006261243,"teacher_disagreement_score":0.0010242118,"about_ca_system_score_codex":0.00022813311,"about_ca_system_score_gemma":0.00017752004,"threshold_uncertainty_score":0.003426373},"labels":[],"label_agreement":null},{"id":"W777891328","doi":"10.2165/11588190-000000000-00000","title":"Intranasal versus Oral Administration of Lisdexamfetamine Dimesylate","year":2011,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Forensic Toxicology and Drug Analysis","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Medicine; Stimulant; Cmax; Pharmacokinetics; Crossover study; Adverse effect; Oral administration; Nasal administration; Dosing; Pharmacology; Anesthesia; Placebo","score_opus":0.33068591961739974,"score_gpt":0.481907058468223,"score_spread":0.15122113885082328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W777891328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975458,0.0005501431,0.00017536982,0.00012910183,0.00021982146,0.00010343514,0.00017213011,0.000033573426,0.0010706262],"genre_scores_gemma":[0.9961901,0.00071166345,0.00046607977,0.000077021075,0.00015950343,0.000090516594,0.00015710606,0.000010287688,0.0021376866],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995117,0.00014309697,0.00004153563,0.000100070654,0.000051507686,0.0001521034],"domain_scores_gemma":[0.999196,0.00027050552,0.00013263413,0.00009370369,0.000047003225,0.00026007908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000577342,0.0005659172,0.0016936056,0.0003301927,0.00031633978,0.0005711586,0.00058108167,0.0008801004,0.0058570527],"category_scores_gemma":[0.0013312781,0.00037276934,0.0005063979,0.0003091717,0.0009646532,0.0010107269,0.0002609929,0.0014235894,0.001142148],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8755621,0.014417546,0.0011433444,0.00019900112,0.00014531739,0.00020912496,0.00013794134,0.0002625337,0.072309695,0.0003411702,0.00077564456,0.034496583],"study_design_scores_gemma":[0.071586855,0.8123012,0.011744636,0.00006392993,0.0006797001,0.00057773653,0.0004457831,0.0034225679,0.095682345,0.00039009604,0.0030140593,0.00009105134],"about_ca_topic_score_codex":0.0015478808,"about_ca_topic_score_gemma":0.0027106018,"teacher_disagreement_score":0.0058570527,"about_ca_system_score_codex":0.0004290027,"about_ca_system_score_gemma":0.0012293139,"threshold_uncertainty_score":0.019593775},"labels":[],"label_agreement":null},{"id":"W87703995","doi":"10.2165/00044011-200828100-00003","title":"Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins","year":2008,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada)","funders":"","keywords":"Medicine; Atorvastatin; Combination therapy; Rosuvastatin; Fenofibrate; Rosuvastatin Calcium; Simvastatin; Statin; Pharmacotherapy; Internal medicine; Pharmacology; Clinical endpoint; Clinical trial; Fibrate; Randomized controlled trial; Gastroenterology","score_opus":0.2015735245686092,"score_gpt":0.40608301158157345,"score_spread":0.20450948701296426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W87703995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99732924,0.0014503802,0.0003422969,0.00014923072,0.000067519926,0.0001523926,0.000068836016,0.000022010547,0.00041810464],"genre_scores_gemma":[0.9973259,0.0008348197,0.0009769389,0.000087560424,0.000078954414,0.00007582299,0.00015072415,0.000006723739,0.00046244822],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995938,0.00016014307,0.000037843376,0.00006568699,0.0000825841,0.00005992447],"domain_scores_gemma":[0.99974376,0.000057404966,0.00004313948,0.000016488668,0.000030332565,0.00010882811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005532799,0.00046296004,0.0009999007,0.00038337382,0.00032927134,0.00055174826,0.0005814398,0.00067688647,0.0016375156],"category_scores_gemma":[0.00071688934,0.00025419542,0.00048451137,0.00023652134,0.00038749605,0.00047556794,0.00022424034,0.001218538,0.0003337659],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37531054,0.033246055,0.0040667853,0.0008551371,0.00082480285,0.0012200502,0.00032153973,0.00097009866,0.4698463,0.00041689552,0.0009166421,0.112005085],"study_design_scores_gemma":[0.06266229,0.6869828,0.022919513,0.00010307236,0.0021947299,0.0021355532,0.00040269885,0.0048380625,0.20832366,0.000111261215,0.009230527,0.000095735144],"about_ca_topic_score_codex":0.0012040713,"about_ca_topic_score_gemma":0.0015120893,"teacher_disagreement_score":0.0016375156,"about_ca_system_score_codex":0.00038251738,"about_ca_system_score_gemma":0.0006475658,"threshold_uncertainty_score":0.0054780245},"labels":[],"label_agreement":null},{"id":"W89469982","doi":"10.2165/11539360-000000000-00000","title":"Effects of Adalimumab versus Placebo on Risk of Symptom Worsening in Psoriasis and Subsequent Impacts on Health-Related Quality-of-Life","year":2010,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Abbott Laboratories","keywords":"Medicine; Adalimumab; Psoriasis; Quality of life (healthcare); Pharmacotherapy; Placebo; Intensive care medicine; Internal medicine; Physical therapy; Alternative medicine; Dermatology; Disease","score_opus":0.050805862688002475,"score_gpt":0.3349130731399031,"score_spread":0.2841072104519006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W89469982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942281,0.003200235,0.00014733938,0.00030241735,0.00043000912,0.00013720554,0.00029333698,0.00003749428,0.0012238873],"genre_scores_gemma":[0.99763906,0.0006326793,0.00024548575,0.00014997914,0.00020096338,0.00010934653,0.0001421333,0.000005058862,0.0008752525],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99889344,0.0005521189,0.000103129765,0.00017785573,0.00007293604,0.00020052795],"domain_scores_gemma":[0.9977944,0.001182408,0.0002808465,0.000107622145,0.0000853794,0.0005493833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019878717,0.0010951161,0.0036030177,0.00041272747,0.00045889826,0.00091904216,0.000628832,0.001498817,0.0045927693],"category_scores_gemma":[0.0034540223,0.00050430204,0.0020530263,0.0002542274,0.00068983046,0.0011208706,0.00040297685,0.0024563684,0.0003922182],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98068064,0.004269148,0.0009877351,0.00016092478,0.00047245115,0.00003429408,0.000020830248,0.00021473781,0.0013056679,0.0000381079,0.00015711709,0.011658325],"study_design_scores_gemma":[0.41634533,0.5108068,0.059917353,0.000097552635,0.0041043633,0.00021206844,0.00018091337,0.003918258,0.0027673491,0.0005688245,0.0009841782,0.00009696274],"about_ca_topic_score_codex":0.0012356427,"about_ca_topic_score_gemma":0.0016929391,"teacher_disagreement_score":0.0045927693,"about_ca_system_score_codex":0.0004710374,"about_ca_system_score_gemma":0.0006138921,"threshold_uncertainty_score":0.015364349},"labels":[],"label_agreement":null}]}